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type 1 diabetes mellitus and hypoglyCemia
more than 400 million adults worldwide are living with diabetes mellitus [1]. the vast majority 
of this patient group are diagnosed with type 2 diabetes. type 2 diabetes is associated with 
obesity and physical inactivity, and characterized by a combination of insulin resistance and 
insulin deficiency [2]. in western countries including the netherlands, approximately 10% 
of the patients with diabetes are diagnosed with type 1 diabetes; an autoimmune disease, 
characterized by the destruction of insulin-producing ß-cells in the pancreas [3]. insulin is the 
key hormone for glucose homeostasis, as it promotes the uptake of glucose from the blood 
into fat, liver and muscle cells. insulin deficiency causes uncontrollable high blood glucose 
levels (hyperglycemia), which leads to severe metabolic disturbances and ultimately death, 
when not replaced by therapeutic insulin. As such, patients with type 1 diabetes require daily 
administration of exogenous insulin to regulate their blood glucose levels.
 therapeutic insulin was discovered in 1922, and has changed type 1 diabetes from 
a deadly to a chronic disease. We now know that achieving near-normal glucose control with 
insulin replacement therapy, and thus avoiding hyperglycemia, is important to reduce the risk 
of microvascular and macrovascular complications of diabetes [4,5]. unfortunately, therapeutic 
insulin is still poor at mimicking endogenous insulin and glucose control in patients with type 
1 diabetes consequently remains suboptimal. 
hypoglycemia
the most frequent side-effect of insulin therapy is hypoglycemia, i.e., too low blood glucose 
levels. Hypoglycemia is the principal barrier for achieving true normal glucose levels for 
patients with type 1 diabetes [6]. At the very least, hypoglycemia is a nuisance and an 
interruption of daily life. But the effects of hypoglycemia could be more severe. Hypoglycemia 
may impair judgment, cognitive function, behaviour and the performance of physical task [7]. 
Profound drops in glucose may even lead to neurological impairments, seizures, coma and 
(rarely) sudden death [7,8].
 Patients with type 1 diabetes experience on average two to three times a week a 
hypoglycemic episode [9]. When glucose levels drop, normally a hierarchically organized 
counterregulatory response is initiated, including the appearance of hypoglycemic warning 
symptoms and hormonal responses (see chapter 2 for more details). these warning signs allow 
patients to recognize hypoglycemia and to restore glucose levels by ingesting carbohydrates. 
However, up to a third of the patients with type 1 diabetes suffer from the clinical syndrome 
of impaired awareness of hypoglycemia (iAH), meaning that the appearance of hypoglycemic 
symptoms is suppressed [10]. iAH increases the risk of severe hypoglycemia, defined as a 
hypoglycemic event that requires help from another person for recovery, and is potentially 
hazardous when such help cannot be given [11].
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pathogenesis of impaired awareness of hypoglycemia
recurrent hypoglycemic episodes lead to iAH, a process which can be reversed by scrupulous 
avoidance of hypoglycemia [12,13]. However, in practice, this is very hard to achieve. the exact 
underlying mechanisms of how recurrent hypoglycemia causes iAH are not fully understood, 
but most certainly involve (multiple) cerebral adaptations. current mechanistic hypotheses 
include: enhanced cerebral glucose metabolism, increased cerebral storage of glycogen, 
enhanced cerebral perfusion, and/or the use of alternative non-glucose fuels to support 
brain metabolism [10,14,15]. notably, these potential mechanisms are not mutually exclusive. 
chapter 2 provides a more detailed descriptions of these mechanisms.
 this thesis focuses on two potential mechanisms that may contribute to the 
development of iAH. the first mechanism is the use of lactate as an alternative fuel when 
glucose supply is low. glucose is the main and most important fuel for our brain, but also 
small amounts of lactate are oxidized [16]. in fact, under physiological circumstances, 
it is estimated that the contribution of lactate to cerebral metabolism is approximately 
10% [17,18]. upregulation of lactate oxidation during hypoglycemia may preserve brain 
metabolism, and this may be enhanced in patients with iAH as an adaptation to recurrent 
hypoglycemia. several observations point towards a role for lactate in the development of 
iAH. it is known that administration of lactate during hypoglycemia reduces the symptomatic 
and counterregulatory hormone response to hypoglycemia [19-22]. Furthermore, in a rodent 
model of iAH, it was shown that elevated lactate levels preserve neuronal function during 
hypoglycemia [23,24]. Finally, lactate transport capacity across the blood-brain barrier is 
reported to be upregulated in iAH [25,26].
 the second mechanism investigated in this thesis which may contribute to the 
development of iAH is an adapted cerebral perfusion. An increase in global cerebral blood 
flow (cBF) may lead to enhanced supply of glucose and other nutrients to the brain. As such, 
an increase in cBF may protect the brain during hypoglycemia, but at the same time, may 
impede hypoglycemic sensing in iAH. regional changes in cBF (i.e., a redistribution of cBF) 
are linked to neuronal activation [27]. Hence, regional changes in cBF may provide insight into 
the coordination of sympathetic responses to hypoglycemia, which may be altered in iAH.
 cerebral lactate levels can be assessed with magnetic resonance spectroscopy (mrs). 
cBF can be quantified non-invasively with another imaging technique, called arterial spin 
labeling magnetic resonance imaging (AsL-mri). As such, mr techniques provide powerful 
tools to study various aspects of brain metabolism and perfusion which may help in unravelling 
the mechanism behind iAH. the next part of this chapter provides a more detailed introduction 
into mrs and AsL-mri.
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magnetiC resonanCe 
magnetic resonance spectroscopy (mrs) is closely related to a more well-known imaging 
technique called magnetic resonance imaging (mri). mri is a highly versatile imaging modality, 
often used in a clinical setting to make anatomical images. By comparison, mrs is used to 
analyse the chemical composition of tissue. Both mri and mrs use a high magnetic fi eld and 
are based upon nuclear magnetic resonance (nmr).
spin, precession and magnetization
Atoms consist of a nucleus (containing protons) and a shell. spin is a physical property of 
any atomic nucleus, just like mass, electric charge and magnetism. spin is often depicted as 
a particle spinning around its axis (Figure 1.1A) – although in reality particles are not actually 
rotating around their own axis. spin is a highly abstract concept, which can only be described 
completely by quantum mechanics.
 each nucleus has a spin quantum number (i), and any nucleus with a non-zero spin (i≠0) 
can be used in an mr experiment. the most used nucleus for mr purposes is the proton (1H) with 
i=½ , because of a high natural abundance and a high mr sensitivity (i.e., a high gyromagnetic ratio 
(γ; in rad·s-1·t-1)). . Particles with a non-zero spin have an intrinsic magnetic moment, which can be 
conceptualized as a magnetic fi eld generated by rotating currents within the spinning particle.
 normally, the orientation of nuclear spins is random throughout space. summation 
over all orientations leads thus to a cancelation of all magnetic moments and hence to the 
absence of a magnetization vector; there is no net macroscopic magnetization. now, if such 
nuclei are placed in a magnetic fi eld (e.g., in an mr scanner) they will start precessing around 
this external magnetic fi eld (Figure 1.1A). this effect is referred to as Larmor precession and the 
corresponding Larmor frequency of this precession (ω0; in mHz) is given by: ω0=γB0               (1.1)
Where B0 is the external magnetic fi eld in tesla (t).
Spin
Precession
B0
Spin up
Spin down
B0
A. B.
B0
C.
figure 1.1 A) A nuclear spin will precess with the Larmor frequency if placed in a magnetic fi eld (B0) B) 
in a macroscopic ensemble of spins with a quantum number of ½, there are two preferred energy states: 
sin up and spin down. the average spin distribution is slightly biased towards the spin up state. (A and 
B are adapted from [28]) c) more realistic representation of B. nearly all spins exist in a near-spherical 
distribution around the external magnetic fi eld (source: [29])
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 if the spin quantum number of the nucleus under investigation equals ½ (as for the 
1H-nucleus) there are two preferred energy states: spin up (or α) and spin down (or ß). if we 
consider a macroscopic sample (which contains many spins) placed in a magnetic field, the 
orientation of the average spin distribution is slightly biased towards the spin up state (Figure 
1.1B). it should be noted that this does not mean that individual spins reside exclusively in one 
of these two states. in fact, nearly all spins exist in a near-spherical distribution around the 
direction of the magnetic field (Figure 1.1c). the number of spins that are biased towards the 
spin up orientation reflect an energy difference (∆e). the distribution over spin orientations is 
given by the Boltzmann equation:
= e ∆e ⁄ kt
nspin up
nspin down 
        (1.2)
Where k is Boltzman constant (1.38·10-23 J/K) and t the temperature in Kelvin.
 due to this population difference, there will be a longitudinal net magnetization (m), 
parallel with B0. By convention, this magnetization is along the z-direction of a cartesian axis 
system. the spins will not have the same phase and their transversal vector components are 
randomly distributed. At thermal equilibrium, the amplitude of the macroscopic magnetization 
vector is:
m= 
γh    2 nB0
2π  4kt
       (1.3)
Where h is Planck’s constant (6.63·10-34 m2 kg/s) and n the total number of nuclear spins. 
excitation and relaxation
it is very difficult to detect the macroscopic magnetization vector of the spins as long as it is 
orientated in the direction of the much larger external magnetic field. so, to detect the net 
magnetization of a sample, it needs to be turned into the transversal plane. this rotation can 
be achieved by applying another magnetic field (B1), which oscillates at the Larmor frequency. 
this B1 field is applied as a radio frequency (rF) pulse and has two effects on spins: the net 
magnetization vector will spiral down towards the transversal plane and the spins come into a 
state of phase coherence.
 After the rF pulse, the spins will return to their original distribution. this occurs by 
means of longitudinal (t1) and transversal (t2) relaxation processes. t 1 relaxation is the process 
by which the net magnetization returns to its initial value, parallel to B 0. t2 relaxation describes 
the process of the decrease in phase coherence. t1 and t2 are tissue-dependent time constants 
and form the basis of contrast in mri.
 As long as there is magnetization in the transverse plane it will precess around the B0 
 field. this precessing transversal magnetization will induce an oscillating current which can be 
picked up by a receive coil. the received signal is called a free induction decay (Fid), and holds 
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all relevant information about the nuclear spins under investigation (e.g., their resonance 
frequency and relative abundance).
Chemical shift
so far, we have assumed that a macroscopic samples consist of only one type of nuclear spin. 
if this would be the case, the Larmor frequency would be equal for all spins. However, nuclei 
are surrounded or ‘shielded’ by electrons. these electrons will affect the magnetic field that is 
sensed by the nucleus, and thus its Larmor frequency. the resonance frequency of a nucleus 
(ω) is then defined as:
ω=γB0 (1-σ)                     (1.4)
Where σ is the shielding constant, depending on the chemical environment of the nucleus.
 this slight difference in resonance frequencies of two otherwise identical nuclei 
residing in a different chemical environment is referred to as chemical shift (δ) and is defined as:
×106
  ω-ωref
   ωref 
δ= (1.5)
Where ωref is the resonance frequency of a reference compound, which in 
1H-mr is 
tetramethylsilane (δ=0). chemical shift is expressed in parts per million (ppm) and is 
independent of the magnetic field strength, since ω and ωref are proportional to B0.
 An Fid recorded from a certain tissue is thus composed of different frequency 
components. Fourier transformation of an Fid results in a spectrum (the mr spectrum), where 
every peak represents a certain metabolite (Figure 1.2). the relative area under each peak is 
directly proportional to the tissue concentration of the corresponding nucleus. mrs can thus 
be used to quantify metabolite content.
012340.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
0
0
Chemical shift (ppm)Time (ms)
Fourier Transformation
FID MR spectrum
figure 1.2 Fourier transformation of the recorded time-domain signal (free induction decay; Fid) results 
in a mr spectrum
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J-Coupling
the chemical environment of a nucleus is not the only factor affecting the local magnetic 
fi eld. the interaction of two nuclear spins within the same molecule may also have this effect. 
electron clouds of two spins can infl uence each other through space (dipolar coupling) or 
through chemical bonds (J-coupling). While the effects of dipolar coupling are mostly cancelled 
out due to rapid tumbling of molecules, J-coupling does affect the local magnetic fi eld and 
gives rise to the phenomenon of splitting of spectral peaks.
 As described above, for a proton there a two preferred energy states: spin up or spin 
down. now, in a combined spin-system of two isolated protons (proton A and proton B) there 
are four possible preferred energy states: both spin up (αα), both spin down (ßß), spin up – spin 
down (αß) or spin down – spin up (ßα). All states are equally likely and there are four permitted 
transitions. the energy differences of the two transitions of proton A are equal (∆eA), as are 
the transitions of proton B (∆eB). the corresponding spectrum will show two singlet peaks at 
the chemical shift of both protons (Figure 1.3B; ωA and ωB). However, according to the Pauli 
exclusion principle, if protons are J-coupled to each other, electrons spins are antiparallel. 
A J-coupled spin system still allows all four energy state s, but the state in which the nuclear 
spins are both spin up or both spin down is now energetically less favourable compared to the 
anti-parallel states. As the energy difference for the transitions are no longer equal (∆eA1≠∆eA2 
and ∆eB1≠∆eB2), this results in small changes in the Larmor frequencies which, in turn, results 
in peak splitting. the peaks, of which the amplitude is half of the original, are centred on the 
original frequencies separated by the J-coupling constant (Figure 1.3c).
ω
β
α
ΔE
αα
ββ
βα
ΔEA ΔEB
ΔEB ΔEA
ωA ωB
αβ
αα
βα
αβ
ββ
ΔEA2 ΔEB2
ΔEB1 ΔEA1
ωA ωB
JAB JAB
Single spin Uncoupled spins J-coupled spins 
Proton A Proton B Proton A Proton B
A. B. C.
figure 1.3 energy level diagrams and corresponding spectra for A) a single spin, B) two uncoupled spins 
and c) two J-coupled spins.
General introduction
17
1
localized single-voxel 1h-mrs
usually, the value of a global mr spectrum of the whole body (part) in the mr scanner is limited. 
one is typically interested in spectral information of a well-defined volume (i.e., the mrs voxel). 
this is possible with so-called localization techniques, which minimizes contamination of 
adjacent tissues such as extracranial lipids or cerebrospinal fluid in the brain. 
 to select a single voxel, slice-selective rF pulses in three directions in space (x, y and 
z directions) are needed. these slice-selective rF pulses determine orthogonal planes, and the 
intersection of these planes correspond to the volume (i.e., the mrs voxel) studied (Figure 1.4).
Z
YX
figure 1.4 the intersection of three orthogonal planes defines the mrs voxel (depicted in grey).
J-differenCe editing 1h-mrs to assess Cerebral laCtate 
Content
Lactate is present in the brain in a relatively low concentration of ~0.5 µmol/g tissue. Lactate 
has four protons, which give rise to a doublet at 1.3 ppm (methyl protons) and a quartet at 4.1 
ppm (methine proton) in a 1H-mr spectrum (Figure 1.5A). due to its low tissue concentration 
and the fact that the lactate signal at 1.3 ppm can be overlapping with macromolecular signals 
(Figure 1.5B), lactate is best observed with J-difference editing techniques [30].
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012345
Chemical shift (ppm)
OH
H
H
H
O
OH
C CC H
MethylMethine
3 2 14
tNAA
tCre
tChotCre
Glu
mI
mI
tNAA
Glu
Chemical shift (ppm)
Lac?
A. B.
figure 1.5 A) chemical structure and simulated 1H-mr spectrum of lactate B) in vivo 1H-mr spectrum 
from the human brain, recorded with an echo time of 30 ms. the lactate doublet at 1.3 ppm is overlapped 
with macromolecular signals. Abbreviations: mi, myo-inositol; tcre, total creatine; tcho, total choline; 
tnAA, total n-acetylaspartate; glu, glutamate; Lac, lactate.
ppm
Frequency selective RF pulses ON
Frequency selective RF pulses OFF
Dierence spectrum (ON-OFF)
3.0 2.5 2.0 1.5 1.0
Lac
tNAA
tCho tCre
figure 1.6 example of J-difference-edited spectra. the lactate doublet at 1.3 ppm is upright when frequency 
selective rF pulses are used (centered on the lactate quartet at 4.1 ppm) and inverted when the frequency 
selective rF pulses are not used. subtraction of the spectra results in a difference spectrum, which only 
contains the (positive) lactate doublet, removing the signals from all other metabolites in the spectrum. 
(Abbreviations: tcho, total choline; tcre, total creatine, tnAA, total n-acetylaspartate; Lac, lactate)
 the coupling constant (J) of lactate is 6.93 Hz. this J-coupling does not only lead to 
splitting of peaks in a doublet and in a quartet, it also gives rise to a phase evolution of the doublet 
at 1.3 ppm, meaning that the signals from the methyl protons goes in and out of phase every 1/J ~ 
144 ms. in other words: the lactate doublet is inverted if acquired with an echo time (te; the time 
between the excitation pulse and the top of the Fid) of 144 ms and will be positive at a very short 
echo time or at a long echo time of 288 ms. this forms the basis of J-difference editing.
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 J-difference editing involves the acquisition of two spectra, both with an echo time 
of 1/J. in one of the acquisitions, frequency selective rF pulses are used, centred on the 
lactate quartet at 4.1 ppm, which refocuses the phase evolution of the J-coupled spins. As a 
result, the lactate doublet at 1.3 ppm will always be positive. in the other acquisition, these 
frequency selective rF pulses are not used. subtracting both spectra eliminates all uncoupled 
resonances, allowing selective detection of the coupled spins of lactate (Figure 1.6) [30,31].
 throughout this thesis, we used a semi-LAser sequence [32] with frequency selective 
megA pulses [31] for editing (see Figure 1.7 for the rF-signal of the sequence). the semi-
LAser sequence consists of a slice-selective shinnar-Le-roux optimized 90° excitation pulse 
and two pairs of adiabatic full passage (AFP, duration of 5 ms) 180° pulses, which results in 
only a low chemical shift displacement artefact as compared to more conventional localization 
sequences such as Press [32]. the first and fourth AFP pulses select a plane perpendicular 
to the plane of excitation (y-direction) and the second and third AFP pulses are slice-selective 
in the z-direction. the frequency selective megA pulses (bandwidth of 75 Hz and a duration 
of 30 ms) are centred around 4.1 ppm in the even acquisitions, and at -1.5 ppm in the odd 
acquisitions, and are separated by half the echo time.
TE/2
Acq
90°180° 180°180° 180°
AFP AFP AFP AFPMEGA MEGA
figure 1.7 rF-diagram of the semi-LAser sequence with frequency selective megA pulses used for 
J-difference editing. Abbreviations: AFP: adiabatic full passage pulses; Acq: acquisition; te, echo time.
 1H-mrs is a unique investigational tool allowing non-invasive in-vivo quantification of 
metabolite concentrations. in general, 1H-mrs is accepted to be a reproducible and reliable 
method for this purpose [33,34]. Although lactate is a low-concentration metabolite, which may 
hampers accurate quantification [35], lactate detection using J-difference editing 1H-mrs is 
reported to be accurate [36,37].
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arterial spin-labeling mri to assess Cerebral perfusion
Arterial spin-labeling (AsL) mri allows non-invasive (i.e., without the use of a contrast-agent) 
quantification of tissue perfusion, mostly applied to the brain. cerebral perfusion, often referred 
to as cerebral blood flow (cBF), is an important physiological parameter. cBF is defined as 
the supply of oxygen and nutrients to brain cells by means of steady blood flow [38], and is 
measured in ml per 100 gram tissue per minute; not to be mistaken for volume flow of blood 
in vessels (in ml/min).
 AsL-mri involves the acquisition of three mr images: a ‘tagged’ image, a ‘control’ 
image and a proton density image. to acquire the ‘tagged’ image, water in the arterial blood is 
magnetically labeled and used as a tracer. this labeling occurs with an rF pulse that inverts the 
water protons in flowing blood in vessels. this inversion takes place proximal to the imaging 
region, in the brain-feeding internal carotid arteries (Figure 1.8). As such, the magnetically 
labeled blood water flows into the capillary bed of the brain, where perfusion takes place. the 
tagged water molecules exchange their magnetization with those in the tissue. now, image 
acquisition takes place. this procedure is repeated without labeling, resulting in the ‘control’ 
image which is otherwise as identical as possible to the first image. subtracting the ‘tagged’ 
and ‘control’ images provides a signal that is proportional to the amount of labeled blood water 
in each voxel in the tissue (Figure 1.9). From this perfusion map, cBF can be quantified using 
the proton density image as an internal reference [39,40].
figure 1.8 Water protons in blood are magnetically labeled as they flow (within the brain-feeding arteries) 
through the labeling plane that is proximal to the imaging volume. (source: [40])
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Tagged image
- =
Perfusion mapControl image
figure 1.9 example of a ‘tagged’ image and a ‘control’ image. subtracting the ‘tagged’ image and ‘control’ 
image results in a perfusion map.
 there are three main approaches to perform the labeling in AsL-mri: (pseudo) 
continuous labeling, pulsed labeling and velocity selective labeling. As recommended by the 
white-paper of Alsop et al. [39] we used a pseudo-continuous labeling (pcAsL) approach in 
the work in this thesis. Labeling occurs over a relative long period (1-3 s), as blood flows 
through a single labeling plane and is inverted by a long train of short slice-selective rF pulses. 
this pulse train results in a phenomenon known as flow-driven adiabatic inversion [41]. After 
labeling, the longitudinal magnetization will decay with the time constant t1 (about 1650 ms 
at 3t). this ‘lifetime’ of the label is about similar to the time it takes for blood to flow from the 
labeling plane to the target tissue. therefore, the choice of post labeling delay (PLd; the time 
between labeling and image acquisition) is a compromise. 
 For quantification of cBF, a relatively simple model can be used, assuming that 1) the 
entire labeled blood is delivered to the tissue, 2) there is no outflow of labeled blood, and 3) the 
relaxation of the labeled spins are governed by t1 of blood. under these assumptions, cBF (in 
ml/100g/min) in each voxel can be calculated with [39]:
6000·λ·(sicontrol-silabel)·e
2·α·t1 blood·siPd·(1-e                 )
PLd
t1 blood
cBF= τ
t1 blood
-
(1.6)
Where λ is the brain/blood partition coefficient (0.9 mL/g), si the signal intensities of the labeled 
image, the control image and the proton density image, α the labeling efficiency (estimated at 
0.85 for pcAsL) and τ the label duration.
 since perfusion replaces only 1-3% of the tissue water with inflowing arterial blood 
water per second, the signal-to-noise ratio (snr) of AsL-mri is intrinsically low. However, 
AsL-mri has numerous advantages over other techniques which can be used to assess 
cBF. First of all, no exogenous contrast agent is needed when performing AsL-mri. other 
perfusion-imaging techniques, such as dynamic susceptibility contrast (dsc) and dynamic 
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contract enhanced (dce) mri, 15o-positron emission tomography (Pet) or perfusion computer 
tomography (ct), all require the administration of an exogenous contrast agent, making it 
less attractive options for research. Furthermore, no ionizing radiation is used in AsL-mri. 
Finally, unlike other techniques, AsL-mri allows direct absolute quantification of cBF, which 
is reported to be reliable and reproducible [42-45].
outline of this thesis
the general aim of this thesis is to unravel cerebral adaptations in response to hypoglycemia 
in patients with type 1 diabetes and impaired awareness of hypoglycemia (iAH), and to 
compare these adaptations to those in patients with type 1 diabetes and normal awareness 
of hypoglycemia (nAH) and healthy non-diabetic controls. the work in this thesis focusses 
on two potential mechanisms that may contribute to the development of iAH: alterations in 
brain lactate handling in response to hypoglycemia, and hypoglycemia-induced adaptations 
in cerebral blood flow (cBF). Both mechanism are likely aimed at neuroprotection, either by 
providing an alternative fuel when glucose supply is low or by increasing nutrient supply to the 
brain, but may at the same time compromise the hypoglycemic sensing capacity.
 this thesis describes a series of integrated experiments, using 1H-mrs to measure 
brain lactate content, both under physiological and supraphysiological plasma lactate levels. 
Furthermore, we used AsL-mri to study changes in cBF in response to hypoglycemia.  
Chapter 2 discusses more extensively current understanding of cerebral metabolism during 
hypoglycemia and adaptations described in patients with iAH.
 to accurately measure brain lactate levels, we have used J-difference editing 
1H-mrs. J-difference editing involves the consecutive acquisition of two spectra which need 
to be subtracted. Accurate phase and frequency alignment prior to subtracting those spectra 
is very important to avoid artefactual contributions to the lactate signal. Chapter 3 presents 
a method for simultaneous phase and frequency alignment of two spectra, making use of the 
correlation over a spectral region.
 in chapter 4 we investigated the effect of hypoglycemia on brain lactate levels in 
patients with type 1 diabetes and iAH, patients with nAH and healthy controls. Participants 
underwent an euglycemic-hypoglycemic clamp, which allows for constant plasma glucose 
levels at a predefined level over the experimental time frame, by using a constant insulin 
infusion and a variable glucose infusion. cerebral lactate concentrations were measured 
continuously, using J-difference editing 1H-mrs.
 Because studies have shown that elevated plasma lactate levels suppress hypoglycemic 
awareness, as seen in patients with iAH, we subsequently investigated the effect of endogenously 
elevated plasma lactate levels on brain lactate levels during hypoglycemia. High-intensity 
interval training (Hiit), a training modality that consist of repeated brief bouts of exercise at 
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high intensity, acutely increases plasma lactate levels to >10 mmol/l. Participants underwent a 
hypoglycemic clamp after performing a bout of Hiit. Before Hiit and during hypoglycemia, brain 
lactate levels were determined. the results of this study are presented in chapter 5.
 After a Hiit session, plasma lactate levels will return to baseline levels in approximately 
90 minutes. in chapter 6 we used intravenous lactate infusion to reach stable exogenously 
elevated plasma lactate levels. Lactate was infused in a dose sufficient to suppress awareness 
of hypoglycemia in patients with type 1 diabetes with nAH. We compared the effect on cerebral 
lactate with a placebo condition and with patients with iAH. 
 As stated above, altered brain lactate handling is probably not the only cerebral 
adaptation that leads to iAH. An increase in global cBF may lead to an increase in nutrient 
supply to the brain, and as such, may be a neuroprotective mechanism during hypoglycemia. A 
redistribution of cBF has been related to neuronal activation. As such, hypoglycemia-induced 
changes in regional cBF may give insight into the coordination of the sympathetic response 
to hypoglycemia. in chapter 7 we therefore studied the effect of hypoglycemia on cBF. in this 
chapter, we compared difference in both global and regional cBF in response to hypoglycemia 
in patients with and without iAH and in non-diabetic controls.
 Chapter 8 summarizes the work in this thesis and discusses its (clinical) implications. 
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abstraCt 
Hypoglycemia is the most frequent complication of insulin therapy in patients with type 
1 diabetes. since the brain is reliant on circulating glucose as its main source of energy, 
hypoglycemia poses a threat for normal brain function. Paradoxically, although hypoglycemia 
commonly induces immediate decline in cognitive function, long-lasting changes in brain 
structure and cognitive function are uncommon in patients with type 1 diabetes. in fact, recurrent 
hypoglycemia initiates a process of habituation that suppresses hormonal responses to and 
impairs awareness of subsequent hypoglycemia, which has been attributed to adaptations in 
the brain. these observations have sparked great scientific interest into the brain’s handling 
of glucose during (recurrent) hypoglycemia. Various neuroimaging techniques have been 
employed to study brain (glucose) metabolism, including Pet, fmri, mrs and AsL. this review 
discusses what is currently known about cerebral metabolism during hypoglycemia, and how 
findings obtained by functional and metabolic neuroimaging techniques have contributed to 
this knowledge.
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introduCtion
the brain is one of the most metabolically active organs in the body and it consumes energy 
disproportionate to its size. in humans, the brain represents only about 2% of total body 
weight, yet it accounts for approximately 20% of the body’s oxygen use and 25% of the body’s 
use of glucose. glucose is the primary fuel for the adult brain. in young adults, the ‘resting’ 
brain consumes approximately 110 grams of glucose per day, i.e. 5.5 mg glucose per 100 g of 
brain tissue per minute [1]. since the brain’s energy stores are small, normal brain function 
depends on a continuous supply of glucose from the bloodstream. under normal conditions, 
the human body takes great effort and is very efficient in avoiding hypoglycemia in almost all 
circumstances to maintain sufficient glucose delivery to the brain. 
 type 1 diabetes mellitus is an autoimmune-mediated disease, characterized by 
destruction of most, if not all, of the insulin-producing capacity of pancreatic beta-cells. 
As a consequence, supplemental insulin treatment is required to maintain glucose control 
and decrease the risk of complications resulting from hyperglycemia [2]. unfortunately, 
therapeutic insulin is still poor at mimicking the pharmacology of endogenous insulin. As 
a consequence, people with type 1 diabetes – in particular those aiming for strict glycemic 
control – are at continuous risk of hypoglycemia, the average frequency of which has been 
estimated at two non-severe, symptomatic episodes per week [3-5] and one severe, potentially 
hazardous event, per year [4,6,7]. Although there is substantial variation in both the rate and 
the severity of hypoglycemia, both between and within persons [4,8], this estimation means 
that the brains of people with type 1 diabetes are exposed to many thousands of hypoglycemic 
episodes over a lifetime of diabetes. 
 studying brain metabolism during hypoglycemia may reveal the potential harmful 
effects of (recurrent) hypoglycemia on the brain and may increase our understanding of 
metabolic adaptations that might underlie impairments in the defenses against hypoglycemia 
[9]. modern neuroimaging techniques have enabled the study of cerebral metabolism in vivo 
in a relatively non-invasive manner. this review will focus on the effect of hypoglycemia on 
brain (glucose) metabolism, with a particular emphasis on recent findings from functional and 
metabolic neuroimaging studies. 
gluCose Counterregulation
in healthy, non-diabetic humans, hypoglycemia is unlikely to ever occur due to a hierarchically 
coordinated system that integrates insulin secretion and counterregulatory hormone and 
symptom responses (Figure 2.1) [10,11]. When glucose levels in the low-physiological range 
(e.g. late post-absorptive or fasting state) tend to fall, insulin secretion is suppressed to such 
an extent that true hypoglycemia can almost always be prevented. When insulin is given to 
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experimentally induce hypoglycemia in people without diabetes, glucose levels at or below ~3.8 
mmol/L will induce a glucagon response, the secretion of which by pancreatic alpha-cells is 
probably controlled by the neighboring beta-cells [10,11]. such a glucose level also stimulates 
the secretion of adrenaline, whereas slightly lower levels are needed to elicit autonomic 
warning symptoms, such as sweating, palpitations, trembling and feeling hungry [10,11]. 
these symptoms are aimed at initiating a behavioral response (i.e. ingesting carbohydrates). 
Further falls in plasma glucose values result in neuroglycopenic symptoms, which range from 
mild cognitive impairment, such as difficulty in concentrating, to overt confusion and even 
coma or seizures in its most severe form [10,11].
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figure 2.1 Physiological and behavioural defences against hypoglycemia. cns: central nervous system; 
sns: sympathetic nervous system; Pns: parasympathetic nervous system (adapted from [10])
 in patients with type 1 diabetes, hypoglycemia typically results from the interplay 
between therapeutic peripheral hyperinsulinemia and impaired defenses against falling 
plasma glucose levels [10]. these impairments firstly include the inability to decrease insulin 
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and to increase glucagon in response to hypoglycemia. the latter is not a structural defect, 
but specific for hypoglycemia and probably secondary to loss of control by non-functioning 
beta-cells [12]. in patients with longer diabetes duration and more frequent exposure to 
hypoglycemia, adrenaline responses to hypoglycemia become attenuated, in part due to a 
shift of these responses to lower glucose values [13]. the defective adrenaline responses are 
associated with, although not necessarily the cause of, similar defects in the emergence of 
autonomic symptom responses [14,15]. disappearance of these symptoms interferes with 
the ability to timely and accurately perceive, interpret and respond to falling plasma glucose 
levels. this inability is known as the clinical syndrome of impaired awareness of hypoglycemia 
and particularly increases the risk of severe hypoglycemia, defined as those events requiring 
assistance from another person [16], by a factor of six or more [17,18]. Both the attenuated 
adrenaline response and impaired awareness of hypoglycemia are usually the result of 
(recurrent) antecedent hypoglycemia rather than of autonomic neuropathy, for which the 
term ‘hypoglycemia-associated autonomic failure’ (HAAF) has been introduced [19]. HAAF can 
be effectively treated by several weeks to months of scrupulous avoidance of hypoglycemia 
[15,20,21], although it appears that the symptomatic component responds earlier and better 
than the hormonal component [15]. the underlying mechanism(s) explaining the attenuating 
effect of prior hypoglycemia on responses to subsequent events have not been fully elucidated. 
However, there is agreement that alterations in the brain play a pivotal role.
morbidity assoCiated with hypoglyCemia
the glucose level at which cognitive function declines is subject to substantial variation; in 
some people cognitive dysfunction already occurs at plasma glucose levels between 3.0 and 4.0 
mmol/L, whereas others continue to function well at levels below 2.5 mmol/L [8,22]. Almost all 
domains of cognitive function are potentially at risk during acute hypoglycemia, with complex 
tasks (e.g. car driving) being affected earlier than simple tasks [23,24]. Prolonged and/or 
profoundly severe hypoglycemia may eventually cause neuronal death [25,26]. the cerebral 
cortex and hippocampus are the most vulnerable regions in the brain to be injured by severe 
hypoglycemia, while the brain stem and cerebellum are most resistant [27]. However, although 
persistent vegetative states or brain death resulting from hypoglycemia have been described 
[28-30], most patients with type 1 diabetes recover uneventfully from even severe hypoglycemia 
complicated by seizures or coma, especially when they are young and in good clinical condition. 
in addition, evidence for an association between multiple episodes of severe hypoglycemia and 
long-term cognitive decline in people with type 1 diabetes is lacking [31,32]. Finally, although 
4 to 10% of all deaths in patients with type 1 diabetes have been attributed to hypoglycemia, 
most of these deaths are thought to be either accidental (e.g. in traffic) or cardiovascular (e.g. 
arrhythmia) rather than the direct consequence of brain death [33,34]. 
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 it should be noted that both the developing brain of young children with type 1 diabetes 
[35,36] and the brain of the elderly, in particular in patients with type 2 diabetes [37,38], seem 
more susceptible to harm from hypoglycemia. children with type 1 diabetes performed worse 
on cognitive tests when they had a history of severe hypoglycemia below the age of 5 years, 
compared to patients without such a history and non-diabetic controls [35]. in prospective 
cohorts of people with type 2 diabetes, a history of severe hypoglycemia has been associated 
with cognitive decline and frank dementia [38], as well as with greater risks of cardiovascular 
events and death [39,40]. on the cellular level, there are now indications that glucose 
deprivation may accelerate apoptosis of neurons, which could underlie neuronal cell death and 
predispose for cognitive decline [41]. it has also been speculated that the acute, physiological 
changes in hematological and hemodynamic parameters induced by hypoglycemia may 
be particularly damaging when the vasculature has already been injured [42,43], possibly 
explaining the discrepancy between type 1 and type 2 diabetes [44,31]. Another factor explaining 
this discrepancy may lie in the concept of hypoglycemic preconditioning. rodents exposed 
to recurrent hypoglycemic events of moderate severity were less likely to develop neuronal 
damage or cognitive impairments or die during subsequent severe hypoglycemia than age-
matched littermates who were not pre-exposed to hypoglycemia [45,46]. these data may help 
to explain recent observations that patients with type 1 diabetes and impaired awareness of 
hypoglycemia, as a reflection of recurrent hypoglycemia, appeared not at greater risk of dying 
than patients with intact awareness [47].
the role of the brain in gluCose Counterregulation
the brain is not just at the receiving end of hypoglycemia, but it plays an important role in 
both the detection of hypoglycemia and in the subsequent initiation and coordination of 
counterregulatory responses to restore euglycemia, as described above. this system maintains 
glucose homeostasis through a classic sensory-motor integrative pathway in which a decrease 
in plasma glucose levels is detected by an extended network of glucose sensing neurons 
located within the brain and the periphery [48]. specialized glucose-sensing cells are located 
in the hepatic portal/mesenteric vein, gut, carotid body and oral cavity. in the brain, glucose-
sensing neurons are found at a number of locations, but particularly in the ventromedial 
nucleus of the hypothalamus (VmH) and areas that originate from the hindbrain. integrative 
networks receive projections from these sensing neurons and subsequently assimilate their 
input with signals from other brain regions, such as information about circadian rhythm and 
arousal state. this information is relayed to motor neurons, which generate an output that 
drives the counterregulatory response and subsequently restores plasma glucose levels. 
conversely, glucose sensing may influence other neural processes that have no role in glucose 
counterregulatory function [49].
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 Although the VmH is only one of a number of regions involved in the detection of 
hypoglycemia, it is thought to be the most important. the VmH serves as the central rely 
station for signals from many other regions and plays a crucial role in the coordination of the 
counterregulatory responses to falling glucose levels. Animal studies have shown that both 
destruction of the VmH and local perfusion of the VmH with glucose, disrupt counterregulatory 
hormone responses to systemic hypoglycemia [50,51]. conversely, local glucopenia in the 
VmH stimulates these responses in the absence of hypoglycemia [52]. in analogy, glucose 
counterregulation was also found defective in a patient with lesions from sarcoidosis in the 
hypothalamus, presumably due to destruction of the glucose-sensing neurons in the VmH [53]. 
 the mechanism of glucose-sensing by the brain, in particular in the VmH, has not 
been fully clarified. two main types of glucose-sensing neurons have been identified: glucose-
excited neurons, whose activity increases as glucose levels rise, and glucose-inhibited 
neurons, which become more active as glucose levels fall and less active when they rise [54]. 
these neurons ‘sense’ a fall in glucose probably as a result of alterations in AtP/AdP and AmP/
AtP ratios, respectively, following a reduction in glucose metabolism. this could explain why 
fuelling the VmH with an alternative source of energy, such as lactate, suppresses glucose 
counterregulation [55,56]. the subsequent intracellular actions that may ultimately lead to 
a counterregulatory response probably involve activation of AmP-activated protein kinase, 
formation of nitric oxide and release of glutamate in glucose-inhibited neurons. other potential 
mediators involved in these responses include (a decrease in) gamma-aminobutyric acid 
(gABA) release from glucose-excited neurons, noradrenaline, serotonin and corticotrophin-
releasing hormone [57]. For further reading on this subject, we refer to recent reviews by 
mccrimmon [54] and chan and sherwin [57]. 
Cerebral gluCose delivery, uptake and metabolism
glucose is transported across the blood-brain barrier into extracellular fluid (ecF) by 
facilitated diffusion, mediated via glucose transporter protein 1 (gLut1) [58]. the predominant 
transporters involved in subsequent glucose uptake from the ecF in neurons and in astrocytes 
are gLut3 and gLut1, respectively [59], both insulin-independent glucose transporters. once 
intracellular, glucose is phosphorylated by hexokinase as the initial step of glucose metabolism. 
the glucose-6-phosphate (glc-6-P) thus produced can enter several metabolic pathways 
in the brain [60]. Following transport across the blood-brain barrier and phosphorylation by 
hexokinase, glucose is the main substrate for the production of energy (by formation of AtP) 
via glycolysis and the tricarboxylic acid (tcA) cycle (Figure 2.2).
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figure 2.2 A simplified illustration of the multiple metabolic pathways of glucose in the brain the initial 
step of glucose metabolism is phosphorylation of glucose to glucose-6-phosphate (glc-6-P) by hexokinase. 
glc-6-P can enter several metabolic pathways in the brain. it can be metabolized to produce energy via 
glycolysis or the tcA cycle. in addition, glc-6-P is a precursor for glycogen. Lastly, metabolism of glc-6-P 
via the pentose phosphate pathway provides pentose for nucleotide synthesis and nAdPH, required for 
reductive reactions, such as lipid synthesis and for protection against oxidative stress. Pyruvate can be 
converted into lactate or converted into acetyl-coA by pyruvate dehydrogenase. Acetyl-coA is used as 
carbon source for the tcA cycle. Abbreviations: LdH, lactate dehydrogenase; αKg, α-ketoglutarate; glu, 
glutamate; gln, glutamine; oAA, oxalo acetate
 in 1945, Kety and schmidt developed the first method to quantitatively assess brain 
glucose uptake in humans in vivo and to derive data on its subsequent metabolism [61]. this 
highly invasive technique required the use of arterial and internal jugular vein catheterizations 
to determine arteriovenous concentration differences for glucose, which together with 
measurement of global cerebral blood flow (cBF) were then used to calculate the global cerebral 
metabolic rate of glucose [62-64,61]. in humans, the Kety-schmidt method was used to show 
that brain glucose uptake falls during hypoglycemia and that this coincides with the appearance 
of counterregulatory hormone responses and autonomic warning symptoms [65,66]. However, 
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whether these data can be used to reliably assess brain glucose metabolism is a matter 
of debate. indeed, the calculations rely solely on the disappearance rate of glucose from the 
circulation. therefore, this technique cannot discriminate between specific metabolic steps and 
ignores the potential contribution of other metabolites. moreover, the highly invasive nature of 
the Kety-schmidt technique is a considerable limitation for research in humans. 
 the past forty years have shown rapid advances in modern metabolic and functional 
neuroimaging techniques to study brain (glucose) metabolism vis-à-vis cBF during hypoglycemia, 
including positron emission tomography (Pet), functional magnetic resonance imaging (fmri) and 
magnetic resonance spectroscopy (mrs). Pet can be used to measure emissions from a variety 
of radioactively labeled tracers in the brain to quantify cBF, glucose uptake and phosphorylation, 
oxygen consumption and the brain receptors for major neurotransmitters, depending on the type 
of radiotracer used. fmri is primarily used to study regional neuronal activation (patterns) by 
detection of changes in oxygen demand in the brain. mrs is a powerful technique to identify and 
quantify a large number of metabolites relevant for glucose metabolism (1H-mrs) or to study 
brain (glucose) metabolism (13c-mrs). it is important to note that the distribution of cBF and 
the cerebral metabolic rate of glucose (cmrglc) are closely linked to local brain activity. Brain 
activation causes proportionate increases in both local cBF and cmrglc. these processes are 
being referred to as neurovascular coupling or neurometabolic coupling, respectively, and 
hypothesized to be mediated by neurotransmitter release and vasoactive metabolic products 
[67]. many functional neuroimaging techniques, including fmri, rely on neurovascular coupling.
Cerebral nutrient transport CapaCity and hypoglyCemia
glucose uptake
As mentioned above, glucose uptake into the brain occurs through facilitated transport 
independent of insulin. As a consequence, there is a linear relationship between plasma 
glucose concentrations and brain glucose content over a range of plasma glucose values up 
to ~30 mmol/L [68-71]. this linear relationship also extends well into the hypoglycemic range, 
although data below plasma levels of ~2.5 mmol/L are missing in humans (Figure 2.3) [72]. 
to explain HAAF, it has been hypothesized that chronic or repeated hypoglycemia increases 
glucose transport capacity over the blood-brain barrier to compensate for the fall in glucose 
availability to the brain during subsequent hypoglycemia. indeed, several animal studies 
have shown that days to weeks of chronic hypoglycemia cause upregulation of brain glucose 
transporters, including both gLut1 on neuronal membranes [73,74], and gLut3 on the 
vascular endothelium at the blood-brain barrier [75,76]. in accordance, Boyle and co-workers 
applied the Kety-schmidt technique to show preservation of brain glucose transport rather 
than a fall during hypoglycemia in healthy volunteers after prior exposure to hypoglycemia, 
whereas it fell when such exposure had not taken place [65]. the investigators went on to 
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report similar findings of preserved glucose transport in patients with type 1 diabetes and 
near-normal glycosylated hemoglobin (HbA1c), possibly reflecting high hypoglycemic burden, 
as they also had reduced awareness of hypoglycemia [66].
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figure 2.3 Linear relationship between plasma and brain glucose levels under normo- and hypoglycemic 
conditions in healthy subjects (open squares) and patients with type 1 diabetes (closed circles). Brain 
glucose levels were measured with 13c-mrs. the plasma versus brain glucose relation was fitted with 
linear regression analysis to determine reversible michaelis-menten kinetics to show the best fit of the 
data with 95% confidence intervals. r2 = 0.59, P < 0.001. Assuming continuation of this linear relationship 
between plasma and brain glucose levels, brain glucose approaches zero at a plasma glucose level of 
approximately 1.2 mmol/L (from: [104], with permission from the American diabetes Association).
 in mice and in rats, very low plasma glucose values, typically well below 2.0 mmol/L, 
have been found to proportionally increase brain glucose uptake as a function of increased 
cerebral perfusion [70,77]. Various neuroimaging studies investigating glucose transport 
over the blood-brain barrier in humans have produced conflicting results. A 1H-mrs study 
performed under hyperglycemic conditions showed greater brain glucose concentrations in 
patients with type 1 diabetes and impaired awareness of hypoglycemia than in people without 
diabetes [78]. However, a similar study found no evidence of altered brain glucose transport in 
healthy volunteers subjected to antecedent repeated hypoglycemia, despite clearly attenuated 
hormone responses to hypoglycemia [79]. in accordance, global blood-to-brain glucose 
transport, as measured with [1-11c]-glucose Pet, remained unaltered in healthy volunteers 
after exposure to 24 hours of moderate hypoglycemia, albeit interspaced with transient glucose 
normalizations during meals [80]. Finally, a 3-omg-Pet study also showed no differences in 
global brain glucose transport during hypoglycemia between patients with normal and those 
with impaired awareness of hypoglycemia [81]. 
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monocarboxylic acid (mCa) uptake
Although glucose is its principal source of energy, the brain may resort to alternative non-
glucose fuel substrates under glucopenic conditions. these alternative substrates include 
foremost ketones, and lactate, which enter the tcA cycle after conversion to pyruvate or acetyl 
coenzyme A, and can be metabolized in a similar way as glucose to sustain brain metabolism, 
and spare glucose.
 Ketones such as beta-hydroxybutyrate and acetoacetate are synthesized in the liver 
from fatty acids during prolonged fasting, starvation and severe carbohydrate restriction. 
under such conditions, up to 60% of brain energy requirements may be derived from ketone 
metabolism [82], whereas ketogenic diets can more or less restore brain energy metabolism 
and prevent epileptic seizures in patients with gLut1 deficiency who are unable to transport 
glucose into the brain [83,84]. However, because insulin suppresses the production of ketones, 
the brain is usually unable to use this source of energy during insulin-induced hypoglycemia 
[85]. Pet studies with the use of both ketone and glucose tracers may help to unravel the 
complex interaction between the metabolism of ketones and glucose by the brain under 
different circumstances, including hypoglycemia [82].
 in recent years, it has gradually been recognized that lactate plays an important role in 
the energy metabolism in the brain, particularly during hypoglycemia since both hypoglycemia 
and insulin increase plasma levels of lactate, at least in healthy subjects [86-88]. under basal, 
euglycemic, conditions, the contribution of systemic lactate to cerebral energy metabolism 
is approximately 8-10%. However, the proportional contribution of lactate has been reported 
to increase during strenuous exercise, when plasma lactate levels rise substantially [89,90]. 
the role of lactate in specific areas of the brain includes its involvement in or interference 
with hypoglycemia detection in the VmH as stated above. Lactate has also been found to be a 
crucial monitored variable in the detection of energy imbalance in the caudal hindbrain [91]. 
the importance of lactate for the brain was first highlighted when Pellerin and magistretti 
published their astrocyte-neuron lactate shuttle (AnLs) hypothesis. this hypothesis posits 
that glucose is taken up by and metabolized in astrocytes to form lactate, after which lactate 
is exported to neighboring neurons where it is oxidized, especially during activation [92]. this 
concept, which bears analogy to the cell-cell lactate shuttle, through which skeletal muscle 
can transport a non-glucose energy source to other organs [93], thus suggests that astrocytes 
play the primary role in brain glucose metabolism. simpson et al. later came to a different 
conclusion and developed a model that basically adopts the opposite view, in which neurons 
are the principal site of glucose uptake and metabolism, and the chief exporter of lactate. 
this hypothesis was therefore termed the neuron-astrocyte lactate shuttle (nALs) [59] and 
fuelled a heavy debate [94,95]. the debate on the direction of the lactate shuttle is ongoing 
with studies identifying the neuron as the principal locus of glucose uptake [96], and other 
studies indicating that neurons rather than astrocytes are the primary sites for oxidation of 
exogenous lactate [97,89]. 
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 monocarboxylic acid transporters (mcts) facilitate the uptake of lactate as well as 
that of acetate and ketone bodies into the brain, the expression of which may increase following 
sustained hyperketonemia or recurrent hypoglycemia. A recent study in rats demonstrated a 
two-fold increase in the expression of mcts 1 and 2 in the cerebral cortex after the induction 
of diabetes by streptozotocin. After 8 weeks of frequent, prolonged endurance training and 
concomitant exposure to hypoglycemia after and between exercise sessions, the expression 
of both transporters increased even further [98]. such greater transport capacity may explain 
recent observations in which recurrent exposure to hypoglycemia increased the uptake of 
13c-labeled lactate into the rat brain under hypoglycemic conditions [99]. during hypoglycemia, 
the uptake of both acetate and lactate into the human brain, as measured by 13c-mrs during 
infusion of 13c-labeled acetate or lactate, respectively, was found to be considerably greater in 
patients with well-controlled type 1 diabetes than in healthy controls [100,101]. 
transport and uptake of other substrates
oral intake of amino acids has been reported to enhance the glucagon response to 
hypoglycemia and to improve some aspects of cognitive function during hypoglycemia in 
non-diabetic and diabetic subjects [102,103]. Amino acids might also serve as a non-glucose 
substrate that could be used by the brain as an alternative fuel and to sustain cognitive 
function during hypoglycemia. early studies showing utilization of amino acids by the rat 
brain during prolonged hypoglycemia and of amino acids contributing to glycogen synthesis in 
brain cell cultures supported this theory [104,105]. However, data obtained in humans using 
arteriovenous concentration differences found no evidence that greater availability of amino 
acids increased its net brain uptake during hypoglycemia [106] or was able to offset energy 
deficit due to reduced glucose supply [107]. 
 A few studies have investigated whether the human brain can use lipid substrates 
to support cerebral metabolism and brain function during hypoglycemia. Fatty acids can 
readily cross the blood-brain barrier to be oxidized by the brain, as demonstrated by a 13c-mrs 
study in rats [108]. in healthy humans, elevated plasma levels of non-esterified fatty acids 
and glycerol were found to reduce hormonal and symptom responses to hypoglycemia, but 
could not protect against the fall in cognitive function [109]. conversely, in a more recent study, 
ingestion of medium-chain triglycerides maintained cognitive function during hypoglycemia 
without affecting adrenergic or symptomatic responses to hypoglycemia in intensively treated 
subjects with type 1 diabetes [110]. it should be acknowledged, however, that the inferences 
made with respect to the uptake of lipid substrates in the brain were indirect and that no 
neuroimaging studies have been performed that evaluated the effects of these substances on 
cerebral metabolism more directly.
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brain metabolism during hypoglyCemia
glucose metabolism
Both Pet and mrs have been used to investigate the effect of hypoglycemia on brain glucose 
metabolism. Pet has been particularly useful in detecting regional differences in tracer 
accumulation in the brain, both during hypoglycemia [111], and after restoration to euglycemia 
[112]. However, rather than focusing on glucose uptake or metabolism, the close link with neuronal 
activation is then exploited to use the data as input factors for mapping regional brain activity. 
thus, the observation that cmrglc relatively increased during hypoglycemia in patients with type 
1 diabetes and normal awareness of hypoglycemia, and relatively fell in patients with impaired 
awareness of hypoglycemia, was interpreted as an increase in brain activation and absence of 
such a response [81]. When this increased activation would occur in brain areas involved in the 
perception of and the generation of responses to hypoglycemia, the lack of increased activation 
could then underlie loss of hypoglycemic awareness [81,113]. support for this hypothesis came 
from another Fdg-Pet study [114] and a subsequent analysis of these data [115], as tracer 
uptake in areas that engage appetite control and food-seeking behavior was reduced in patients 
with impaired compared to patients with intact awareness of hypoglycemia.
 13c-mrs in combination with infusion of 13c-labeled glucose has the unique property 
that it enables the investigation of cerebral glucose metabolism in humans in vivo. 13c-labeled 
glucose is taken up and metabolized by the brain similar to native (i.e. unlabeled) glucose. 
the fate of the 13c-labeled glucose can be followed with 13c-mrs, and can be used as input 
for a metabolic model to calculate tcA cycle flux and cmrglu. since the snr of 
13c-mrs is 
relatively low, most studies employing this technique used large doses of isotopically enriched 
glucose at high enrichment percentages. measurements have consequently generally been 
performed under hyperglycemic conditions with glucose levels up to 17 mmol/L and plasma 
13c-enrichment values exceeding 60%. under such conditions, Henry et al. [116] reported 
no differences in the tcA cycle rate between patients with type 1 diabetes with impaired 
awareness of hypoglycemia and healthy controls. more recently, an improved sensitivity of the 
13c-mrs method [117] in combination with an optimized 13c-glucose infusion protocol enabled 
us to study glucose metabolism in the human brain during hypoglycemia at lower enrichment 
values [118]. With this optimized technique, no differences were observed in cerebral glucose 
metabolism between hypoglycemia and euglycemia, neither in healthy controls [86], nor in 
patients with type 1 diabetes [119]. under hypoglycemic conditions, however, the tcA cycle 
rate was approximately 45% higher in patients than in healthy subjects, and inversely related 
to HbA1c. Appreciating a low HbA1c as a proxy for a high hypoglycemic burden, these data 
suggested a role for prior hypoglycemic exposure in the higher tcA cycle rate in patients 
with type 1 diabetes. differences in brain glucose levels did not explain the preservation of 
brain metabolism and the higher tcA cycle rate in the patients, which suggested influx of a 
non-glucose carbohydrate source [72]. in an animal study by Herzog et al. [99], brain glucose 
Chapter 2
42
transport capacity during hypoglycemia became rate limiting for tcA cycle activity in control 
animals, but not in rats exposed to antecedent recurrent hypoglycemia. explanations for the 
discrepancy between the human and rodent data include the different species and the fact that 
the hypoglycemic condition was more profound in the animals. indeed, studies in mice suggest 
that intracellular brain glucose concentrations approach depletion at plasma glucose values 
between 2 and 3 mmol/L [77].
glycogen metabolism
the brain is able to store glycogen and to use this compound when plasma glucose levels are 
low, although its capacity to do so is very limited compared to other tissues such as skeletal 
muscle and the liver. it was long assumed that this presence of glycogen was restricted to 
astrocytes. However, a recent study showed that neurons contain a low but measurable 
amount of glycogen, the use of which was found to protect against hypoxic stress, at least in 
neuronal cell cultures and animal models [120]. Both in rodents [121] and in humans [122], 
it was shown that brain glycogen was used during hypoglycemia, and that its stores were 
replenished above baseline levels after restoration of euglycemia, a phenomenon termed 
glycogen supercompensation. it has been speculated that this expanded source of glucose 
within the brain could contribute to the development of impaired awareness of hypoglycemia 
by fuelling the brain or at least those areas involved in glucose-sensing during subsequent 
hypoglycemia [121]. However, prior exposure to recurrent hypoglycemia neither facilitated nor 
impaired access to glucose from glycogen in the rat brain during subsequent hypoglycemia 
[123]. Additionally, brain glycogen content, as measured by 13c-mrs in conjunction with 
13c-glucose administration, was lower rather than higher in patients with type 1 diabetes and 
impaired awareness of hypoglycemia [124]. 
glutamate metabolism
glutamate is the major excitatory neurotransmitter in the brain, but has many other metabolic 
fates, including the formation of glutamine, gABA and glutathione [125]. in addition, a new 
concept has been introduced by sonnewald [126], who proposed that glutamate degradation 
in astrocytes contributes to most of the lactate that is released from the brain under resting 
conditions, offering a novel explanation for the concept of aerobic glycolysis in the resting state 
[126,127]. Lastly, glutamate can be oxidized for the production of energy [125]. to this end, 
glutamate production in the brain is tightly coupled to tcA cycle activity [128]. using 1H-mrs, 
Bischof et al. reported that hypoglycemia reduced the cerebral glutamate to creatine ratio in 
healthy controls, but not in patients with type 1 diabetes [129]. similar results were reported 
by a more recent 1H-mrs study, were hypoglycemia reduced brain glutamate levels in healthy 
controls and in patients with type 1 diabetes with normal hypoglycemic awareness, but not 
in patients with impaired awareness of hypoglycemia [130]. the authors concluded that the 
preservation of brain glutamate during hypoglycemia in the latter group reflected a metabolic 
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adaptation that eliminated the need to oxidize glutamate. they speculated that this adaptation 
could be augmented transport of glucose or of alternative fuels to the brain.
metabolism of monocarboxylic acids
As discussed earlier, mrs studies using 13c-labeled acetate and lactate have clearly suggested 
that the capacity to transport mcAs over the blood-brain barrier during hypoglycemia is 
increased in patients with well-controlled type 1 diabetes. indeed, a study during which 
13c-acetate was infused under hypoglycemic conditions showed more than twofold higher 
brain acetate concentrations in subjects with type 1 diabetes compared to healthy controls. 
this greater acetate availability translated into a fraction of oxidative metabolism that resulted 
from acetate to be similarly increased [100]. in accordance, the relative contribution of acetate 
to brain metabolism in rats exposed to recurrent antecedent hypoglycemia was also increased 
during next-day hypoglycemia, indicating that brain substrate preferences may change rapidly 
from glucose to alternative substrates if needed [131]. to delineate whether this effect was a 
function of diabetes, prior hypoglycemia or both, the investigators repeated their 13c-acetate 
study in patients with type 1 diabetes with normal or impaired awareness of hypoglycemia and 
in healthy controls. they found that absolute rates of acetate metabolism during hypoglycemia 
were only higher in the patients with impaired awareness of hypoglycemia, suggesting that 
changes in acetate metabolism are the consequence of prior exposure to hypoglycemia rather 
than of diabetes per se [132].
 Lactate uses the same mct as acetate to cross the blood-brain barrier. since plasma 
levels of lactate are approximately 10-fold higher than those of acetate, and hypoglycemia 
stimulates the production of lactate [87], lactate is the more likely substrate for brain 
metabolism when glucose levels are low. studies dating back to the 1990s have shown that 
exogenous administration of lactate attenuates counterregulatory responses to and preserves 
cognitive function during hypoglycemia, presumably because lactate is used as an alternative 
source of energy by the brain [133-136]. in agreement, brain lactate concentrations during 
hypoglycemia, derived from the cerebral uptake of 13c-labeled lactate, were several fold higher 
in patients with type 1 diabetes with a history of frequent hypoglycemic episodes than in non-
diabetic subjects [101] and in rats exposed to recurrent hypoglycemia versus those not exposed 
[99]. surprisingly, the authors found no indication of greater lactate oxidation, as reflected by 
unchanged 13c fractional enrichments of brain glutamate and glutamine [101]. data from the 
rodent study, in which lower glucose levels were achieved than in the human study, suggested 
that prior hypoglycemic exposure increased both the uptake and the oxidation of glucose by the 
brain, despite the higher lactate levels [99]. However, when the animal brain was stimulated 
during hypoglycemia, animals exposed to recurrent hypoglycemia had a partial loss of their 
functional cortical response, which was only normalized after the administration of lactate. 
this suggests that the higher capacity for lactate transport only becomes critical when the 
brain is activated during (deep) hypoglycemia.
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Cerebral blood flow and hypoglyCemia
there is uncertainty as to whether hypoglycemia affects global cBF and in what direction. 
Previous research in both patients with type 1 diabetes and healthy controls has reported either 
no change in global cBF during hypoglycemia [107,65,66], a modest increase [137-139], or even 
a slight decrease [111]. differences in the plasma glucose levels achieved during hypoglycemia 
and, more importantly, in imaging techniques probably explain many of the discrepancies. 
studies that investigated the effect of hypoglycemia on regional relative changes in cBF seem 
to have produced more consistent data. Both in healthy controls [137] and in patients with 
type 1 diabetes [140], hypoglycemia was found to increase blood flow to the frontal lobes. this 
relative redistribution of regional cBF was already observed under euglycemic conditions in 
patients with type 1 diabetes, and was more pronounced in patients who had experienced 
frequent hypoglycemia [141]. since the frontal lobes are among the most vulnerable brain 
areas to suffer structural damage, this may be an adaptive response to prevent such damage 
by maintaining fuel supply during subsequent hypoglycemia. 
 Hypoglycemia has also been found to increase cBF in the thalamus [111,142,143] 
and hypothalamus [144,145]. mild or moderate hypoglycemia caused a rise in cBF in the 
hypothalamus in healthy non-diabetic subjects, as assessed by fmri [144] or arterial spin 
labeling (AsL) mri [145], which preceded the rise in counterregulatory hormone responses 
seen during hypoglycemia [145]. interestingly, mangia et al. found blunting of this increase in 
thalamic perfusion during hypoglycemia in patients with type 1 diabetes with hypoglycemia 
unawareness, and a correlation between thalamic perfusion and the adrenaline response to 
hypoglycemia [143]. in contrast, recurrent hypoglycemia enhanced, rather than decreased, 
thalamic perfusion during subsequent hypoglycemia in healthy controls [146], so that the role 
of this brain region in the adaptation to hypoglycemia remains uncertain.
disCussion 
the scientific field of metabolic and functional neuroimaging techniques for the brain has 
tremendously progressed over the past couple of decades. the application of these techniques to 
hypoglycemia research has considerably advanced our understanding of the brain’s responses 
to hypoglycemia. As plasma glucose falls below levels that can be reversed by responses at 
the level of pancreatic islets, i.e. suppression of insulin release and stimulation of that of 
glucagon, the brain’s sensing abilities are activated to allow timely detection of hypoglycemia. 
data from functional and metabolic neuroimaging techniques now suggest that such moderate 
hypoglycemia neither affects the perfusion to nor the uptake of glucose into the brain, at 
least not globally, unless much deeper levels of glucose are achieved [70,77]. in accordance, 
cerebral glucose metabolism appears largely maintained during moderate hypoglycemia 
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[99,86,119]. However, on the regional level, moderate hypoglycemia causes redistribution of 
cBF to various brain areas involved in the detection of hypoglycemia, particularly the (hypo)
thalamus [111,142-145], where enhanced neuronal activation stimulates glucose uptake and 
metabolism. such enhanced neuronal activation has also been found to occur in brain areas 
involved in appetitive motivational networks [115], thus linking the detection of hypoglycemia 
to a behavioral response. 
 modern neuroimaging studies have revealed that recurrent hypoglycemia, which 
typically affects people with type 1 diabetes and underlies the clinical syndrome of impaired 
awareness of hypoglycemia, may initiate cerebral adaptations at many different levels. First, 
there is interference with the accurate detection of hypoglycemia, probably occurring at 
the level of the VmH. Brain areas that control appetite and induce fear and anxiety may not 
become activated during hypoglycemia. Whether or not locally increased glucose uptake in or 
reduced neuronal activation of the hypothalamic area (or both) form the underlying mechanism 
remains to be revealed. importantly, it should be acknowledged that neurovascular coupling 
may be altered as a consequence of diabetes per se [147], chronic hyperglycemia [148] or 
microangiopathy [149], thus limiting the interpretation of studies relying on this concept. there 
is conflicting evidence as to whether recurrent hypoglycemia can stimulate brain glucose uptake 
during hypoglycemia [65,66], although most studies employing neuroimaging techniques found 
no evidence for this suggestion [79-81]. nevertheless, patients with type 1 diabetes, particularly 
those with impaired awareness of hypoglycemia [130], seem better able in maintaining brain 
(glucose) metabolism during hypoglycemia than healthy controls [86,119,129,130], probably as 
a consequence of prior hypoglycemia [119]. since profound hypoglycemia will eventually cause 
brain glucose metabolism to deteriorate [99], such an adaptation may shift the threshold for 
deterioration of the metabolic rate to lower plasma glucose levels. 
 several mechanisms have been proposed that could explain the discrepancy between 
hypoglycemia-induced preservation of cerebral glucose metabolism and the fall in glucose 
availability during hypoglycemia. it seems likely that influx of a non-glucose energy substrate 
plays a role. recent (neuroimaging) studies found little evidence to support enhanced blood to 
brain transport of amino acids [106,107] or lipid substrates transport [109,110] and ketones 
are unlikely candidates because its production is suppressed by insulin. Also, the lower brain 
glycogen content in patients with type 1 diabetes with impaired awareness of hypoglycemia 
compared to controls [124] argues strongly against the glycogen supercompensation 
hypothesis. several arguments suggest a major role for lactate in preserving brain glucose 
metabolism during hypoglycemia. these include: 1. lactate can be used by the brain and may 
even be preferred over glucose under non-hypoglycemic conditions [150,151]; 2. the capacity 
for lactate transport over the blood-brain barrier is increased in patients with impaired 
awareness of hypoglycemia and in rats after exposure to hypoglycemia [100,99]; 3. the use 
of lactate by glucose-sensing neurons in the VmH may interfere with hypoglycemia sensing 
[54,56,57]. However, there are data that suggest that lactate is not used as major energy 
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source for the brain during moderate hypoglycemia, despite greater availability [101,99]. Also, 
it is not yet known whether brain uptake or metabolism of endogenously produced lactate is 
increased during hypoglycemia in patients with type 1 diabetes and impaired awareness of 
hypoglycemia. Finally, it has been suggested that lactate may serve as a metabolic regulator 
or intercellular signaling molecule rather than a fuel, modulating brain glucose metabolism, 
oxygen delivery and cBF [152,153]. mechanisms by which lactate might exert this effect [154] 
include modulation of prostaglandin action (and thus cBF) [155,153], adjustment of the nAdH/
nAd+ redox ratio [93], and the regulation of neuronal cAmP formation via the lactate receptor 
g-protein-coupled receptor 81 (gPr81)[156]. 
ConClusion
Hypoglycemia is the principal barrier for achieving optimal, let alone normal, glycemic control 
for indefinite periods of time in patients with type 1 diabetes and advanced insulin-requiring type 
2 diabetes [157]. recurrent hypoglycemia forms the basis of HAAF and the clinical syndrome of 
impaired awareness of hypoglycemia by attenuating physiological defenses against subsequent 
hypoglycemia, consequently increasing the risk for severe hypoglycemia. Paradoxically, the 
mechanism(s) underlying these glucose counterregulatory impairments may be related to, or 
even caused by, processes that are seemingly aimed at protecting the brain against harm from 
severe hypoglycemia. the progress in metabolic and functional neuroimaging techniques has 
revealed that recurrent hypoglycemia causes cerebral adaptations to occur on many different 
levels. these adaptations include those in the regional delivery (blood flow) and transport of 
glucose to the brain, the handling of glucose by the brain and that of non-glucose alternative 
fuels, as well as activation or de-activation of brain areas involved in behavioral responses. it 
remains to be elucidated whether, and if so under which circumstances and in which brain 
areas, the brain uses non-glucose alternative sources of energy, particularly lactate, and 
whether this contributes to the emergence of impaired awareness of hypoglycemia. such 
information is needed first to foster personalized decision-making with respect to glycemic 
targets, but should eventually lead to treatments that eliminate hypoglycemia from the lives of 
people with type 1 diabetes without compromising glucose control. 
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abstraCt 
object: J-difference editing is often used to select resonances of compounds with coupled spins 
in 1H-mr spectra. Accurate phase and frequency alignment prior to subtracting J-difference-
edited mr spectra is important to avoid artefactual contributions to the edited resonance. 
material and methods: in vivo J-difference-edited mr spectra were aligned by maximizing the 
normalized scalar product between two spectra (i.e., the correlation over a spectral region). the 
performance of our correlation method was compared with alignment by spectral registration 
and by alignment of the highest point in two spectra. the correlation method was tested at 
different snr levels and for a broad range of phase and frequency shifts
results: in vivo application of the proposed correlation method showed reduced subtraction 
errors and increased fit reliability in difference spectra as compared with conventional peak 
alignment. the correlation method and the spectral registration method generally performed 
equally well. However, better alignment using the correlation method was obtained for spectra 
with a low snr (down to ~2) and for relatively large frequency shifts.
conclusion: our correlation method for simultaneously phase and frequency alignment is 
able to correct both small and large phase and frequency drifts and also performs well at low 
snr levels.
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introduCtion
Because of a limited chemical shift range and a high number of proton-containing metabolites, 
a typical in vivo 1H-mr spectrum of the brain contains many overlapping peaks. this complicates 
the assignment and quantification of specific metabolite signals that (partly) co-resonate with 
signals of other metabolites. selection of resonances by J-difference editing is widely used 
to overcome this problem for J-coupled spin systems [1-3]. J-difference editing involves the 
consecutive acquisition of two spectra in which frequency-selective radiofrequency (rF) pulses 
are alternatively switched on and off on one resonance of the coupled spin-system. For doublet 
resonances the echo time (te) is set to the reciprocal of the J-coupling constant of the spins of 
interest (te = 1/J), and for triplet resonances to te=1/2J [3]. due to the frequency-selective rF 
pulse, the evolution of the J-coupling of the spin system is refocused, whereas the J-coupling 
evolves throughout the echo time when the selective rF pulses are switched off or placed 
off-resonance. the so-called ‘on’ and ‘off’ spectra are subtracted to eliminate all unaffected 
resonances, leaving only those of the selectively refocused coupled spins for quantification.
 small phase and/or frequency differences between the ‘on’ and ‘off’ spectra will occur 
due to system instabilities between the two acquisitions (e.g., by B0 drift or subject movement) 
or caused by the selective inversion rF pulses. if uncorrected, these shifts result in artifacts 
and subtraction-errors in the difference spectra that may affect the appearance and, thus, the 
quantification of the edited resonances. correction is commonly performed by alignment using 
a large peak in the spectrum as a reference before averaging or subtracting (e.g., in [4,5]), or 
by consecutive phase alignment by a least-squares algorithm and frequency alignment by a 
cross-correlation algorithm (e.g., in [6,7]). Furthermore, the ‘on’ and ‘off’ spectra are often 
separately aligned (e.g., in [8,9]), which may leave residual intensity in the difference spectra 
and therefore hampers quantification of the edited peaks. recently, near et al. presented an 
alignment method, referred to as ‘spectral registration’, in which frequency and phase drifts in 
mrs data were corrected simultaneously in the time domain [10]. their algorithm minimizes 
the difference between the first part of a free induction decay (Fid) with varying phase and 
frequency terms, and a reference Fid.
 We propose a new correction method for simultaneous phase and frequency alignment 
in the frequency domain, which is applicable to a complete dataset comprising both the ‘on’ 
and ‘off’ spectra. our alignment method makes use of the scalar product of spectra (i.e., the 
correlation over a spectral region) to express how closely they are aligned. it aims for alignment 
of a relative large spectral region, excluding the part where the frequency selective rF pulses are 
placed and excluding the water signal and signal free regions. the performance of the method is 
tested at different snr levels and for a broad range of phase and frequency shifts. the method 
is demonstrated for the in vivo J-difference editing of the methyl resonance of lactate and the 
methylene resonance of γ-aminobutyric acid (gABA) at 3.0 ppm in the human brain. 
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materials and methods
the proposed correlation method was developed as part of a study in which brain lactate levels 
were determined [11]. As such, the method has been extensively tested on J-difference-edited 
spectra of brain lactate. the evaluation and noise simulation of the alignment procedures of 
spectra were performed in matlab (matlab 2016a, the mathWorks inc.).
alignment by the correlation method
in the correlation method the first recorded spectrum in a series was chosen as the reference 
spectrum (sref), to which all other spectra of the dataset (sn) were aligned. the scalar product 
of sref with sn was calculated with varying phase shifts (∆φ) and simultaneously varying 
frequency shifts (∆f) of sn, where the scalar product of two complex vectors a = [a1…an] and 
b=[b1…bn] was defined as as a·b =∑
n
i=1aibi. only the spectral region marginally affected by the 
frequency-selective inversion pulses was used in the alignment algorithm. the optimal phase 
and frequency shifts was be found by maximizing the normalized scalar product [c(∆φ,∆f )] 
between both spectra (eq. 3.1).
c(∆φ,∆f)=
re(sn(f+∆f)e
-i∆φ·sref)
||sref||  ||sn(f+∆f)e
i∆φ ||
      (3.1) 
mrs protocol for J-difference editing of lactate
the study involving lactate editing included 13 healthy volunteers (six males, age: 26.2 ± 5.5 
years) and informed consent was obtained from all participants. mrs measurements were 
performed at 3.0 t (tim mAgnetom trio; siemens, erlangen, germany), using a 12-channel 
head coil for signal reception. A t1-weighted anatomical image (mPrAge; 256 x 256 mm
2 
field of view, 256 slices, 1 mm3 voxels) was acquired for voxel localization.
 Brain lactate was measured from a 22.5-25.0 cm3 voxel located in the periventricular 
and supraventricular region with an interleaved J-difference editing [12] semi-LAser 
spectroscopy sequence [13] with an echo time (te) of 144 ms, a repetition time (tr) of 3000 
ms, an acquisition time (tA) of 1:42 min (two dummy scans and 32 averages) and a bandwidth 
of 1200 Hz (spectral resolution: 1200 Hz/1024=1.17 Hz). J-difference editing was performed 
with frequency selective inversion pulses (megA) with a bandwidth of 75 Hz and a duration 
of 30 ms, centered on the lactate quartet at 4.1 ppm (resulting in the ‘on spectrum’). in 
the second acquisition, the frequency selective inversion pulses were centered at -1.5 ppm 
(resulting in the ‘off spectrum’). ‘on’ and ‘off’ spectra were acquired in blocks of 32 averages. 
three to five ‘on’ and ‘off’ spectra were acquired per subject, resulting in a total number of 
59 ‘on’ and ‘off’ spectra. 
 All spectra were first zero-filled from 1024 to 2048 data points and a Fourier 
transform was applied. subsequently, spectra were aligned with the method described 
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above. the performance of our correlation method was compared with alignment by spectral 
registration (part of the open source mAtLAB based software toolkit Fid-A [10,14]), which 
was applied over the same frequency range (i.e., from 1.6 to 3.4 ppm), and by frequency 
alignment of the highest point in sn with the highest point in sref. the latter is equivalent to the 
automatic alignment function in jmrui [15]. Also, difference spectra were obtained without 
prior alignment. All difference spectra were apodized with a 5 Hz Lorentzian.
 As an estimate of the quality of the alignment, the integral of the absolute intensity 
of the difference spectrum between 1.6 and 3.4 ppm (ɛalignment) was calculated per difference 
spectrum for each alignment strategy.
 the three or five difference spectra per subject were averaged to increase the signal-
to-noise ratio for quantification. the lactate doublet in the averaged difference spectra were 
fitted with the AmAres algorithm in jmrui. As a measure of the precision of the fit of the 
lactate doublet, the coefficient of variation (coV) of the fit was calculated by dividing the standard 
deviation of the amplitude by the amplitude. Fits with a coV >30% were discarded. 
 to asses differences between alignment strategies, AnoVA followed by Bonferroni 
post hoc tests were performed on the coV’s. A p value less than 0.05 was considered 
statistically significant.
mrs protocol for the J-difference editing of gaba
in addition, we applied the correlation method to J-difference-edited spectra of gABA 
optimized for detection of the gABA signal at 3.0 ppm. spectra were acquired from a healthy 
volunteer from an 8 cm3 voxel with a megA-Press sequence (tr = 1500 ms; te = 68 ms; 
128 averages; spectral width = 1200 Hz) at 3.0 t (tim mAgnetom trio; siemens, erlangen, 
germany). the frequency-selective refocusing pulses, with a bandwidth of 50 Hz, were 
placed at 1.9 ppm (‘on’ spectrum) and subsequently at 7.5 ppm (‘off’ spectrum). spectra 
were zero-filled from 512 to 1024 data points. ‘on’ and ‘off’ spectra were aligned using the 
correlation method over the spectral region from 2.8 to 4.1 ppm. Furthermore, to evaluate 
the performance of the correlation method on spectra with both upright and inverted peaks, 
alignment was performed on two gABA difference spectra. these spectra were acquired by 
subtracting the ‘on’ and ‘off’ spectra using manufacturer-specific software. A frequency shift 
of 6 Hz and a phase shift of 15° was applied to one of the spectra (sn), prior to alignment. 
Alignment of these spectra with the correlation method was performed over the spectral 
region from 0.5 to 4.2 ppm.
effect of noise
one ‘off’ spectrum from the J-difference-edited lactate spectra was used to evaluate the 
performance of the proposed correlation method at different snr levels. this spectrum 
(sref) was zero-filled to 4096 points and duplicated to create a spectrum which has to be 
aligned (sn). normally distributed random noise was added to sref and sn separately to 
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generate spectra with an snr of 30, 10, 3, 2 and 1.5. snr was defined as the maximum of 
the amplitude of the nAA-peak divided by the standard deviation of the noise. A frequency 
drift (applied in the time domain, from -30 to 30 Hz in 2 Hz steps) and a phase drift (-20° 
to 20° in 2.5° steps) was applied on each average of sn. For each snr value this procedure 
was repeated 25 times. Frequency and phase drift correction was performed on s n using the 
correlation method as well as spectral registration. only the spectral region from 1.6 to 3.4 
ppm was used in both alignment methods. the performance of the two alignment methods 
was evaluated by calculating the phase estimation error and frequency estimation error, 
defined as the absolute difference between the true phase or frequency drift and estimated 
phase or frequency drift.
results
For all J-difference-edited lactate spectra, a clear maximum of the normalized scalar product 
was found for a certain phase and frequency shift. the mean (±sd) normalized scalar product 
between sref and sn after aligning the spectra with our alignment method (correlation method) 
was 0.95 ± 0.08. the snr of an in vivo spectrum of 32 averages was approximately 90.
 typical difference spectra of one volunteer, depicting the lactate doublet at 1.3 ppm, 
obtained without alignment, alignment with the highest peak (HP) method, alignment using 
spectral registration and alignment with the correlation method are shown in Figure 3.1. 
Without prior alignment or when spectra were aligned with the HP method, large subtraction 
errors are present, especially at the spectral regions around nAA (2.0 ppm), creatine (cre; 
3.0 ppm) and choline (cho; 3.2 ppm). these subtraction errors are greatly reduced when 
spectral registration or the correlation method was used for aligning the ‘on’ and ‘off’ spectra, 
as confirmed by a lower ɛalignment (no alignment: 76.0 ± 38.8; HP method: 67.9 ± 36.9; spectral 
registration: 38.2 ± 6.4; correlation method: 39.2 ± 6.6).
 the lactate doublet at 1.3 ppm in the final averaged difference spectra was fitted 
reliably in all difference spectra acquired with spectral registration and with the correlation 
method (i.e., coV < 30%), whereas the lactate doublet could not be fitted reliably in one 
difference spectrum acquired without prior alignment and in two difference spectra aligned 
with the HP method. the precision of the lactate doublet fit increased after aligning the spectra 
using spectral registration and by using the correlation method, as shown by a decreased 
coV of the fit (mean coV ± sd: 19.43 ± 4.56, 16.84 ± 2.89, 15.60 ± 3.06 and 15.60 ± 3.02% for 
no alignment, HP method, spectral registration and correlation method respectively; p < 0.05 
correlation method vs. no alignment and spectral registration vs. no alignment; Figure 3.2).
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Correlation
method
Highest Peak
method
No alignment
Spectral
Registration
figure 3.1 Averaged difference spectra. An example of difference spectra, obtained without aligning the 
‘on’ and ‘off’ J-difference-edited lactate spectra before subtraction (bottom), by aligning the highest peak in 
both spectra (third row), by aligning with spectral registration (second row) and by our correlation method 
i.e., maximizing the normalized scalar product between the ‘on’ and ‘off’ spectra (top row). the lactate 
doublet in the final difference spectra at 1.3 ppm is indicated. subtraction errors are present around the 
choline (3.2 ppm; cho), creatine (3.0 ppm; cre) and nAA (2.0 ppm) frequencies (indicated with dashed lines) 
when no alignment protocol or the highest peak method is used, but are greatly reduced after alignment 
with spectral registration and after aligning with our correlation method
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figure 3.2 Assessment of alignment quality. the coefficient of variation (coV) of the fit of the lactate doublet 
at 1.3 ppm was calculated per averaged difference spectrum for each alignment strategy. no alignment, 
highest peak method, spectral registration and the correlation method are compared. *p < 0.05
A. ‘On’ and ‘o’ spectra 
3.0 2.0 1.0 ppm0.04.0
3.0 2.0 1.0 ppm0.04.0 3.0 2.0 1.0 ppm0.04.0
3.0 2.0 1.0 ppm0.04.0
Before alignment
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GABA+GluGABAGlx MM
GABA+GluGABAGlx MM
B. Dierence spectra
figure 3.3 Alignment of J-difference-edited gABA spectra before and after subtraction. A: gABA ‘on’ 
(red) and ‘off’ (blue) spectrum before alignment (top row) and after alignment with the correlation method 
(bottom row). B: top row: two typical gABA difference spectra before alignment (sref in red and sn in blue). 
A frequency shift of 6 Hz and a phase shift of 15 degrees was applied to sn. Bottom row: sref and sn after 
alignment with the correlation method. cre, creatine; glx, glutamate and glutamine; cho, choline; nAA, 
n-acetylaspartate; gABA, g-aminobutyric acid; mm, macromolecular resonances
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 the performance of the correlation method was tested on in vivo J-difference-edited 
gABA spectra (Figure 3.3A). Visual inspections shows that alignment of the ‘on’ and ‘off’ spectra 
works properly. Also, alignment of gABA-edited difference spectra (Figure 3.3B), comprising 
both inverted and upright peaks, is successful using the correlation method. 
 upon comparison of the performance of the correlation method and spectral 
registration for alignment of spectra with increasing noise, the phase estimation errors were 
comparable for both methods (Figure 3.4 and table 3.1). For both methods the phase estimation 
error increases with decreasing snr and phase estimation appears to be not accurate for an 
snr below 3. the correlation method can accurately estimate the frequency drift throughout 
the whole frequency drift range, which is not the case for the spectral registration method 
(Figure 3.5). For larger frequency shift (e.g. >20 Hz for an snr of 10) the spectral registration 
technique does not align the correct peaks (Figure 3.6). As such, the frequency estimation error 
was calculated for both methods only over the frequency range in which spectral registration 
worked properly (table 3.2). in this range, the frequency estimation error is comparable for 
both alignment method until an snr of 3. For an snr below 3, the frequency estimation error 
is smaller for the correlation method compared with spectral registration.
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figure 3.4 Phase drift estimation. Actual and estimated phase drift, obtained by the correlation method 
(top row) and by spectral registration (bottom row), at five different snr levels (snr of 30, 10, 3, 2 and 1.5) 
over 25 repetitions
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table 3.1: Phase estimation error (degree)
snr 30 snr 10 snr 3 snr 2 snr 1.5
Correlation method 0.26 ± 0.20 3.39 ± 2.66 11.21 ± 8.09 15.20 ± 11.54 21.25 ± 15.64
Spectral registration 0.48 ± 0.36 3.05 ± 2.30 11.17 ± 8.58 17.41 ± 12.78 24.48 ± 18.21
Absolute difference between the true phase drift and estimated phase drift. data are mean ± sd
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figure 3.5 Frequency drift estimation. Actual and estimated frequency drift, obtained by the correlation 
method (top row) and by spectral registration (bottom row), at five different snr levels (snr of 30, 10, 3, 2 
and 1.5) over 25 repetitions
table 3.2: Frequency estimation error (Hz)
snr 30 snr 10 snr 3 snr 2 snr 1.5
Correlation method 0.12 ± 0.0 0.25 ± 0.19 0.78 ± 0.62 1.29 ± 0.97 4.00 ± 7.41
Spectral registration 0.03 ± 0.02 0.29 ± 0.91 0.91 ± 0.79 2.15 ± 1.82 n/a 
Absolute difference between the true frequency drift and estimated frequency drift, calculated over the 
frequency rang in which spectral registration works properly (see Figure 3.5). data are mean ± sd
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figure 3.6 Alignment of spectra with a frequency shift of 10 Hz and 20 Hz. top row: example of two spectra 
(sref in red and sn in blue) with an snr of 10 before alignment. A frequency shift of 10 Hz (A) and 20 Hz (B) 
was applied on sn . middle row: sref (red) and sn (blue) after alignment using the correlation method. spectra 
are accurately aligned for both frequency shifts. Bottom row: sref and sn after alignment using spectral 
registration. Alignment is successful for a frequency shift of 10 Hz. For a frequency shift of 20 Hz, spectral 
registration erroneously aligns the choline peak in sn with the creatine peak at 3.0 ppm in s ref
disCussion
Here we present a simple and robust method for simultaneous phase and frequency alignment of 
in vivo J-difference-edited mr spectra. Proper alignment reduces subtraction errors and increases 
the precisions of the fit of the metabolite signal of interest. this is especially of importance when 
the signal of interest is small, e.g., in the case of cerebral lactate, which is normally present at 
a tissue concentration of about 0.5 mm [16]. Also for reliable quantification of other compounds 
such as gABA, of which the resonances overlap significantly with large resonances of other 
metabolites, proper alignment of J-difference-edited spectra is important.
 We compared our alignment method against a more conventional method in which 
the highest peaks in two spectra are aligned [15] and with spectral registration [10]. the limited 
spectral resolution of our dataset might have resulted in a slight underperformance of the highest 
peak method. the performance of the spectral registration method regarding subtraction errors 
Chapter 3
70
and the precision of the fit of the lactate doublet, is comparable with the correlation method. 
However, our correlation method, appears to be more robust for correcting relatively large 
frequency drifts (i.e. > 20 Hz). if such large frequency drifts are present, spectral registration may 
erroneously align for example the choline peak (at 3.2 ppm) with the creatine peak (at 3.0 ppm), as 
the frequency difference between these resonances is slightly more than 20 Hz at 3 t. this does 
not occur when using the correlation method. Furthermore, at lower snr levels, frequency drifts 
(but not phase drifts) are corrected more accurately using the correlation method compared with 
spectral registration. Also, as described by near et al., spectral registration may not be suitable 
for correcting a phase drift, if the first point of the Fid of the signal is close to zero. this may 
be the case when the net intensity of the spectrum is close to zero due to the presence of both 
positive and negative peaks, as in, for example, gABA-edited difference spectra. We showed that 
the correlation method is capable of properly aligning such spectra. 
 Various other alignment strategies have been previously described, based on prior peak 
fitting or modeling of a singlet peak such as those from nAA [17] or cre [4,18], or based on 
principal component analysis (PcA) [5,19]. the latter has been demonstrated to be very robust, 
but is usually also applied on a predefined single resonance peak. these methods are therefore 
not directly applicable when such a reference peak is not present, for example in spectra obtained 
from tumors or in X-nuclei mr spectra. our alignment algorithm is model-free and uses a broad 
spectral range. this makes our method very easy to be implemented, independent of distortions 
or of a poor snr, and it does not require the presence of a distinct reference peak. 
 As the correlation method works in the frequency domain, the frequency estimation 
error is computationally limited by the vector size of the spectrum. As such, the minimal 
frequency estimation error which can be obtained is approximately equal to half of the spectral 
resolution. this is not the case for spectral registration, where the frequency estimation error can 
be (in theory) equal to zero. However, this limitation of the correlation method can be overcome 
by zero-filling. Another constraint is that the spectral region used for the grid search in the 
correlation method, should be only marginally affected by the frequency-selective rF pulses, to 
warrant spectral similarity. model-based alignment methods may not suffer from this limitation. 
With regard to these two constraints, our proposed alignment method may also be valuable for 
aligning conventional non-edited mr spectra, e.g., for a time series prior to averaging.
ConClusion
We demonstrated that maximizing the normalized scalar product between two spectra (i.e., 
the correlation over a spectral region) is a robust method for spectral alignment, an essential 
procedure prior to spectral subtraction in J-difference-edited mrs. the presented correlation 
method corrects both small and large phase and frequency drifts accurate and performs well 
at an snr down to approximately 2. 
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abstraCt 
Brain lactate may be involved in the development of impaired awareness of hypoglycemia 
(iAH), a condition that affects approximately 25% of patients with type 1 diabetes and increases 
the risk of severe hypoglycemia. the aim of this study was to investigate the effect of acute 
hypoglycemia on brain lactate concentration in patients with iAH, as compared to those with 
normal awareness of hypoglycemia (nAH) and healthy control subjects (n = 7 per group). After 
an overnight fast, all subjects underwent a two-step hyperinsulinemic euglycemic (5.0 mmol/
L)-hypoglycemic (2.8 mmol/L) glucose clamp. Brain lactate concentrations were measured 
continuously with 1H-mrs using a specific lactate detection method. Hypoglycemia generated 
symptoms in patients with nAH and healthy control subjects but not in patients with iAH. Brain 
lactate fell significantly by ~20% in response to hypoglycemia in type 1 diabetes patients with 
iAH but remained stable in both healthy control subjects and in patients with nAH. the fall in 
brain lactate is compatible with increased brain lactate oxidation providing an alternative fuel 
source during hypoglycemia, which may contribute to impaired detection of hypoglycemia.
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introduCtion
Approximately 25% of patients with type 1 diabetes have lost the capacity to timely detect 
hypoglycemia, a condition referred to as impaired awareness of hypoglycemia (iAH) [1]. iAH 
increases the risk for severe, potentially hazardous hypoglycemia up to sixfold [2] and is usually 
the end-result of a process of habituation to recurrent hypoglycemia [1]. 
Although the precise mechanisms underlying iAH remain to be revealed, there may be a pivotal 
role for alteration in the brain’s handling of energy substrates other than glucose [3]. indeed, 
using 13c-mrs, we found that brain metabolism was largely preserved during hypoglycemia 
in both subjects without diabetes and subjects with type 1 diabetes, despite a similar fall in 
brain glucose availability [4-6]. these observations indicate that metabolism of a non-glucose 
carbohydrate energy source may be involved. 
 several observations suggest that this non-glucose energy source is lactate. Lactate 
is a valuable energy source for the brain during euglycemia [7-9] and may be critical to maintain 
brain function during severe hypoglycemia [10]. Administration of lactate during hypoglycemia 
impairs hypoglycemic symptoms, attenuates counterregulatory hormone responses, and 
preserves cognitive function, mirroring the changes seen in subjects with iAH [11,12]. Finally, 
brain lactate transport capacity through monocarboxylic acid transporters was found to be 
increased during hypoglycemia in patients with iAH [13,14].
 the brain of patients with type 1 diabetes and iAH may have been conditioned to 
use lactate under glucopenic conditions to maintain brain function, thereby simultaneously 
impairing hypoglycemia sensing. We therefore hypothesized that brain lactate levels would 
fall during hypoglycemia in people with type 1 diabetes and iAH. to test this hypothesis, we 
measured brain lactate under hypoglycemic conditions with a dedicated 1H-mrs method 
optimized for lactate detection [15]. 
researCh design and methods
subjects
We recruited seven patients with type 1 diabetes and iAH, seven patients with normal awareness 
of hypoglycemia (nAH) and seven healthy subjects without diabetes. Awareness state was based 
on the dutch modified version of the cox questionnaire, where scores of 0-1 out of 5 indicate 
normal awareness and scores ≥3 indicate impaired awareness [16,17]. Patients were eligible if 
they had an HbA1c <9.0% (75 mmol/mol) and were free from microvascular complications, except 
for background retinopathy. exclusion criteria were contraindications for mri examinations, 
a history of brain injury or cardiovascular events, and the use of drugs other than insulin 
interfering with glucose metabolism. the institutional review board of the radboud university 
medical center approved the study, and all subjects gave written informed consent. 
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hyperinsulinemic glucose clamps
All participants presented at 8:00 Am after an overnight fast having abstained from caffeine, 
alcohol and smoking for 24 h and from strenuous exercise for 3 days. subjects with diabetes 
were instructed to adjust their basal insulin dose the evening before the clamp to prevent 
nocturnal hypoglycemia and to omit their morning prandial insulin dose. the brachial artery 
of the non-dominant arm was cannulated under local anesthesia for frequent blood sampling. 
An intravenous catheter was inserted into the antecubital vein of the contralateral arm 
to administer glucose 20% (Baxter, deerfeld, iL) and insulin (insulin aspart; novo nordisk, 
Bagsvaerd, denmark). After cannulation and baseline measurements, the subjects were 
positioned in the mr scanner and a hyperinsulinemic (60 mu/m2/min) two-step euglycemic 
(5.0 mmol/L)-hypoglycemic (2.8 mmol/L) glucose clamp was initiated. during the clamp, 
arterial plasma glucose and lactate levels were determined every 5 minutes (Biosen c-Line, 
eKF diagnostics, cardiff, uK). counterregulatory hormone and insulin levels were determined 
at the end of each glycemic phase. insulin levels were also measured at baseline. subjects 
completed an 18-item semiquantitative symptom questionnaire just prior to initiating the 
glucose clamp and at the end of the hypoglycemic phase, in which symptoms were scored 
from 0 (none) to 6 (severe). 
analytical methods
Plasma insulin was assessed by an in-house radioimmunoassay (riA) [18]. Plasma adrenaline 
and noradrenaline was measured by high performance liquid chromatography combined with 
fluorometric detection [19]. 
mrs protocol
mr measurements were performed at 3t (tim mAgnetom trio; siemens, erlangen, germany) 
using a 12-channel receive-only head coil. First, an anatomical image was acquired (t1-
weighted mPrAge; 256x256 mm² field of view, 256 slices, 1 mm³ isotropic voxels). subsequently, 
1H-mrs data were acquired from a 25 cm3 voxel (Figure 4.1A), in data blocks consisting of two 
consecutive acquisitions to determine tissue concentrations of brain lactate and of the other 
major brain metabolites, respectively. Brain lactate concentrations were determined using an 
interleaved J-editing semi-LAser sequence [20] optimized for lactate detection [15] (echo time 
(te) 144 ms; repetition time (tr) 3000 ms; 32 averages; total duration of acquisition (tA) 1.40 
min). J-editing was performed with megA pulses with a bandwidth of 75 Hz. spectra with 
a shorter te with water suppression were acquired to determine the tissue concentrations 
of other major brain metabolites (sLAser, te 30 ms, tr 3000 ms and 32 averages, tA 1.40 
min). Lastly, spectra were acquired without water suppression used for quantification of the 
metabolite concentrations (te 30 ms, tr 5000 ms, 8 averages). 
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analysis of mrs data
After zero-fi lling (from 1024 to 2048 points) and Fourier transformation, all J-edited spectra 
from each subject were phase and frequency aligned with the fi rst spectrum recorded by 
maximizing the scalar product between this so-called reference spectrum and the other 
spectra. difference spectra were apodized with a 5-Hz Lorentzian function, and moving 
averaging with a sliding window of three scans was performed. in the fi nal difference spectra, 
the lactate doublet was fi tted with the AmAres algorithm in jmrui [21]. 
 the spectra acquired with a te of 30 ms were analyzed with the Lcmodel software 
to quantify the other major brain metabolites, including total n-acetylaspartate, total choline, 
total creatine, myo-inositol, aspartate, glutamine, glutamate, scyllo-inositol, and taurine. only 
metabolites with a cramér-rao lower bound <20% were considered to be reliably quantifi ed 
and included in further analyses [22]. All metabolite concentrations were calculated taking 
voxel composition (determined by segmenting the t1-weigthed anatomical images using 
sPm8) and differences in t2 relaxation of metabolite spins into account. 
statistical analysis
Within-group differences were compared with two-sided student t tests. Between-group 
differences were analyzed by AnoVA followed by pairwise Bonferroni post hoc tests between 
all groups. All data are expressed as mean ± sem unless otherwise indicated. A P value < 0.05 
was considered statistically signifi cant. statistical analyses were performed with iBm sPss 
statistics 20.
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figure 4.1 representative mr data from one healthy subject. A: t1-weighted anatomical image with 
typical location of the voxel  (2.0x5.0x2.5 cm) for the acquisition of the mrs data B: megA off, megA on 
and difference spectra of one subject. J-editing was performed with megA-pulses centered on the lactate 
quartet at 4.1 ppm (megA on) and subsequently at -3 ppm (megA off). As a consequence, the lactate 
doublet at 1.3 ppm is inverted in the megA off spectrum and upright in the megA on spectrum. subtracting 
the megA on spectrum from the megA off spectrum results in the difference spectrum, which contains 
only the positive lactate doublet, removing the signals from all other metabolites in the spectrum. c: mr 
sp ectrum recorded with a te of 30 ms. mi, myo-inositol; tcre, total creatine; tcho, total choline; tnAA, total 
n-acetylaspartate; glu, glutamate; Lac, lactate.
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results
the groups were well matched for relevant parameters (table 4.1). Baseline plasma glucose 
values were elevated to similar extent in both diabetes groups (Figure 4.2A). during the clamp, 
plasma glucose levels (mean ± sd) were sequentially clamped at 5.0 ± 0.1 and 2.8 ± 0.1 mmol/L 
without differences between the groups. insulin levels were also comparable during the clamps 
(data not shown).
table 4.1: subject characteristics
t1dm iah 
(n = 7)
t1dm nah 
(n = 7)
healthy subjects 
(n = 7)
Age, years 24.7 ± 8.1 26.2 ± 5.8 27.6 ± 6.9
Sex, M/F 3/4 4/3 3/4
BMI, kg/m2 23.4 ± 1.3 24.7 ± 2.9 23.5 ± 1.7
HbA1c ,% (mmol/mol) 7.5 ± 0.6 (58.7 ± 6.3) 7.3 ± 0.4 (56.6 ± 3.8) -
Duration of diabetes, years 10.0 (2.5, 17.5) 10.0 (6.0, 14.0) -
Score Cox questionnaire (range) 3.7 ± 0.8 (3-5) 0.4 ± 0.5 (0-1) -
data are presented as number, means ± sd or median and interquartile range. F, female; m, male; t1dm, 
type 1 diabetes mellitus.
 Hypoglycemic symptom scores increased significantly in response to hypoglycemia in 
both healthy volunteers and in patients with nAH but not in patients with iAH (mean increase 
2.0 ± 0.9, 12.9 ± 3.9 and 17.4 ± 3.7 for patients with iAH, patients with nAH and healthy control 
subjects, respectively). Adrenaline responses to hypoglycemia were lower in patients with 
diabetes than in healthy volunteers (P < 0.05), particularly those with iAH, although the difference 
between the two patient groups was not statistically significant (P = 0.88) (supplementarty 
table s4.1).
 Baseline plasma lactate levels were similar across the three groups, but time courses 
during the clamp were different (Figure 4.2B). during the hypoglycemic phase of the clamp, 
mean plasma lactate levels were significantly higher in healthy subjects than in subjects with 
diabetes (P < 0.01).
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figure 4.2 time courses of plasma glucose (A) and plasma lactate (B). the dashed lines represent the 
beginning of the euglycemic phase, the end of the euglycemic phase, and the beginning of the hypoglycemic 
phase, respectively. Baseline values represent the sample obtained upon arrival at the research facility. 
Black triangles: patients with type 1 diabetes (t1dm) and iAH; black squares: patients with t1dm and nAH; 
open circles: healthy subjects.
 in one patient with nAH, the 1H-mr spectral quality was insufficient for analysis 
because of head movement during data acquisition. the J-edited difference spectra of all other 
subjects showed a clear lactate doublet at 1.3 ppm (Figure 4.1B). the mr voxel contained 65.5 
± 2.9% white matter, 31.2 ± 2.8% gray matter and 3.2 ± 0.5% cerebral spinal fluid, with no 
differences between groups (data not shown). 
 Brain lactate concentration dropped from 0.52 ± 0.02 to 0.41 ± 0.02 µmol/g wet weight 
(ww) in response to hypoglycemia in patients with iAH (P < 0.001), corresponding with a fall of 
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~20% (Figure 4.3). in contrast, brain lactate concentrations remained stable during euglycemia 
and hypoglycemia in both healthy subjects (0.49 ± 0.02 versus 0.46 ± 0.01 µmol/g ww, P = 0.12) 
and patients with nAH (0.46 ± 0.03 versus 0.45 ± 0.03 µmol/g ww, P = 0.73). there were no 
differences between groups in absolute brain lactate concentrations during euglycemia (P = 
0.17) or during hypoglycemia (P = 0.36). 
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figure 4.3 Hypoglycemia-induced changes in brain lactate. mean (with sem) group differences (horizontal 
bars) and individual changes (black squares) between average euglycemic and hypoglycemic brain lactate 
concentrations (percent change from euglycemic value) are depicted. *P < 0.001 for euglycemia vs. 
hypoglycemia and †P < 0.05 vs. t1dm nAH and healthy subjects.
 1H-mr spectra without editing and with a te of 30 ms (Figure 4.1c) revealed a 
significant drop in brain glutamate concentrations in response to hypoglycemia in healthy 
subjects (from 6.0 ± 0.3 to 5.7 ± 0.3 µmol/g ww P < 0.01), but not in patients with nAH (6.6 ± 0.3 
versus 6.4 ± 0.3 µmol/g ww, P = 0.13) or in patients with iAH (7.3 ± 0.3 versus 7.1 ± 0.3 µmol/g 
ww, P = 0.11). there were no significant changes in response to hypoglycemia regarding other 
major brain metabolites.
disCussion
the major finding of this study is that brain lactate concentrations decrease by ~20% in response 
to hypoglycemia in patients with type 1 diabetes and iAH but not in patients with nAH or in healthy 
control subjects. this finding suggests that adaptations in cerebral lactate handling are involved in 
the etiology of iAH. 
 A recent 1H-mrs study also reported decreased brain lactate concentrations in response 
to hypoglycemia, albeit this change was only significant in patients with diabetes and normal 
adrenaline responses to hypoglycemia [23]. However, the mr methods in that study were focused 
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on glutamate detection, and patients were stratified according to the observed adrenaline response 
to hypoglycemia rather than according to the awareness of hypoglycemic symptoms.
 A change in brain lactate concentration reflects a change in the balance between uptake, 
export, production (through glycolysis), and oxidation of cerebral lactate [24]. the hypoglycemia-
induced reduction in brain lactate in patients with iAH most likely resulted from increased lactate 
oxidation as an adaptation to recurrent exposure to hypoglycemia to preserve brain metabolism 
when glucose supply is low. our observation that plasma lactate levels fell in the iAH group argues 
against increased brain lactate export. Furthermore, it is unlikely that the lower brain lactate levels 
were the result of decreased cerebral lactate uptake, given that plasma lactate levels fell to similar 
extent in both patient groups and that lactate transport capacity is reported to be increased in 
patients with iAH [14]. We cannot completely exclude that the fall in lactate reflected a decrease in 
glycolysis due to reduced neuronal activation [25]. 
 in a recent 13c-mrs study, de Feyter et al. [13] showed that the human brain oxidizes 
13c-labeled lactate that was infused during hypoglycemia. somewhat surprisingly, they found no 
differences in lactate oxidation between patients with diabetes and healthy control subjects, despite 
a higher calculated brain lactate concentration in the patients with diabetes, which seems at odds 
with our findings. However, inherit to their study design, infusion of 13c-lactate may have resulted 
in greater brain lactate availability. therefore, the physiological context (blood lactate levels and its 
source, pH, etc.) may be different, which renders comparison with our data difficult.
 the strengths of our study include the ability to detect and quantify brain lactate 
concentrations in vivo in humans in a direct and optimized manner without the use of exogenous 
lactate and the three distinctly different groups of subjects, which enabled us to differentiate 
between the impacts of diabetes and iAH. Although mr spectra were recorded continuously, 
1H-mrs does not provide information about lactate fluxes or consumption, which is a limitation of 
our study. 
 in conclusion, we found that brain lactate concentration dropped in response to acute 
hypoglycemia in patients with type 1 diabetes and iAH but not in the other two groups. the fall in 
brain lactate is compatible with increased brain lactate oxidation during hypoglycemia in patients 
with iAH, and hence, the need for glucose by the brain and the consequent initiation of hypoglycemic 
symptoms are suppressed. together our findings indicate that changes in brain lactate levels play 
an important role in the pathophysiology of iAH. 
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table s4.1 counterregulatory hormone levels
t1dm iah t1dm nah healthy subjects
Euglycemia Hypoglycemia Euglycemia Hypoglycemia Euglycemia Hypoglycemia
Glucagon 
(pmol/L)
9.57 ± 2.61 22.71 ± 8.24† 11.29 ± 1.52 16.14 ± 1.82† 9.57 ± 1.45 58.43 ± 11.09*
Adrenaline 
(nmol/L)
0.30 ± 0.07 1.50 ± 0.25* 0.39 ± 0.05 2.18 ± 0.50* 0.22 ± 0.05 2.89 ± 0.52*
Noradrenaline 
(nmol/L)
1.29 ± 0.14 1.48 ± 0.18 1.01 ± 0.13 1.43 ± 0.14* 1.08 ± 0.11 1.60 ± 0.17*
Cortisol 
(µmol/L)
0.44 ± 0.10 0.62 ± 0.09* 0.54 ± 0.11 0.69 ± 0.12* 0.38 ± 0.06 0.64 ± 0.07*
hGH 
(mU/L)
3.80 ± 2.47 73.97 ± 11.62* 10.35 ± 6.01 55.97 ± 10.96* 2.64 ± 1.47 51.36 ± 4.86*
data is presented as mean±sem. *P < 0.05 for euglycemia versus hypoglycemia and †P < 0.05 versus 
healthy subjects
Plasma glucagon was measured by riA, with a commercially available kit (eurodiagnostica, 
malmö, sweden). Plasma growth hormone and cortisol were determined using a routine 
analysis method with an electrochemiluminescent immunoassay on a modular Analytics e170 
(roche diagnostics, gmbH, manheim, germany). Plasma adrenaline and noradrenaline were 
measured by HPLc combined with fluorometric detection [1]. 
reference 1. Willemsen JJ, ross HA, Jacobs mc, Lenders JW, thien t, swinkels Lm, Benraad tJ: Highly 
sensitive and specific HPLc with fluorometric detection for determination of plasma epinephrine and 
norepinephrine applied to kinetic studies in humans. clin chem 1995;41:1455-1460
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abstraCt 
since altered brain lactate handling has been implicated in the development of impaired 
awareness of hypoglycemia (iAH) in type 1 diabetes, the capacity to transport lactate into the brain 
during hypoglycemia may be relevant in its pathogenesis. High-intensity interval training (Hiit) 
increases plasma lactate levels. We compared the effect of Hiit-induced hyperlacticacidemia 
on brain lactate during hypoglycemia between 1) patients with type 1 diabetes and iAH, 2) 
patients with type 1 diabetes and normal awareness of hypoglycemia (nAH), and 3) healthy 
participants without diabetes (n = 6 per group). All participants underwent a hypoglycemic (2.8 
mmol/L) clamp after performing a bout of Hiit on a cycle ergometer. Before Hiit (baseline) 
and during hypoglycemia, brain lactate levels were determined continuously with J-difference 
editing 1H-mrs, and time curves were analyzed using nonlinear mixed effects modeling. At the 
beginning of hypoglycemia (after Hiit), brain lactate levels were elevated in all groups but most 
pronounced in patients with iAH. during hypoglycemia, brain lactate decreased ~30% below 
baseline in patients with iAH but returned to baseline levels and remained there in the other 
two groups. our results support the concept of enhanced lactate transport as well as increased 
lactate oxidation in patients with type 1 diabetes and iAH. 
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introduCtion
impaired awareness of hypoglycemia (iAH) affects 25-30% of patients with type 1 diabetes, is 
characterized by the suppression of symptoms during hypoglycemia [1,2] and considerably 
increases the risk for severe hypoglycemia [1]. iAH results from habituation to prior hypoglycemia 
[3], but the underlying mediators have yet to be fully revealed. 
 one likely mediator is brain lactate [4-6]. We have previously shown that brain lactate 
levels fall in response to hypoglycemia in patients with type 1 diabetes and iAH, whereas 
lactate levels remain unaltered in patients with normal awareness of hypoglycemia (nAH) and 
in healthy participants [6]. this fall in brain lactate likely reflects increased cerebral lactate 
oxidation, which may preserve brain metabolism and interferes with the brain’s capacity to 
detect hypoglycemia. 
 this concept is supported by the finding that intravenous administration of lactate has 
brain glucose-sparing effects under euglycemic conditions [7], suppresses counterregulatory 
hormone and symptom responses to hypoglycemia, and preserves cognitive function [8,9]. We 
observed similar, albeit less pronounced, effects when plasma lactate levels were endogenously 
raised during hypoglycemia after a bout of high-intensity interval training (Hiit) in patients with 
type 1 diabetes and nAH [10].
 using isotopically enriched lactate infusions, de Feyter et al. [5] observed increased 
brain lactate concentrations during hypoglycemia in patients with iAH compared with 
volunteers without diabetes but no increase in cerebral lactate oxidation. this finding contrasts 
with observations that endogenous hyperlacticacidemia after exercise enhances both brain 
lactate uptake [7,11,12] and oxidation [7,13,14], at least under euglycemic conditions. the 
effect of endogenously elevated plasma lactate levels on brain lactate concentrations during 
hypoglycemia is currently not known. therefore, we used a single bout of Hiit to raise endogenous 
plasma lactate levels, and used 1H-mrs to assess cerebral lactate levels during subsequent 
hypoglycemia in patients with type 1 diabetes with and without iAH, and healthy participants.
researCh design and methods
participants
We enrolled six patients with type 1 diabetes and iAH, six patients with type 1 diabetes and 
nAH and six healthy participants. Patient assignment was initially based on the dutch modified 
version of the cox questionnaire [15], but one patient initially classified as having iAH switched 
groups because of intact hormonal and symptomatic responses to hypoglycemia. Patients with 
type 1 diabetes were excluded from participation if their HbA1c levels exceeded 75 mmol/mol 
(9.0%) or if they had microvascular complications, except for background retinopathy. other 
exclusion criteria were as follows: age >40 years, Bmi >30 kg/m2, cardiopulmonary disease, 
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contraindications for mri examination, and a history of brain injury. the study was approved 
by the institutional review board of the radboud university medical center and all participants 
gave written informed consent. 
study protocol
All participants presented in the morning (8:00 Am) after an overnight fast, having abstained 
from caffeine, alcohol and smoking for 24 h and from strenuous exercise for 2 days. Patients 
with type 1 diabetes were instructed to check their plasma glucose levels regularly in the 24 
h before the experimental day to prevent hypoglycemia and to omit their morning prandial 
insulin dose. An intravenous catheter was inserted in the antecubital vein to administer insulin 
(insulin aspart; novo nordisk, Bagsvaerd, denmark) and glucose 20% (Baxter, deerfield, 
iL). the brachial artery of the contralateral arm was cannulated under local anesthesia for 
frequent blood sampling to determine plasma glucose and plasma lactate levels every 5 
minutes (Biosen c-line; eKF diagnostics).
 After cannulations, a hyperinsulinemic (60 mu/m2/min)-euglycemic (5.0 mmol/L) 
glucose clamp was initiated, and baseline magnetic resonance (mr) measurements were 
acquired. Participants were subsequently taken out of the scanner and performed a Hiit 
session on a cycle ergometer, consisting of three 30-s all-out sprints interspersed with 4 min 
of active recovery, as described previously (10). After the Hiit session, participants were placed 
in the mr scanner at the earliest opportunity, and meanwhile plasma glucose levels were 
gradually decreased to 2.8 mmol/L and maintained there for 50-60 minutes.
 Before the Hiit session and at the end of hypoglycemia, participants completed an 
18-item questionnaire in which hypoglycemic symptoms were scored from 0 (none) to 6 (most 
severe), and blood samples were drawn to determine counterregulatory hormone responses 
and insulin levels (see Figure 5.1A for a schematic overview of the study protocol).
mrs protocol and data analysis
mr data were acquired using a 3t mr system (tim magnetom trio; siemens, erlangen, germany). 
each mr session, i.e., at baseline and post-exercise, started with the acquisition of an anatomical 
image (t1-weighted mPrAge, 256 x 256 mm² field of view, 256 slices) for voxel localization and 
for later voxel content determination. the 20 x 45 x 25 mm voxel was placed in the periventricular 
region of the brain (Figure 5.2A). during both mr sessions, brain lactate levels were determined 
continuously with a time resolution of ~4 minutes, using a J-difference editing megA-semi-LAser 
sequence (te 144 ms, tr 3000 ms and 32 averages), as described previously [6]. 
 the J-difference-edited spectra were zero-filled from 1024 to 2048 points and Fourier 
transformed. thereafter, spectra were phase and frequency aligned [16], subtracted pairwise, 
and apodized in the time domain with a 5-Hz Lorentzian. A three-point moving average filter over 
time was applied. the lactate doublets at 1.3 ppm in the final difference spectra were fitted with the 
AmAres algorithm in jmrui [17]. cerebral lactate was quantified using the unsuppressed water 
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signal as a reference, taking voxel composition, differences in t2 relaxation, and the contribution 
of plasma lactate into account, assuming a vessel volume in the (mainly white matter voxel) of 2% 
[18]. Baseline cerebral lactate levels (before Hiit) were averaged; cerebral lactate levels acquired 
after Hiit were analyzed over time.
analytical methods
Plasma insulin was determined by an in-house radioimmunoassay (riA) [19] and plasma 
glucagon by a commercially available riA (eurdiagnostica, malmö, sweden). Plasma adrenaline 
and noradrenaline were analyzed by high-performance liquid chromatography combined with 
fluorometric detection [20]. 
statistical analysis
Within-group differences were compared with two-sided student t tests or Wilcoxon signed 
rank test for nonparametric data, and between-group differences with AnoVA followed 
by Bonferroni post hoc tests or with the Kruskal-Wallis test and post hoc mann-Whitney u 
tests. the change in brain lactate from baseline to the start of hypoglycemia (∆LacstartHypo), the 
difference in steady state lactate levels between hypoglycemia and baseline (∆LacPlateau) and the 
decay rate (k) were estimated per group using a nonlinear mixed effects (nLme) model. the 
following exponential decay function was fitted to the data:
Lac(t)=(∆LacstartHypo-∆LacPlateau)e
-kt+∆LacPlateau     (5.1)
differences in model parameters (i.e., ∆LacstartHypo, ∆LacPlateau and k) were compared between 
groups and within groups. All data are expressed as mean ± sd, unless otherwise stated. P 
< 0.05 was considered statistically significant. statistical analyses were performed in sAs 9.2 
(nLmiXed procedure) or with iBm sPss statistics 20. 
results
the study participants were well matched for relevant parameters (table 5.1). upon arrival, 
plasma glucose levels were elevated to a similar extent in both patient groups (7.9 ± 3.1, 9.5 ± 
2.2 mmol/L for type 1 diabetes and iAH and type 1 diabetes and nAH, respectively). insulin levels 
at baseline and during hypoglycemia did not differ between groups (data not shown). during the 
clamp, plasma glucose levels were maintained at 5.1 ± 0.1 mmol/L and 2.8 ± 0.1 mmol/L, without 
differences between study groups (Figure 5.1B). Plasma lactate levels for the three groups were 
comparable at baseline and increased markedly and to a similar extent in response to Hiit. during 
hypoglycemia, plasma lactate fell gradually but remained above baseline levels (Figure 5.1c).
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table 5.1 Participant characteristics
t1dm iah t1dm nah healthy subjects
Age (years) 23.5 ± 6.1 21.5 ± 2.5 23.8 ± 3.0
Sex (male/female) 3/3 3/3 3/3
BMI (kg/m2) 22.8 ± 1.2 22.7 ± 2.4 23.5 ± 1.6
Duration of diabetes (years) 12.0 ± 8.8 10.2 ± 4.8 
HbA1c  (mmol/mol [%]) 51.7 ± 10.0 [6.9 ± 0.91] 60.7 ± 8.1 [7.7 ± 0.74]
Self reported exercise (h/week) 4.9 ± 3.0 4.8 ± 3.1 3.3 ± 2.0
data are presented as number or mean ± sd. t1dm, type 1 diabetes
 As expected, total symptom scores did not change in response to hypoglycemia in 
patients with iAH (mean increase: 0.67 ± 1.26) but increased considerably in patients with nAH 
and in healthy participants (14.83 ± 3.61 and 10.83 ± 2.06, respectively). the plasma adrenaline 
response to hypoglycemia was reduced in patients with iAH compared to patients with nAH 
and healthy participants (supplementary table s5.1). 
 Baseline brain lactate levels were similar across the three groups (Figure 5.3). the 
first mr spectra were acquired on average 38.5 ± 5.5 minutes after the Hiit session, when 
plasma glucose levels were <3.6 mmol/L. Figure 5.2B shows a typical example of difference 
spectra with the evolution of the lactate doublet over time. According to the nLme model, 
brain lactate levels at the beginning of hypoglycemia were elevated compared with baseline 
levels (∆LacstartHypo in eq. 5.1) by 0.20 ± 0.05 µmol/g (P = 0.01) in patients with iAH, by 0.11 ± 
0.05 µmol/g (P = 0.03) in patients with nAH, and by 0.06 ± 0.02 µmol/g (P = 0.01) in healthy 
participants. the increase in brain lactate after Hiit was higher in patients with iAH compared 
with healthy participants (P = 0.04). during hypoglycemia, brain lactate levels returned to and 
remained at baseline levels in patients with nAH and healthy participants (0.00 ± 0.04 and 
-0.07 ± 0.04 µmol/g), whereas a further -0.20 ± 0.06 µmol/g decrease below baseline (P = 0.02; 
Figure 5.3) was observed in type 1 diabetes and iAH during hypoglycemia (∆Lacplateau in eq. 
5.1). there was no difference in the estimated exponential decay rate of brain lactate between 
groups (P = 0.52). 
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figure 5.1 study protocol and plasma glucose and plasma lactate levels. A: schematic overview of the 
study protocol. mrs measurements were performed prior to Hiit (baseline) and during hypoglycemia. 
counterregulatory hormone responses and hypoglycemic symptom score were assessed prior to the Hiit 
session and at the end of hypoglycemia. time courses of (B) plasma glucose and (c) plasma lactate levels. 
the Hiit session is indicated by the gray area. the dashed lines represent the beginning and the end of the 
hypoglycemic phase. Black triangles, patients with type 1 diabetes (t1dm) and iAH; black squares, patients 
with t1dm and nAH; open circles, healthy participants.
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figure 5.2 example of difference spectra. A: typical location of the mrs voxel, indicated by the white 
rectangles (20x45x25 mm) on a t1-weighted anatomical image of one subject with type 1 diabetes and iAH. 
B: representative difference spectra (i.e., megA on – megA off) of one subject with type 1 diabetes and iAH, 
depicting the lactate doublet at 1.3 ppm over time. the baseline difference spectra was recorded before 
Hiit. After Hiit, hypoglycemia was induced and brain lactate concentrations were measured continuously.
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figure 5.3 Brain lactate levels. mean cerebral lactate levels before (baseline) and after Hiit during 
hypoglycemia. For illustration purpose only, mean (± sem) brain lactate levels after the Hiit training were 
calculated on a 4-min time interval grid (±sd). dashed lines represent the nLme model fit. open circles, 
patients with type 1 diabetes (t1dm) and iAH; open triangles, patients with t1dm and nAH; open squares, 
healthy participants.
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disCussion
the current study shows that endogenously raised plasma lactate levels by a single bout 
of Hiit results in increased brain lactate concentrations at the start of hypoglycemia. this 
increase is most pronounced in patients with iAH, and this was the only group where brain 
lactate levels decreased below baseline values at the end of the hypoglycemic episode. these 
findings support altered brain lactate handling in iAH. 
 the Hiit-induced increase in brain lactate content is in line with previous studies 
using 1H-mrs in healthy participants in response to endogenously raised plasma lactate levels 
by vigorous exercise, albeit under euglycemic conditions [11,12]. cerebral lactate uptake is 
driven by a concentration gradient from blood to brain. interestingly, although plasma lactate 
levels were similar between groups, we found that the increase in brain lactate concentrations 
after Hiit was most pronounced in patients with type 1 diabetes and iAH, which supports 
enhanced brain lactate transport capacity in patients with iAH [21,22]. this difference is most 
visible at the beginning of hypoglycemia, when plasma lactate levels are highest. 
 during hypoglycemia, we showed that brain lactate levels returned to baseline values 
in healthy volunteers and patients with nAH but dropped to levels below baseline in patients 
with iAH, which could not be explained by differences in plasma lactate levels between the 
study groups. this decrease matches the hypoglycemia-induced fall in brain lactate in patients 
with iAH we observed in a previous study, in which plasma lactate levels were not elevated 
[6], and may reflect enhanced brain lactate oxidation. Previous studies have found that lactate 
contributes substantially to cerebral energy metabolism, when its availability is high [23-25,7]. 
increased lactate oxidation may protect the brain by maintaining metabolism when glucose 
supply is low, while at the same time it could impede the brain’s capacity for hypoglycemia 
sensing. this is in line with the observation that a prior bout of Hiit attenuated awareness of 
and cognitive deterioration during subsequent hypoglycemia, particularly in patients with nAH 
[10], which may have been mediated by brain lactate.
 Hiit not only increases plasma lactate levels, but has also an impact on (stress) 
hormones, brain activation and physical parameters, which may have influenced our results. 
Because the Hiit session was performed outside the mr system, we were unable to capture 
early changes in brain lactate after exercise. Brain lactate levels may have been higher in 
the time gap between Hiit and the post-Hiit scans. All participants were young, healthy, and 
fit, which should be kept in mind when interpreting the results. A strength of our study is 
the inclusion of three clinically distinct, but well-matched, groups of participants, allowing to 
differentiate between the effect of type 1 diabetes and the effect of iAH. Furthermore, plasma 
glucose and lactate levels were almost identical among the groups.
 in conclusion, we found that brain lactate concentrations increase after a bout of 
Hiit, particularly in patients with diabetes and iAH. in addition, brain lactate levels fall below 
baseline during the subsequent hypoglycemic period in patients with iAH but not in those 
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with nAH or in healthy participants. these results support upregulation of lactate transport 
capacity and increased cerebral lactate oxidation during hypoglycemia in patients with iAH. 
Both adaptations in cerebral lactate handling may contribute to iAH by lactate serving as an 
alternative non-glucose fuel for the brain during hypoglycemia.
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supplementary data
table s5.1 Hypoglycemia-induced changes in symptom scores and counterregulatory hormones
t1dm iah t1dm nah healthy subjects
Total symptom score 0.67 ± 1.26 14.83 ± 3.61*# 10.83 ± 2.06*#
Adrenaline (nmol/L) 0.60 ± 0.11* 2.81 ± 1.22*# 2.47 ± 0.33*#
Noradrenaline (nmol/L) 0.41 ± 0.17 0.71 ± 0.34 0.26 ± 0.08
Glucagon (pmol/L) -1.70 ± 1.00 2.68 ± 1.43 29.02 ± 7.28*# +
data are presented as mean ± sem. *P < 0.05 euglycemia vs. hypoglycemia; #P < 0.05 vs. t1dm iAH; 
+P < 0.05 vs. t1dm nAH
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abstraCt 
Administration of lactate during hypoglycemia suppresses symptoms and counterregulatory 
responses, as seen in patients with type 1 diabetes and impaired awareness of hypoglycemia 
(iAH), presumably because lactate can substitute for glucose as a brain fuel. Here, we examined 
whether lactate administration, in a dose sufficient to impair awareness of hypoglycemia, affects 
brain lactate levels in patients with normal awareness of hypoglycemia (nAH). Patients with nAH 
(n = 6) underwent two euglycemic-hypoglycemic clamps (2.8 mmol/L), once with sodium lactate 
infusion (nAH w|lac) and once with saline infusion (nAH w|placebo). results were compared 
to those obtained during lactate administration in patients with iAH (n = 7) (iAH w|lac). Brain 
lactate levels were determined continuously with J-difference editing 1H-mrs. during lactate 
infusion, symptom and adrenaline responses to hypoglycemia were considerably suppressed 
in nAH. infusion of lactate increased brain lactate levels modestly, but comparably, in both 
groups (mean increase in nAH w|lac: 0.12 ± 0.05 µmol/g and in iAH w|lac: 0.06 ± 0.04 µmol/g). 
the modest increase in brain lactate may suggest that the excess of lactate is immediately 
metabolized by the brain, which in turn may explain the suppressive effects of lactate on 
awareness of hypoglycemia observed in patients with nAH. 
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introduCtion
Hypoglycemia is the most frequent side-effect of insulin therapy in patients with type 1 
diabetes. When blood glucose levels drop, this normally initiates a hierarchically organized 
counterregulatory response, which includes release of counterregulatory hormones and the 
appearance of hypoglycemic symptoms. it has been demonstrated that the administration of 
lactate considerably diminishes symptomatic and hormonal responses to hypoglycemia and 
simultaneously mitigates cognitive dysfunction during hypoglycemia [1-3]. these effects are 
suggested to be the result of lactate acting as an alternative fuel for the brain, when glucose 
supply is low [2]. clinically, the administration of lactate mimics the situation seen in patients 
with type 1 diabetes and impaired awareness of hypoglycemia (iAH). in iAH, the threshold for 
the onset of hypoglycemic symptoms and counterregulatory hormone responses is shifted to 
lower glucose values, which substantially increases the risk for severe hypoglycemia [4]. 
 most studies that investigated the effects of lactate administration during hypoglycemia 
have focused on clinical effects (i.e., symptoms, hormonal responses and cognitive function), 
and did not examine physiological changes in the brain. Whether elevated plasma lactate levels 
lead to an accumulation of lactate in the brain is subject of debate. in a 13c-mr study, performed 
under euglycemic conditions in non-diabetic subjects, it was calculated that brain lactate levels 
and lactate oxidation increased almost linearly with the increase in plasma lactate levels [5]. in 
contrast, other studies have reported direct oxidation of lactate after its transport across the 
blood-brain barrier, with limited accumulation in the brain [6,7]. thus, lactate oxidation may 
even spare glucose as a cerebral fuel under euglycemic conditions [8].
 the only study that has investigated the effect of exogenous lactate on human brain 
lactate concentrations during hypoglycemia, calculated increased brain lactate concentrations 
without increased oxidation, in patients with type 1 diabetes compared to healthy volunteers 
[9]. such elevated brain lactate levels are in line with studies that demonstrated an enhanced 
capacity to transport lactate into the brain in patients with diabetes and iAH [10,11]. the lack of 
a euglycemic control and a placebo arm (i.e., no lactate infusion) precluded conclusions about 
lactate accumulation during euglycemia versus hypoglycemia, or about the effect of lactate 
infusion on awareness of hypoglycemia. 
 in the current study, we aimed to show that infusion of lactate, in a dose sufficient to 
impair awareness of hypoglycemia in patients with type 1 diabetes and normal awareness of 
hypoglycemia (nAH), increases brain lactate levels. secondly, we aimed to compare the effect 
of lactate administration on brain lactate levels during euglycemia and hypoglycemia between 
patients with nAH and those with iAH. 
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material and methods
participants
We enrolled seven patients with type 1 diabetes and nAH and seven patients with type 1 diabetes 
and iAH. the classification of awareness state was based on the dutch modified version of 
the cox questionnaire [12,13]. Patients with type 1 diabetes were eligible if they were younger 
than 50 years, had an HbA1c below 9.0% (75 mmol/mol) and were free from microvascular 
complications, except for background retinopathy. exclusion criteria included contraindications 
to the mri examination, a history of brain injury, epilepsy, liver or cardiovascular diseases, 
anxiety disorders, and the use of drugs other than insulin interfering with glucose metabolism. 
one participant with nAH moved too much during data acquisition, which hampered mr 
data quality and was consequently excluded from data analysis. the study was approved by 
and studied in accordance with the ethical standards of the institutional review board of the 
radboud university medical center (commissie mensgebonden onderzoek Arnhem-nijmegen) 
and with the Helsinki declaration of 1975/1983. All participants gave written informed consent. 
study protocol
Patients with nAH underwent two hyperinsulinemic euglycemic-hypoglycemic clamp studies, 
once with sodium lactate infusion (nAH w|lac) and once with saline infusion (nAH w|placebo), as 
described below. experiments were carried out in a single-blind fashion (i.e., participants were 
blinded for the infusions) and in randomized order, scheduled at least two weeks apart. in female 
participants, both experiments were performed during equal phases of the menstrual cycle. 
Patient with iAH participated only in the sodium lactate infusion study arm (iAH w|lac). 
 Participants came to the research facility in the morning after an overnight fast, 
having abstained from smoking, alcohol and caffeine containing substances for 24 hours prior 
to the experiment, and from strenuous exercise for at least two days before the experiment. 
in addition, participants were instructed to prevent hypoglycemia and to check their blood 
glucose levels regularly in the 24 hours before the experiment.
 the brachial artery of the non-dominant arm was cannulated under local anesthesia 
(Xylocaine 2%) for frequent blood sampling. Blood was sampled every 5 minutes for the 
determination of plasma glucose and plasma lactate levels (Biosen c-line; eKF diagnostics). 
An intravenous catheter was inserted in the antecubital vein of the contralateral arm for infusion 
of glucose 20% (Baxter B.V., deerfield, iL), insulin (insulin aspart; novo nordisk, Bagsvaerd, 
denmark) and sodium lactate (600 mmol/L; spruyt Hillen, ijsselstijn, the netherlands and 
prepared by the department of Pharmacy, radboud university medical center, nijmegen, the 
netherlands) or normal saline (sodium chloride; 0.9%). 
 After cannulations, a two-step hyperinsulinemic (60 mu/m2/min) euglycemic (5.0 
mmol/L)-hypoglycemic (2.8 mmol/L) glucose clamp was initiated, and participants were 
placed in the mr scanner for baseline mr spectroscopy (mrs) data acquisition. At 15 minutes 
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after the start of the euglycemic clamp, infusion of sodium lactate, or an equivalent volume 
of saline, was started while mrs data acquisition continued. We aimed for plasma lactate 
levels of approximately 3.5 mmol/L and initially used a primed (50 µmol/kg/min for 15 min) 
continuous (30 µmol/kg/min) infusion of sodium lactate. since achieved plasma lactate levels 
were slightly above target levels, the dose was lowered after the first two participants (both 
patients with nAH) to 40 µmol/kg/min for 15 min and 25 µmol/kg/min for the remainder of 
the experiment. After ~25 min, blood glucose levels were allowed to drop to 2.8 mmol/L and 
were maintained at that level for 45 minutes. Hypoglycemic symptoms were quantified with a 
validated questionnaire just prior to positioning the participant in the mr scanner and at the end 
of the stable hypoglycemic phase. Participants were asked to score from 0 to 6 (none to most 
severe) for each of 18 symptoms which included six autonomic symptoms, six neuroglycopenic 
symptoms, four general and two dummy symptoms. Additional blood samples were taken for 
determination of plasma insulin, pH, catecholamines, cortisol and growth hormone prior to 
the start of the sodium lactate or saline infusion (baseline), at the end of the euglycemic phase 
and at the end of the hypoglycemic phase. during hypoglycemia, counterregulatory hormone 
responses were determined at 15-minute intervals (see Figure 6.1A for a schematic overview 
of the study protocol). After completing both experimental days, patients with nAH were asked 
on which day the hypoglycemic phase was most evident or felt more intense.
mrs protocol and data analysis
to measure brain lactate, we performed mr spectroscopy (mrs) on a 3t mr system 
(mAgnetom Prisma, siemens, erlangen, germany) using a body coil for excitation and a 
12-channel receive-only head coil. A t1-weighted anatomical image (mPrAge, echo time (te) 
2.4 ms, repetition time (tr) 1900 ms, and a field of view of 256 x 256 mm2) was acquired, and a 
22.5 cm3 voxel for mrs data acquisition was placed in the periventricular and supraventricular 
region (Figure 6.2A). Brain lactate levels were then determined continuously with an interleaved 
J-difference editing semi-LAser [14] spectroscopy sequence (te 144 ms, tr 3000 ms and 8 
averages). J-difference editing was performed with frequency selective inversion megA pulses 
[15] (30 ms, 75 Hz bandwidth). unsuppressed water spectra (te 33 ms, tr 5000 ms and 8 
averages) were acquired from the same voxel for signal quantification.
 Additionally, at the end of euglycemia and at the end of hypoglycemia we acquired mr 
spectra without J-difference editing from the same voxel (sLAser, te 33 ms, tr 3000 ms, 32 
averages) to explore differences in other major brain metabolites.
 the J-difference-edited spectra were zerofilled from 1024 to 2048 data points and 
phase and frequency aligned [16]. motion-corrupted spectra, identified as a spectrum which 
deviated more than 2.6 standard deviations from the average spectrum of that participant 
[17], were discarded. subsequently, spectra were subtracted pairwise. the difference spectra 
were averaged within participants across six different phases: baseline (i.e. before the start 
of lactate or placebo infusion), euglycemia, transition to hypoglycemia, and each 15-minute 
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block of hypoglycemia. From these final difference spectra, the cerebral lactate doublet at 
1.3 ppm was quantified using the AmAres algorithm in jmrui [18]. Visual inspection of the 
difference spectra showed co-edited macromolecules at ~1.2 ppm, which were included in the 
fitting routine in AmAres to avoid overestimation of the lactate signal [19]. the unsuppressed 
water signal was used as an internal standard for absolute quantification and we took the 
voxel composition and contribution of plasma lactate into account. We assumed a t2 of 240 
ms for cerebral lactate [20], and a t2 of 80 ms and 110 ms for water in gray and white matter, 
respectively [21]. the voxel composition (i.e., percentages white matter, gray matter and 
cerebrospinal fluid) was determined by segmenting the t1-weigthed anatomical images using 
sPm8 (Wellcome trust centre for neuroimaging, ucL, London, uK) and subsequently co-
registering the segmented image with the mrs voxel location. As the voxel mainly contained 
white matter, we assumed a vessel volume of 2% [22,23].
 spectra acquired without J-difference editing were analyzed using the Lcmodel 
software [24]. A basis set was created in Bruker topspin, and extended with a measured 
macromolecular baseline. metabolites quantified with cramér-rao lower bounds >50% were 
not included in the analysis (as recommended by the Lcmodel manual [25]). the unsuppressed 
water signal was used as a reference for absolute quantification of aspartate (Asp), total 
choline (tcho), total creatine (tcre), glutamate (glu), glutamine (gln), myo-inositol (mi), total 
n-acetylaspartate (tnAA), scyllo-inositol (scyllo) and taurine (tau).
analytical methods
Plasma insulin was determined by an in-house radioimmunoassay (riA) [26]. Plasma adrenaline 
and noradrenaline were analyzed by high-performance liquid chromatography combined with 
fluorometric detection [27]. Plasma growth hormone and cortisol were determined using 
a routine analysis method with an electrochemiluminescent immunoassay on a modular 
Analytics e170 (roche diagnostics gmbH, mannheim, germany). pH was measured by routine 
arterial blood gas analysis on the rapidPoint 500 (siemens nederland B.V., den Haag, the 
netherlands). 
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figure 6.1 study protocol, plasma glucose and plasma lactate levels. (A) schematic overview of the 
study protocol. mrs measurements were performed continuously during euglycemia and hypoglycemia. 
counterregulatory hormone responses (cH) and hypoglycemic symptoms (symp) were determined at 
several time points during euglycemia and hypoglycemia, as indicated. (B) time courses of plasma glucose 
and (c) plasma lactate levels. the dashed lines represent the start of the lactate or saline infusion (t=0 
min), the end of euglycemia, and the start of hypoglycemia. open circles: patients with type 1 diabetes 
and nAH with saline infusion (nAH w|placebo); black circles: patients with type 1 diabetes and nAH with 
lactate infusion (nAH w|lac); black triangles: patients with type 1 diabetes and iAH with lactate infusion 
(iAH w|lac)
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statistical analysis
differences in means or medians within the nAH group (nAH w|lac vs. nAH w|placebo) and 
differences within-groups between euglycemia and hypoglycemia were statistically tested with 
paired student t tests or Wilcoxon signed rank tests when data were not normally distributed. 
differences between nAH w|lac and iAH w|lac were compared with two-sided student t tests 
or mann-Whitney u tests, when appropriate. serial data were compared between nAH w|lac 
and nAH w|placebo with a two-way repeated measures AnoVA. to analyze effects over time 
in patients with iAH, a one-way repeated measures AnoVA was performed. since patients 
with iAH were only studied with lactate infusion, comparison to a placebo condition is not 
possible. thus, to determine whether there was an effect of lactate infusion on brain lactate 
levels in patients with iAH, the area under the curve (Auc) of the baseline-corrected brain 
lactate levels was calculated by trapezoidal numerical integration, and a one-sample t test was 
performed. differences in means at baseline across the three groups were analyzed by one-
way AnoVA followed by pairwise Bonferroni post hoc tests. All data are expressed as mean 
± sd unless otherwise indicated. significance levels of student t tests were not corrected for 
multiple testing. A P value < 0.05 was considered statistically significant. statistical analyses 
were performed with iBm sPss statistics 20.
results
Participants were well-matched for relevant clinical parameters, including age, duration of 
diabetes and glycemic control (table 6.1). upon arrival at the research facility, plasma glucose 
levels were slightly elevated with no significant differences between groups (9.4 ± 3.4, 7.4 ± 
1.7 and 10.3 ± 4.9 mmol/L in nAH w|lac, nAH w|placebo and iAH w|lac, respectively). stable 
euglycemia was achieved at a glucose level of 5.1 ± 0.2 mmol/L and stable hypoglycemia at 2.8 
± 0.1 mmol/L, again with no differences between groups or intervention (Figure 6.1B). Plasma 
insulin levels during the clamp were similar for all groups and conditions (data not shown). 
Plasma lactate levels increased similarly in nAH w|lac and iAH w|lac by ~3.5 fold to 3.6 ± 0.5 
mmol/L within ~15 minutes after starting the lactate infusion, and remained at that level for 
the remainder of the experiment (Figure 6.1c). during the control experiment, i.e. when saline 
was infused, plasma lactate levels did not change significantly from baseline levels in nAH 
w|placebo (P = 0.58). sodium lactate infusion caused the pH to increase in both groups to 
similar extent (from 7.41 ± 0.02 at baseline to 7.48 ± 0.01 at the end of hypoglycemia, P < 0.001), 
whereas saline infusion did not affect the pH (7.40 ± 0.02 versus 7.42 ± 0.03). glucose infusion 
rates (gir) during hypoglycemia (supplementary Figure s6.1) were not significantly different 
across groups and intervention (mean gir: 3.1 ± 1.3, 2.7 ± 1.0 and 3.3 ± 1.3 mg/kg/min for nAH 
w|lac, nAH w|placebo and iAH w|lac, respectively). 
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table 6.1 Participant characteristics
t1dm nah t1dm iah
Age (yrs) 28.0 ± 10.3 25.9 ± 6.0
Gender (M/F) 3/3 3/4
BMI (kg/m2) 24.0 ± 2.5 24.0 ± 2.1
Duration of T1DM (yrs) 11.6 ± 5.9 13.2 ± 5.8
HbA1c (mmol/mol [%]) 54.7 ± 9.1 [7.2 ± 0.8] 55.0 ± 5.0 [7.2 ± 0.5]
Self reported exercise (hours/week) 3.5 ± 0.9 2.9 ± 1.5
data are presented as number or mean ± sd. m: male; F: female; Bmi: body mass index; t1dm nAH: type 
1 diabetes with normal awareness of hypoglycemia; t1dm iAH: type 1 diabetes with impaired awareness 
of hypoglycemia.
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figure 6.2 (A) typical location of the mrs voxel on a t1-weighted anatomical image. (B) representative 
examples of difference spectra of one subject nAH (nAH w|placebo and nAH w|lac) and one subject 
with iAH (iAH w|lac). the baseline difference spectra were recorded before the start of lactate or placebo 
infusion. Lac, lactate; mm, macromolecules.
hypoglycemic symptoms and counterregulatory hormones
Lactate infusion clearly suppressed total symptom scores during hypoglycemia in patients 
with nAH, as compared to placebo (P = 0.03, Figure 6.3), and resembled symptom score of 
patients with iAH when lactate was infused (P = 0.18 between groups). symptom subcategories 
are depicted in table 6.2. Five out of six patients with nAH indicated that hypoglycemia 
was less severe on the day of the lactate infusion, one patient experienced no difference 
between both study days. in patients with iAH neither the total nor the subcategory symptom 
score changed significantly in response to hypoglycemia. Lactate infusion considerably 
suppressed the adrenaline response to hypoglycemia in patients with nAH as compared to 
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placebo infusion (P < 0.01; Figure 6.4). Lactate infusion also suppressed cortisol and hgH 
responses to hypoglycemia in patients with nAH (both P < 0.01), but did not significantly 
reduce noradrenaline responses P = 0.18) (supplementary Figure s6.2). 
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figure 6.3 difference in symptom scores. total symptoms scores in response to hypoglycemia in patients 
with type 1 diabetes and nAH with saline infusion (nAH w|placebo), patients with nAH with lactate infusion 
(nAH w|lac) and patients with iAH with lactate infusion (iAH w|lac). *P < 0.05 **P < 0.01
table 6.2 Hypoglycemia-induced changes in symptom subscores (median [interquartile range])
t1dm nah t1dm iah
Placebo infusion Lactate infusion Lactate infusion
Autonomic 7.5 [2.5 ; 15.5] # 2.5 [-0.5 ; 4.5] 1 [-2 ; 3] 
Neuroglycopenic 3.5 [0.75 ; 7] # 2 [-0.25 ; 3.5] 2 [-1 ; 2]
General 3.5 [3 ; 4.75]*,# 2 [0.75 ; 3.25] # 0 [-1 ; 1] 
*P < 0.05 vs. nAH w|lac; #P < 0.05 vs euglycemia. t1dm nAH: type 1 diabetes with normal awareness of 
hypoglycemia; t1dm iAH: type 1 diabetes with impaired awareness of hypoglycemia. 
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figure 6.4 Adrenaline responses. Adrenaline levels were determined at baseline (Bsln; i.e. before the 
infusion of lactate or saline), during euglycemia (eu) and at 15-minute intervals during hypoglycemia. 
open circles: patients with type 1 diabetes and nAH with saline infusion (nAH w|placebo); black circles: 
patients with type 1 diabetes and nAH with lactate infusion (nAH w|lac); black triangles: patients with type 
1 diabetes and iAH with lactate infusion (iAH w|lac);
brain lactate
the tissue content of the mrs voxels was not different between groups and contained on 
average 64.1 ± 11.1% white matter, 32.8 ± 10.5% gray matter and 3.2 ± 1.6% cerebrospinal 
fluid. Baseline brain lactate levels (i.e., before the infusion of lactate or placebo) were similar 
across groups (0.58 ± 0.08, 0.64 ± 0.1 and 0.59 ± 0.05 µmol/g in nAH w|lac, nAH w|placebo and 
iAH w|lac, respectively; P = 0.42). J-edited difference mr spectra, recorded during infusion of 
lactate, showed an increase of the lactate signal in the brain (Figure 6.2B). in patients with nAH, 
brain lactate levels were higher after infusion of lactate than after infusing saline (Figure 6.5A; 
mean difference 0.12 ± 0.05 µmol/g, equivalent to an increase of 20.7 ± 6.6 %; P = 0.048). there 
was no significant interaction effect (time x infusion) or main effect of time. Although brain 
lactate levels in nAH w|lac tended to be elevated compared to placebo values at each time 
point, post hoc analysis revealed that the difference in brain lactate levels reached significance 
during the final 30 minutes of the experiment.
 in patients with iAH, lactate infusion resulted in an increase in brain lactate levels 
compared to baseline values (Figure 6.5B; mean increase: 0.06 ± 0.04 µmol/g, equivalent to an 
increase of 10.2 ± 4.2%; Auc of baseline-corrected brain lactate levels: 4.4 ± 4.3 µmol·min/g; 
P = 0.03). in these patients, brain lactate levels showed a trend towards an increase at each 
time point compared to baseline values, but the trend was stronger at the beginning of lactate 
infusion and disappeared at the end of hypoglycemia. When comparing brain lactate time 
curves with lactate infusion between patients with iAH and nAH, the increase in brain lactate 
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levels in iAH w|lac seemed less pronounced compared to nAH w|lac, but this difference was 
not statistically significant (P = 0.36). Brain lactate levels did not change in patients with nAH 
in response to hypoglycemia when saline was infused. notably, there was no correlation, 
whatsoever, between brain lactate levels and plasma lactate levels (r2 = 0.01, P = 0.27).
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figure 6.5 Figure 6.5: Brain lactate levels. mean (±sem) baseline corrected and percentage change in 
brain lactate levels in (A) patients with type 1 diabetes and nAH (nAH w|placebo and nAH w|lac) and (B) 
patients with type 1 diabetes and iAH (iAH w|lac). the dashed line represent the start of hypoglycemia. 
P values indicate significance of time-series analysis.
other brain metabolites
Brain glutamate levels decreased in response to hypoglycemia in patients with nAH, both 
during lactate infusion (from 7.5 ± 0.7 to 7.1 ± 1.0 µmol/g, P = 0.03) and while infusing placebo 
(from 7.6 ± 0.6 to 7.0 ± 0.8 µmol/g, P = 0.01). in contrast, hypoglycemia did not change brain 
glutamate levels in patients with iAH (8.0 ± 0.7 versus 7.8 ± 0.9 µmol/g, P = 0.59). Additionally, 
we found an increase in myo-inositol in iAH w|lac and a slight decrease in myo-inositol in nAH 
w|lac. none of the other major brain metabolites (Asp, tcho, tcre, gln, tnAA, scyollo and tau) 
was significantly altered by the hypoglycemic condition in any of the groups (supplementary 
Figure s6.3). 
disCussion
the results of the present study confirm that lactate infusion considerably suppresses 
counterregulatory hormone responses to and symptomatic awareness of hypoglycemia in 
patients with nAH. While lactate infusion did increase brain lactate content, the increase was 
modest and not clearly different between patients with nAH and iAH. the lack of pronounced 
brain lactate accumulation suggests that the excess of lactate is immediately oxidized by the 
brain which may explain the suppressive effects of lactate on awareness of hypoglycemia in 
patients with nAH. 
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 our results are in line with those of several other studies reporting that elevated 
plasma lactate levels result in an increase in cerebral lactate transport and oxidation, 
preventing substantial accumulation of brain lactate upon infusion [6-8]. However, an earlier 
study reported fivefold higher brain lactate concentrations in the brain of patients with type 1 
diabetes who were exposed to frequent hypoglycemia, as compared to healthy controls, when 
13c-labeled lactate was administered during hypoglycemia [9]. Another 13c study that used the 
similar methodology in healthy volunteers, found a linear correlation between plasma and brain 
lactate concentrations during euglycemia [5]. According to these calculations, brain lactate 
levels should have been as high as ~2 µmol/g rather than ~0.7 µmol/g with the plasma lactate 
levels of 3.5 mmol/L that we achieved. it should be noted that with 13c-mrs brain lactate levels 
are calculated rather indirectly. these calculations require a number of critical assumptions, 
which may result in an overestimation of brain lactate levels. Here we used 1H-mrs to measure 
the signal intensity of brain lactate, which is directly proportional to the tissue concentration of 
lactate, thus providing a direct measurement of brain lactate levels. 
 Lactate is taken up by the brain through proton-linked facilitated diffusion by 
monocarboxylate transporters (mcts), and its uptake is driven by a concentration gradient 
from blood to brain and further enhanced by neuronal activation [28,29]. therefore, it is likely 
that elevated plasma lactate levels result in an increased uptake of lactate by the brain. 
Furthermore, it has repeatedly been shown that lactate can serve as a metabolic substrate for 
the brain [5,7,8,9,30], especially when plasma lactate levels are elevated [7,31,32]. Lactate taken 
up by the brain needs to be converted to pyruvate before it enters the citric acid cycle, a process 
catalyzed by lactate dehydrogenase (LdH). even relatively small increases in local brain lactate 
concentration can drive lactate utilization by shifting the LdH reaction to pyruvate formation and 
to subsequent oxidation [33]. As we found only a small increase in brain lactate levels, we posit 
that lactate taken up by the brain is largely oxidized, both during euglycemia and hypoglycemia. 
increased brain lactate concentrations during hypoglycemia are likely responsible for the 
suppressive effects on counterregulatory responses in patients with nAH, presumably because 
of increased brain lactate oxidation. Alternatively, lactate may exert its suppressive effects via 
alterations in cerebral blood flow, redox signaling or neuronal activity [34,35]. 
 since brain lactate transport capacity is reported to be upregulated in patients with 
iAH [10,11], one can expect higher brain lactate levels in patients with iAH than in patients with 
nAH. Brain lactate concentrations are the result of a balance between its uptake, production, 
oxidation and export. the absence of a difference in brain lactate concentrations between nAH 
w|lac and iAH w|lac at the currently elevated plasma lactate levels either indicates comparable 
brain lactate uptake in both groups, or upregulation of both lactate uptake and lactate oxidation 
in patients with iAH. Without the use of exogenous lactate infusion, we previously showed that 
brain lactate levels fall in response to hypoglycemia in patients with iAH, but not in those with 
nAH [36]. this may indeed indicate upregulated capacity to oxidize lactate in patients with iAH. 
Analogously, the trend towards increased brain lactate levels in the current study disappeared 
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at the end of hypoglycemia in patients with iAH, again hinting at upregulated capacity to oxidize 
lactate. When we used intense exercise to raise endogenous plasma lactate to much higher 
levels, we observed higher brain lactate levels in patients with iAH than in those with nAH [37]. 
cerebral lactate uptake is not only dependent on plasma lactate concentrations but also on 
pH levels in plasma and in brain [29]. the lactate-induced increase in plasma pH value (i.e. 
a decrease in H+ concentration) observed in the current study may have limited brain lactate 
uptake in comparison to an exercise-induced decrease in plasma pH. However, these effects 
are generally small when pH values remain within the physiological range. 
 We found brain glutamate levels to fall in response to hypoglycemia in patients with 
nAH, which is in line with previous observations [38] and has been attributed to glutamate 
oxidation [39,38,40]. this decrease in brain glutamate was also present in patients with nAH 
when lactate was infused, which suppressed adrenaline responses to hypoglycemia. this is in 
line with the absence of a relation between the hypoglycemia-induced decrease in glutamate 
and the adrenaline response to hypoglycemia, as reported by terpstra et al. [38]. and may 
indicate that even though lactate is abundantly available, it is not sufficient to compensate for 
the decrease in glucose supply to the brain in patients with nAH, or alternatively, that lactate 
oxidation is already saturated in these patients. in contrast, but again in line with previous data 
without lactate infusion [38], brain glutamate did not decrease in patients with iAH, possibly 
because of their greater capacity to use (the excess of) lactate, thus eliminating the need to 
oxidize glutamate. 
 our study has a small sample size, though based on power calculations. However, the 
study population was homogenous in terms of age, HbA1c and diabetes duration, and plasma 
glucose and lactate levels during the clamps were stable and almost identical in all groups. the 
homogeneity of the study population enables efficient comparison, but on the other hand, may 
limit the generalisability of the results. importantly, to quantify the cerebral lactate content, 
we took the contribution of plasma lactate (ranging from ~0.8 mmol/L to ~3.5 mmol/L) to the 
mr signal of brain lactate into account. since the voxel consisted of mainly white matter we 
estimated a 2% vessel volume, based on literature [22,23]. deviations from this estimation 
(within the physiological range) may affect the magnitude of the outcome, but will not affect the 
main conclusion of the study. 
 in conclusion, we show that intravenous lactate administration reduces awareness of 
hypoglycemia and translates into a small increase in brain lactate levels, with no differences 
between patients with nAH and iAH. the rather limited increase in brain lactate suggests that 
the excess of lactate is immediately used by the brain both under euglycemic and hypoglycemic 
conditions. An increase in brain lactate oxidation during hypoglycemia may explain the 
suppressive effects of lactate on awareness of hypoglycemia observed in patients with nAH.
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figure s6.3 concentrations of major brain metabolites quantified during euglycemia (white bars) and 
hypoglycemia (black bars). P values indicate significant differences for euglycemia vs. hypoglycemia within 
a group. Asp, aspartate; tcho, total choline; tcre, total creatine; glu, glutamate; gln, glutamine; mi, myo-
inositol; tnAA, total n-acetylaspartate; scyllo, scyllo-inositol; tau, taurine
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abstraCt 
it is unclear whether cerebral blood flow responses to hypoglycemia are altered in people 
with type 1 diabetes and impaired awareness of hypoglycemia. the aim of this study was 
to investigate the effect of hypoglycemia on both global and regional cerebral blood flow in 
type 1 diabetes patients with impaired awareness of hypoglycemia, type 1 diabetes patients 
with normal awareness of hypoglycemia and healthy controls (n = 7 per group). the subjects 
underwent a hyperinsulinemic euglycemic-hypoglycemic glucose clamp in a 3t mr system. 
global and regional changes in cerebral blood flow were determined by arterial spin labeling 
magnetic resonance imaging, at the end of both glycemic phases. Hypoglycemia generated 
typical symptoms in patients with type 1 diabetes and normal awareness of hypoglycemia and 
healthy controls, but not in patients with impaired awareness of hypoglycemia. conversely, 
hypoglycemia increased global cerebral blood flow in patients with impaired awareness of 
hypoglycemia, which was not observed in the other two groups. regionally, hypoglycemia 
caused a redistribution of cerebral blood flow towards the thalamus of both patients with 
normal awareness of hypoglycemia and healthy controls, consistent with activation of brain 
regions associated with the autonomic response to hypoglycemia. no such redistribution 
was found in the patients with impaired awareness of hypoglycemia. An increase in global 
cerebral blood flow may enhance nutrient supply to the brain, hence suppressing symptomatic 
awareness of hypoglycemia. Altogether these results suggest that changes in cerebral blood 
flow during hypoglycemia contribute to impaired awareness of hypoglycemia. 
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introduCtion
Hypoglycemia is the major and most feared complication of insulin therapy in patients with 
type 1 diabetes (t1dm). these patients experience on average two hypoglycemic events per 
week and one severe, potentially hazardous event every year [1]. A drop in blood glucose levels 
induces a hierarchically organized counterregulatory response, including activation of the 
sympathetic nervous system and endocrine responses, aimed at quickly restoring euglycemia. 
However, in about 20-30% of the patients with t1dm, hypoglycemic warning symptoms and 
counterregulatory hormone responses appear only at very low plasma glucose levels or do not 
appear at all, which is known as the clinical syndrome of impaired awareness of hypoglycemia 
(iAH) [2,3]. Patients with t1dm and iAH are at a several fold higher risk of severe hypoglycemia 
than patients with normal awareness of hypoglycemia (nAH). 
 iAH is thought to result from a habituation process to recurrent hypoglycemia. the 
exact underlying mechanism of this process is unclear, but most certainly involves cerebral 
adaptations, which may include alterations in cerebral blood flow (cBF). An increase in global 
cBF has been reported in healthy volunteers [4,5] and in t1dm patients [6] at plasma glucose 
levels of 2.2 mmol/L or lower. this could be a neuroprotective response, as it may improve 
nutrient supply to the brain [7]. At milder hypoglycemic levels, cBF was not found to change 
[8,9], whereas one study reported a slight decrease in cBF in response to a glucose nadir 
of 3.0 mmol/L [10]. remarkably, Boyle et al. [11] found that plasma glucose values of 2.5 
mmol/L caused a non-statistically significant increase in cBF in t1dm patients at optimal 
glycemic control, whereas cBF remained unchanged in poorly controlled patients and non-
diabetic subjects.
 Besides global effects, hypoglycemia has also been reported to cause a redistribution 
in cBF. in healthy individuals, hypoglycemia has been found to increase cBF to the thalamus 
[10,12,13], hypothalamus [14] and prefrontal cortex [10] changes that have been correlated to 
neuronal activation [15]. interestingly, mangia et al. [13] found a blunted hypoglycemia-induced 
increase in thalamic cBF in t1dm patients with iAH as compared to healthy controls, which 
suggests that the thalamus is involved in the coordination of the sympathetic response to 
hypoglycemia. However, hypoglycemia has also been reported to enhance rather than suppress 
thalamic cBF in a human model of iAH [16].
 With arterial spin labeling (AsL) magnetic resonance imaging (mri) it is possible to 
reliably quantify cBF in a non-invasive manner, which can be applied in hypoglycemia research. 
the aim of our study was to assess both global and regional cBF changes in response to 
hypoglycemia in t1dm patients with iAH, t1dm patients with nAH and healthy controls.
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materials and methods
subjects
in total, 21 subjects gave written informed consent. imaging data of one of the subjects with 
t1dm and iAH were excluded during post-processing because of the presence of artefacts due 
to significant movement of the head during data acquisition. As a result, six subjects with t1dm 
and iAH, seven subjects with t1dm and nAH and seven healthy, non-diabetic controls were 
included for further data analysis (table 7.1). none of the subjects used medication interfering 
with glucose metabolism other than insulin.
table 7.1 subject characteristics
t1dm iah
n = 6
t1dm nah 
n = 7
healthy controls
n = 7
Age (years) 25.2 ± 8.8 26.2 ± 5.8 27.6 ± 6.9
Sex (M/F) 3/3 4/3 3/4
BMI (kg/m2) 23.2 ± 1.2 24.7 ± 2.9 23.5 ± 1.7
HbA1C (mmol/mol (%)) 59.3 ± 6.7 (7.5 ± 0.3) 56.6 ± 3.8 (7.3 ± 0.4) -
Duration of diabetes (years) 15.3 ± 11.3 12.6 ± 9.3 -
data are presented as number or mean ± sd. F: female; m: male; Bmi: body mass index; t1dm iAH: type 
1 diabetes with impaired awareness of hypoglycemia; t1dm nAH: type 1 diabetes with normal awareness 
of hypoglycemia.
 the state of awareness of the subjects with diabetes was determined at the time 
of recruitment according to the dutch modified version of the cox questionnaire, where 
scores of 0-1 out of 5 indicated nAH and scores ≥3 indicated iAH [17,18]. Patients with 
t1dm were excluded from participation if they were poorly controlled (i.e., HbA1c exceeding 
75 mmol/mol (9.0%)) or if there was evidence of micro- or macro-vascular complications, 
except for background retinopathy, that might alter the cBF or its response to hypoglycemia. 
other exclusion criteria were contraindications to mr examination and a history of brain 
injury. the study was approved by and studied in accordance with the ethical standards 
of the institutional review board of the radboud university medical center (commissie 
mensgebonden onderzoek Arnhem-nijmegen).
general experimental protocol 
subjects arrived at the mr facility in the morning after an overnight fast, having abstained from 
caffeine, alcohol and smoking for 24 h. instructions to prevent hypoglycemia in the 24 h before 
the clamp were given to the subjects with t1dm. experiments were to be rescheduled in cases 
of hypoglycemia in the 24 h before the clamp, but this did not occur in any of the subjects.
 An intravenous catheter was placed in the antecubital vein for infusing insulin (Aspart 
insulin; novo nordisk, Bagsvaerd, denmark) and glucose 20% (Baxter B.V., iL, usA). the 
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brachial artery of the contralateral arm was cannulated under local anesthesia (Xylocaine 2%) 
for blood sampling. in cases of hyperglycemia in the subjects with t1dm, a small bolus of insulin 
was given immediately after cannulations. subsequently, subjects were positioned in head-
first supine position in the mr scanner and a hyperinsulinemic (60 mu/m2/min) euglycemic-
hypoglycemic glucose clamp was initiated. Arterial blood samples were collected every 5 minutes 
for immediate centrifugation and determination of plasma glucose levels (Biosen c-Line, eKF 
diagnostics, cardiff, uK). Plasma glucose levels were maintained at 5.0 mmol/L (30 min) and 
2.8 mmol/L (45 min) during the euglycemic and hypoglycemic phase, respectively (Figure 7.1). 
Blood was also sampled immediately after cannulation for the determination of plasma insulin 
levels and at the end of both glycemic phases to determine plasma insulin, adrenaline and 
glucagon levels. symptoms of hypoglycemia were quantified with a semiquantitative symptom 
questionnaire just prior to positioning the subject in the mr scanner and at the end of the 
hypoglycemic phase. subjects were asked to score from 0 (none) to 6 (most severe) for each 
of 18 symptoms which included six autonomic symptoms, six neuroglycopenic symptoms, four 
general symptoms and two dummy symptoms. Questionnaires were not administered at the 
end of the euglycemic phase to avoid head movements that might interfere with data collection.
laboratory analysis
Plasma insulin was assessed by an in-house radioimmunoassay (riA) [19]. Plasma glucagon 
was measured by riA with a commercially available kit (eurodiagnostica, malmö, sweden). 
Plasma adrenaline was measured by high-performance liquid chromatography combined with 
fluorometric detection [20]. 
magnetic resonance imaging
the mr measurements were performed on a 3t mr scanner (tim magnetom trio, siemens, 
erlangen) using a body coil for excitation and a 12-channel receive-only head coil. First, a 3d 
high-resolution structural image was acquired using a t1-weighted magnetization prepared 
rapid acquisition with gradient-echo (mPrAge) sequence with a field of view (FoV) of 256 x 256 
mm² and 1 mm³ isotropic voxels.
 this study was an explorative part of an extensive study protocol that included 1H-
mr spectroscopy [21] and AsL measurements. Perfusion images were obtained at three time 
points: just prior to initiating the glucose clamp (baseline), at the end of the euglycemic phase 
and at the end of the hypoglycemic phase (Figure 7.1). Before each perfusion measurement, a 
low resolution 3d time of flight angiogram was performed to detect the brain-feeding internal 
carotid and vertebral arteries. 
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figure 7.1 schematic overview of the study protocol. AsL measurements were performed just prior to 
initiating the glucose clamp (i.e., at baseline (BL)), at the end of the euglycemic phase and at the end of 
the hypoglycemic phase. Hypoglycemic symptom scores (symp) were acquired just prior to positioning the 
subject in the mr scanner and at the end of the hypoglycemic phase. 
 the cBF-weighted images were acquired with a pseudo-continuous AsL mri (pcAsL) 
research sequence. A 17-mm thick labeling plane was placed perpendicular to the brain-
feeding arteries, between 2.0 and 3.5 cm below the cerebellum. Labeling duration was 1.8 s 
and the post-labeling delay was set to 1.8 s. the imaging FoV was aligned with the anterior 
commissure - posterior commissure line. A 3d gradient and spin-echo (grAse) readout was 
used (FoV: 230 x 173 mm², 26 slices of 4.5-mm thickness, in-plane resolution: 3.6 x 3.6 mm², 
interpolated to 1.8 x 1.8 mm²). A partial-Fourier factor of 6/8 was used in z-direction (inferior-
to-superior direction) and two z-segments were acquired. echo and repetition time (te and tr) 
were 30.88 ms and 4.8 s, respectively. the total scan duration was 5.1 min in which 16 pairs 
of label and control images were acquired. scans were acquired with two hyperbolic secant 
pulses for background suppression.
 Additionally, for cBF quantification and for later distortion correction, two reference 
images without spin labeling were obtained after each AsL series. these images were acquired 
with the same sequence as the control images, but without background suppression and with a 
tr of 7 s. For the second measurement, in-plane phase-encoding direction was reversed.
processing of perfusion images
image analysis was performed with the FsL (FmriB software Library) software package [22]. 
AsL and reference images were motion-corrected via a six-parameter rigid-body transformation 
using mcFLirt [23]. Label and control images were subtracted pairwise, and each series was 
averaged to generate one perfusion-weighted image. A susceptibility-induced off-resonance 
field was estimated from the two reference images with opposed phase-encoding directions 
[24,25]. this off-resonance field-map was used to correct for susceptibility distortions with 
the FsL function toPuP [26]. A quantitative value for cBF was estimated voxel-wise using 
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the equation and parameters described in Alsop et al. [27]. global cBF values were obtained 
by averaging the cBF in gray matter. the resulting cBF maps were co-registered with the 
subject’s structural image. Furthermore, all structural images were linearly registered to the 
montreal neurological institute (mni) template mni152 [28] using a 12 degrees of freedom 
affine transformation (FLirt) and additionally a non-linear registration (Fnirt) [23]. to analyze 
the redistribution of regional cBF, each cBF map was resampled to the mni152 template, 
normalized to its global gray matter mean and smoothed with a gaussian filter of 6-mm full 
width at half maximum. A mask of the thalamus, implemented in FsL, was used to quantify 
regional cBF in the thalamus.
statistical analysis
group analyses on global cBF were performed in mni152 space. the difference in global cBF 
between euglycemia and hypoglycemia within groups was calculated and expressed relative to 
euglycemia and compared with a two-sided student t tests. Between group differences were 
assessed with a one-way analysis of variance (AnoVA) and Bonferroni multiple comparison 
test (iBm sPss 20). to assess hypoglycemia-induced changes in regional cBF in each group, 
voxel-wise statistical analysis with cluster significance correction was performed in Fmri 
expert Analysis tool [29] (FeAt, Version 6.0). Average plasma glucose levels, counterregulatory 
hormone responses and symptom scores were compared between groups using AnoVA 
with a Bonferroni post-hoc test and within groups using a two-sided student t test. data are 
expressed as mean ± standard error of the mean (sem), unless otherwise indicated. A p value 
less than 0.05 was considered statistically significant.
results
mean (±sd) plasma glucose levels were similar in the three groups during both the euglycemic 
phase (5.0 ± 0.1, versus 5.0 ± 0.2 and 4.9 ± 0.2 mmol/L for t1dm and iAH, t1dm and nAH 
and healthy subjects, respectively) and the hypoglycemic phase (2.8 ± 0.1, versus 2.8 ± 0.0 
and 2.8 ± 0.1 mmol/L). insulin levels were comparable between the groups at baseline, and 
increased to a similar extent during the euglycemic and hypoglycemic phase (data not shown). 
As expected, hypoglycemia failed to induce hypoglycemic symptoms, neither autonomic nor 
neuroglycopenic, in subjects with t1dm and iAH. in subjects with t1dm and nAH and in healthy 
controls, symptom scores increased significantly in response to hypoglycemia (table 7.2). 
glucagon levels increased in response to hypoglycemia in healthy subjects, but did not change 
in either of the two patient groups (Figure 7.2A). Adrenaline levels increased in response to 
hypoglycemia in healthy subjects by 2.7 ± 0.5 nmol/L (p < 0.01 versus euglycemia), by 1.8 ± 0.5 
nmol/L in subjects with t1dm and nAH (p < 0.05) and by 1.1 ± 0.8 nmol/l in subjects with t1dm 
and iAH (p < 0.05) (Figure 7.2B). 
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table 7.2: change in hypoglycemic symptom score
t1dm iah t1dm nah healthy controls
Autonomic symptoms 1.3 ± 0.8 5.7 ± 1.6 * 7.7 ± 1.4 *,#
Neuroglycopenic symptoms 0.2 ± 0.6 2.6 ± 1.4 4.9 ± 1.5 *
General symptoms 0.0± 0.6 4.6 ± 1.3 *,# 4.6 ± 1.4 *,#
Difference between scores just before the euglycemic clamp and after 45 min of hypoglycemia. *p < 0.05 
for baseline vs. hypoglycemia, #p < 0.05 vs. T1DM IAH. T1DM IAH: type 1 diabetes with impaired awareness 
of hypoglycemia; T1DM NAH: type 1 diabetes with normal awareness of hypoglycemia.
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figure 7.2 Hypoglycemia-induced changes in glucagon (A) and adrenaline (B). glucagon and adrenaline 
levels were assessed at the end of the euglycemic (open bars) and hypoglycemic (grey bars) phase. means 
(with sem) as well as individual values (dots) are depicted. *p < 0.05 for euglycemia vs. hypoglycemia.
global cerebral blood flow
the quality of the perfusion maps was sufficient to include all subjects and time points in the 
analysis. there was no change in global cBF between baseline and the end of the euglycemic 
phase in any of the groups (0 ± 2%, -2 ± 1% and -1 ± 3% in t1dm and iAH, t1dm and nAH and 
healthy controls, respectively), which excludes an effect of insulin on global cBF. in response to 
hypoglycemia, global cBF increased in subjects with t1dm and iAH by 8 ± 3% (p < 0.05 versus 
euglycemia), tended to increase slightly in subjects with t1dm and nAH (+5 ± 2%, p = 0.08), but 
did not change in healthy controls (-2 ± 2%, p = 0.70, p < 0.05 versus t1dm and iAH) (Figure 7.3). 
regional cerebral blood flow
Hypoglycemia altered the regional distribution of cBF in all three groups, but to a different 
extent (Figure 7.4 and Figure 7.5). in healthy subjects and patients with t1dm and nAH, 
hypoglycemia increased regional cBF in the left and right thalamic area by 22 ± 4% (p < 0.01) 
and 14 ± 4% (p < 0.05) respectively (p = 0.6 for between group differences). no such increase in 
thalamic cBF was observed in subjects with t1dm and iAH. in subjects with t1dm and nAH, 
there was further redistribution of regional cBF during hypoglycemia with a relative increase 
in the bi-lateral frontal lobes and a relative decrease in cBF in the right occipital lobe and 
temporal lobe, and in the right insular cortices. in subjects with t1dm and iAH, regional cBF 
only decreased in the left lateral occipital lobe. 
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figure 7.3 Hypoglycemia-induced changes in global cBF (%). mean (with sem) change as well as individual 
values (dots) are depicted. *p < 0.05 for hypoglycemia versus euglycemia and #p < 0.05 versus healthy 
controls.
T1DM IAH
T1DM NAH
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z=1.96 z>3.5z<-3.5 z=-1.96
figure 7.4 redistribution of cBF normalized to its global gray matter mean in response to hypoglycemia for 
t1dm subjects with iAH (top row), t1dm subjects with nAH (middle row) and healthy controls (bottom row). 
colors represent z-scores of hypoglycemia-induced significant changes in regional cBF, superimposed on 
the transverse view of the mni-152 atlas (from left to right column: z =-8 mm, 2 mm, 12 mm, 22 mm, 42 
mm in mni-152 coordinate space) and indicate a significant increase (red to yellow) or decrease (dark to 
light blue) in relative regional cBF in hypoglycemia versus euglycemia.
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+20%-20% 0%
figure 7.5 mean quantitative redistribution of cBF in response to hypoglycemia for t1dm subjects with 
iAH (top row), t1dm subjects with nAH (middle row) and healthy controls (bottom row). colors represent 
mean changes in regional cBF, superimposed on the transverse view of the mni-152 atlas (from left to right 
column: z=-8 mm, 2 mm, 12 mm, 22 mm and 42 mm in mni-152 coordinate space) and indicate an increase 
(red to yellow) or decrease (dark to light blue) in relative regional cBF in hypoglycemia versus euglycemia. 
note that statistical significance was only reached for the increase in regional cBF in the left and right 
thalamic area in healthy controls and t1dm nAH, the redistribution towards the bi-lateral frontal lobes in 
t1dm nAH and the relative decreases in cBF in the right occipital lobe, temporal lobe and the right insular 
cortices in t1dm nAH and in the left lateral occipital lobe in t1dm iAH (as depicted in Figure 7.4).
disCussion
our study suggests that changes in cBF are involved in the pathogenesis of iAH. this 
conclusion is based on the finding of this study that hypoglycemia induced a significant 
increase in global cBF in t1dm patients with iAH, but not in the two control groups. such an 
increase may enhance the supply of energy nutrients (e.g., glucose) to the brain, which could 
suppress the brain’s ability to detect a fall in metabolism required to induce hypoglycemic 
symptoms. this is in accordance with the blunted redistribution of cBF towards the thalamus 
in response to hypoglycemia in patients with t1dm and iAH and consistent with an attenuated 
activation of brain regions associated with the autonomic response to hypoglycemia.
 earlier studies among healthy subjects showed increases in global cBF in response 
to decrements in plasma glucose levels below 2.2 mmol/L [4-6], but not in response to 
milder forms of hypoglycemia [8,9]. Accordingly, the glucose nadir of 2.8 mmol/L that we 
obtained did not elicit alterations in global cBF in the healthy controls. our finding that 
global cBF increased in patients with t1dm and iAH in response to this relatively mild form 
of hypoglycemia is novel. 
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 With regard to regional cBF, the hypoglycemia-induced increase in thalamic cBF in 
patients with t1dm and nAH and in healthy volunteers is in line with earlier reports [10,12,13,16], 
and probably reflects activation of brain regions associated with autonomic responses to 
hypoglycemia. this would explain the absence of an increase in regional cBF in t1dm patients 
with iAH, as observed in our study, and as mentioned before [13]. in contrast, Arbeláez et al. 
[16] reported enhanced rather than reduced thalamic cBF in healthy volunteers subjected 
to antecedent hypoglycemia, an accepted model for iAH. obviously, these healthy volunteers 
differ greatly from t1dm patients with iAH with respect to the magnitude of prior hypoglycemic 
exposure, suggesting that adaptations in (regional) cBF occur late in the pathogenesis of iAH.
We posit that the increase in global cBF as observed in patients with t1dm and iAH is the result 
of an altered threshold, i.e., the increase in flow occurs at higher glucose values than normal, 
as an adaptation to recurrent hypoglycemia. the increase may serve as a neuroprotective 
response to prior hypoglycemia, as it enhances the supply of glucose and other energy 
nutrients to the brain [7]. in addition, the consequent maintenance of brain metabolism may 
impede or delay hypoglycemia sensing by the brain, and therefore suppresses activation of 
counterregulatory responses, including symptoms, as seen in patients with iAH. in subjects 
with t1dm and nAH, we saw a trend towards a small increase in global cBF in response to 
hypoglycemia. this does not refute the role of hypoglycemia, since these t1dm patients are not 
as hypoglycemia-naïve as people without diabetes, but it may indicate that changes in cBF are 
not the only factor required for the development of iAH. 
 in the subjects with t1dm and nAH, but not in healthy controls, we observed a clear 
redistribution of cBF with an increase in regional cBF to the frontal lobes during hypoglycemia. 
since the frontal lobes are among the regions most vulnerable to the effect of hypoglycemia 
[30], such an increase in cBF may be seen as an early adaptive response to protect that brain 
region from potential harmful effects of hypoglycemia. 
 A limitation of this explorative study is that acquisition of the perfusion images was 
limited to single time points at the end of both glycemic phases. studies in healthy volunteers 
have suggested that hypoglycemia sequentially activates and deactivates different brain regions 
over time in a dynamic process [31]. We do not have such information about the temporal 
evolution of hypoglycemia-induced changes in cBF. the small sample size is another limitation, 
although the study population was quite homogenous in terms of gender, age, Bmi and disease 
duration. strengths of our study are that we investigated global and regional changes in cBF in 
three groups of participants, which enabled us to differentiate between the impact of diabetes 
and iAH. clamps were performed using arterial blood sampling, which ensures accuracy with 
respect to the glycemic conditions. Finally, an effective distortion correction strategy was 
applied to improve the accuracy of AsL imaging.
 in conclusion, hypoglycemia increases global cBF in patients with t1dm and iAH, but 
not in patients with nAH and non-diabetic subjects. We posit this to be an adaptive response 
aimed at neuroprotection that enhances nutrient supply to the brain during hypoglycemia 
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and therefore explains, at least in part, iAH. Analogously, the blunted hypoglycemia-induced 
redistribution of cBF without increased perfusion in the thalamus in subjects with t1dm and 
iAH reflects absence of activation of brain regions associated with the autonomic response 
to hypoglycemia. together these results suggest that changes in cBF may contribute to the 
development of iAH.
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key findings
•	 the level of lactate in the brain decreases in response to hypoglycemia in 
patients with type 1 diabetes and impaired awareness of hypoglycemia, while it 
remains stable in patients with normal awareness of hypoglycemia and in non-
diabetic controls.
•	 An elevated plasma lactate concentration caused by high-intensity interval 
training (Hiit) results in increased brain lactate levels. 
•	 the Hiit-induced increase in brain lactate content is most pronounced in patients 
with impaired awareness of hypoglycemia, as compared to patients with normal 
awareness of hypoglycemia and non-diabetic controls. over the subsequent 
hypoglycemic period, brain lactate levels drop to a lower steady-state level in 
patients with impaired awareness of hypoglycemia.
•	 We confirm that lactate infusion suppresses counterregulatory responses 
during hypoglycemia in patients with type 1 diabetes and normal awareness of 
hypoglycemia
•	 infusion of lactate, resulting in stable elevated plasma lactate concentrations 
of ~3.5 mmol/L, only modestly increases brain lactate to comparable levels 
in patients with type 1 diabetes and impaired awareness of hypoglycemia and 
patients with normal awareness of hypoglycemia.
•	 Hypoglycemia increases blood flow in the whole brain of patients with type 1 
diabetes and impaired awareness of hypoglycemia, but not in patients with 
normal awareness of hypoglycemia and non-diabetic controls.
•	 Hypoglycemia induces a regional relative increase in blood flow in the thalamus 
of patient with type 1 diabetes and normal awareness of hypoglycemia and 
non-diabetic controls, while this increase is blunted in patients with impaired 
awareness of hypoglycemia.
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summary
Patients with type 1 diabetes require insulin therapy to regulate their blood glucose levels. tight 
glycemic control is generally advocated to reduce risks of microvascular and macrovascular 
complications, but this treatment goal is accompanied by an increased risk of hypoglycemia. 
in fact, patients with type 1 diabetes experience hypoglycemic events on a weekly basis, which 
translates into thousands of hypoglycemic events during a lifetime with diabetes. When 
recurrent, hypoglycemia may induce a process of habituation, so that normal symptomatic 
responses of hypoglycemia are no longer, or only partially, perceived. this condition is referred 
to as impaired awareness of hypoglycemia (iAH) and affects up to a third of patients with type 
1 diabetes. Patients with type 1 diabetes and iAH are at particularly high risk for developing 
severe, potentially hazardous, hypoglycemia. 
 the exact mechanisms underlying the development of iAH are currently not fully 
understood, but most likely involve alterations in the brain. this thesis describes the results of studies 
that focussed on two potential cerebral mechanisms which may contribute to the development of 
iAH: adaptations in cerebral energy metabolism and adaptations in cerebral perfusion, using mr 
spectroscopy and perfusion mri (AsL-mri) as non-invasive investigational tools.
chapter 1 and chapter 2 present an introduction into the clinical syndrome of iAH and the mr 
techniques used in this thesis. Chapter 2 provides information on cerebral glucose metabolism in 
general and elaborates on the effects of hypoglycemia on brain glucose metabolism specifically. 
Based on several functional and metabolic neuroimaging studies, we argued that the brain is able 
to largely maintain glucose metabolism during acute (moderate) hypoglycemia. this preservation 
of brain metabolism may lead to, or is related to, cerebral adaptations at various different levels 
in patients with iAH. these may include regional delivery of glucose by blood flow, transport to 
and handling of glucose and of non-glucose alternative fuels, such as lactate, in the brain, as well 
as activation or de-activation of brain areas involved in behavioral responses.
 throughout this thesis 1H-mr spectroscopy (mrs) was used to measure tissue 
concentrations of metabolites in the human brain, with the main focus on the assessment of 
lactate. this metabolite can be measured best using J-difference editing 1H-mrs, which involves 
the consecutive acquisition of two mr spectra in which frequency-selective radiofrequency 
(rF) pulses are alternatively switched on and off on the coupled-spin system of lactate. these 
‘on’ and ‘off’ spectra are then subtracted pairwise, leaving only the lactate signal present in 
the difference spectrum. As small phase and/or frequency shifts will occur between the ‘on’ 
and ‘off’ spectra, it is critical to accurately phase and frequency align these spectra before 
subtraction. in chapter 3, we presented a new method for this alignment by maximizing the 
normalized scalar product between spectra. this method satisfactorily corrects both small 
and large phase and frequency drifts, even at low signal-to-noise ratios (snr).
 in chapter 4, we compared the effect of hypoglycemia on brain lactate levels, 
measured with J-difference editing 1H-mrs, in three groups of participants: non-diabetic 
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subjects, patients with type 1 diabetes with normal awareness of hypoglycemia (nAH) and 
patients with type 1 diabetes and iAH. Brain lactate levels were determined during euglycemia 
(i.e., normal plasma glucose concentrations) and hypoglycemia. Brain lactate levels fell by 
~20% in response to hypoglycemia in patients with iAH, whereas they remained stable in 
patients with nAH and healthy controls. We concluded that the fall in brain lactate in patients 
with iAH most likely reflects increased brain lactate oxidation during hypoglycemia. if lactate 
is indeed used as an alternative fuel, this may suppress the need for glucose by the brain and 
consequently the appearance of hypoglycemic symptoms. 
 We then investigated the effect of elevated plasma lactate levels on brain lactate 
levels during hypoglycemia. since altered brain lactate handling has been implicated in the 
development of iAH in type 1 diabetes, the capacity to transport lactate into the brain during 
hypoglycemia may be relevant in its pathogenesis. We first investigated the effect of raised 
endogenous plasma lactate levels, using an intensive exercise protocol (chapter 5). Again, 
three groups of participants (non-diabetic subjects, patients with type 1 diabetes and nAH and 
patients with type 1 diabetes and iAH) were exposed to hypoglycemia after they had performed 
a high-intensity interval training (Hiit). this exercise modality dramatically increased plasma 
lactate concentrations, and although the lactate concentration gradually decreased after Hiit, 
it remained elevated during subsequent hypoglycemia. Before Hiit and during hypoglycemia, 
brain lactate levels were determined continuously with J-difference editing 1H-mrs. After Hiit, 
at the beginning of hypoglycemia, brain lactate levels were elevated in all groups, but most 
pronounced in patients with iAH. Again, brain lactate fell well below baseline levels during 
hypoglycemia in patients with iAH, but returned to baseline levels and remained there in the 
other two groups, very similar to what was observed earlier. these results support the concept 
of enhanced lactate transport as well as increased lactate oxidation in patients with type 1 
diabetes and iAH. 
 A single bout of Hiit clearly raises plasma lactate levels, but these levels gradually 
return to baseline values after the Hiit protocol, so that measurements cannot be done 
under steady-state conditions. For the next study, we therefore infused lactate intravenously 
to obtain stably elevated plasma lactate levels (chapter 6). Previous studies had shown that 
administration of lactate considerably diminishes symptomatic and hormonal responses to 
hypoglycemia, thus mimicking the situation seen in patients with iAH. indeed, the dose of 
lactate we administered was sufficient to impair awareness of and the adrenaline response 
to hypoglycemia in patients with nAH. Patients with nAH underwent two euglycemic-
hypoglycemic clamps, once with sodium lactate infusion and once with saline infusion. Brain 
lactate levels, again determined with J-difference editing 1H-mrs, were only modestly elevated 
during lactate infusion, comparable to the increase in brain lactate observed in patients with 
iAH. the lack of a pronounced increase in brain lactate suggests that the excess of lactate is 
immediately metabolized by the brain, which in turn may explain the suppressive effects of 
lactate on awareness of hypoglycemia observed in patients with nAH.
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 Apart from changes in glucose and/or lactate metabolism during hypoglycemia also 
cerebral blood flow (cBF) may be altered in patients with iAH. in chapter 7, we investigated 
both global and regional cBF changes in response to hypoglycemia in patients with iAH, 
patients with nAH and non-diabetic subjects, determined by arterial spin labeling (AsL) mri. 
As expected, hypoglycemia generated typical symptoms in patients with nAH and healthy 
controls, but not in patients with iAH. regionally, hypoglycemia caused a redistribution of 
cBF towards the thalamus of both patients with nAH and healthy controls, consistent with 
activation of brain regions associated with the autonomic response to hypoglycemia. no such 
redistribution was found in the iAH group. conversely, hypoglycemia increased global cBF in 
patients with iAH, but not in the other two groups. An increase in global cBF may enhance 
the supply of energy nutrients (e.g., glucose) to the brain, and consequently maintain brain 
metabolism. simultaneously, this could suppress or delay hypoglycemic sensing by the brain, 
required to induce hypoglycemic symptoms. Altogether these results suggest that changes in 
cBF during hypoglycemia contribute to the development of iAH. 
general disCussion
As impaired awareness of hypoglycemia (iAH) can have detrimental and dangerous consequences 
for patients with type 1 diabetes, it is relevant to better understand the mechanisms underlying 
iAH. in this thesis, we showed that there are indeed hypoglycemia-induced cerebral adaptations 
in iAH, involving brain lactate handling and cerebral blood flow (cBF). 
 our demonstration that hypoglycemia decreases brain lactate levels in iAH is 
compatible with an increase in lactate oxidation (Figure 8.1). upregulation of lactate oxidation 
may be a protective mechanism when glucose supply is low, but at the same time, may result 
in impeded hypoglycemic sensing by the brain. the fall in brain lactate during hypoglycemia 
in iAH was also present after endogenous plasma lactate levels had been elevated by a single 
bout of Hiit, but only when plasma lactate levels were already decreased to ~2 mmol/L, and not 
at higher plasma lactate levels. Likewise, when plasma lactate concentrations were raised to 
a stable level of 3.5 mmol/L by lactate infusion, brain lactate levels did not fall below baseline 
level in patients with iAH. cerebral lactate uptake is driven by a concentration gradient from 
blood to brain, and is thus directly related to the plasma lactate concentration. We posit 
that cerebral lactate oxidation in iAH is driven by metabolic demand or, in other words, by 
the ‘need’ for an alternative fuel. As such, we hypothesize that if plasma lactate levels are 
profoundly elevated (e.g., immediately after Hiit or during lactate infusion), the effects of 
increased lactate transport overrules the upregulated oxidation of lactate, particularly in 
patients with iAH whose lactate transport capacity across the blood-brain barrier is reported 
to be upregulated [1,2]. similarly, at lower plasma lactate concentrations, the increased brain 
lactate oxidation becomes more dominant than the increased brain lactate transport. this 
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may explain why brain lactate levels fell at the end of hypoglycemia after Hiit, but not when 
lactate was infused continuously.
 in this thesis, two different approaches were used to raise plasma lactate levels. First, 
we used a single bout of Hiit, which causes endogenous plasma lactate levels to raise to >10 
mmol/L. After reaching peak levels, plasma lactate levels declined in about 90 minutes back to 
the baseline level of 0.5-1 mmol/L. secondly, we used an intravenous lactate infusion to ensure 
stable elevated plasma lactate levels of 3.5 mmol/L. Although the increase in brain lactate in 
response to these plasma lactate elevations was somewhat comparable in magnitude (i.e., 
brain lactate levels increased in both studies not more than 30%), we also found differences. in 
response to endogenously raised plasma lactate levels, the increase in brain lactate levels was 
greater in iAH compared to patients with nAH and healthy controls, which can be explained 
by a greater lactate transport capacity in iAH. this difference was not present after infusion 
of lactate, if anything, brain lactate levels seemed higher in nAH compared to iAH (although 
not statistically significant). the continuous supply of lactate resulting in stable plasma lactate 
levels rather than a (non-stable) decline probably accounted, at least in part, for this difference. 
in addition, brain lactate uptake is not only dependent on a concentration gradient of this 
metabolite over the blood-brain barrier, but also on pH levels (see Figure 8.1), with equilibrium 
being reached when [Lac]brain / [Lac]plasma = [H
+]plasma / [H
+]brain [3]. As plasma pH levels decrease 
in response to exercise but increase in response to lactate infusion, the net influx of lactate is 
expected to be greater after exercise than during lactate infusion, under similar circumstances. 
this effect may be enhanced in patients with iAH, in whom the capacity to transport lactate is 
reported to be higher [1,2]. notably, in both cases, elevated plasma lactate levels result in a net 
lactate influx into the brain, assuming that brain pH levels remain largely unchanged due to 
cerebral homeostasis.
 our results are compatible with an increased capacity to oxidize lactate in iAH during 
hypoglycemia. As we did not measure cerebral lactate oxidation directly, it is worth discussing 
possible other roles for lactate. Lactate may regulate cBF [4], and changes in cBF seem 
present in iAH as reported in this thesis. However, we did not find a relation between changes 
in cBF and changes in cerebral lactate (data not shown) which argues against this mechanism. 
Alternatively, a change in brain lactate concentration alters the brain’s redox state, which may 
inhibit or promote alternative energy pathways such as glycolysis [5], and studies suggest 
that lactate acts mainly as signalling molecule instead of an alternative energy source during 
hypoglycemia [6-8]. in rats exposed to recurrent hypoglycemia, an animal model of iAH, 
supraphysiological elevation of plasma lactate levels resulted in increased lactate transport 
across the blood-brain barrier, but not in increased lactate oxidation [7]. remarkably, this 
increased transport of lactate in (and out) of the brain resulted in a maintenance of glucose 
oxidation and preserved neuronal functioning during hypoglycemia, which was blunted in 
control rats at similar (elevated) plasma lactate levels. the authors concluded that lactate is 
able to modulate metabolic activity rather than acting as a metabolic substrate. in the same 
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direction points a study in humans [6] showing similar cerebral lactate influx and cerebral 
lactate efflux in patients with type 1 diabetes during hypoglycemia, at supraphysiological 
plasma lactate levels. metabolic modelling suggested that brain lactate concentrations in 
patients with type 1 diabetes are fivefold higher than in healthy controls during hypoglycemia 
[6]. We were not able to reproduce these results in any of our studies, even though our study 
protocol in chapter 6 was very comparable. it should be noted that metabolic modelling 
requires some critical assumption, which may explain the discrepancy. to calculate brain 
lactate levels, the authors assumed an equal fractional enrichment of lactate and glutamate 
upon infusion of 13c-labeled lactate, which implies no cerebral lactate compartmentation 
as in cultured neurons [9], astrocytes [10] and possibly in the rat brain [11]. this may not be 
accurate. Furthermore, a constant cerebral glutamate concentration during hypoglycemia was 
assumed, which is not in line with results of the studies described in this thesis nor with other 
studies [12,13]. Both assumptions may lead to higher calculated brain lactate levels. still, our 
results can neither exclude nor proof that lactate is a metabolic regulator instead of (or next 
to) an important alternative fuel during hypoglycemia in patients with iAH. if lactate is indeed 
a metabolic regulator, the exact mechanism and its relationship to the hypoglycemia-induced 
fall in cerebral lactate levels in iAH remains to be elucidated. 
 A valid question is whether the presumed upregulation of lactate oxidation and 
increased global cBF in iAH is sufficient to compensate for the glucose deficit during 
hypoglycemia. Although we cannot provide a definitive answer to this question since we 
investigated cerebral lactate levels, not lactate oxidation rates, and because it is difficult to 
estimate the quantitative effect of cBF changes on substrate delivery, it is worth speculating. 
While the uptake of glucose by the brain declines almost linear with plasma glucose 
concentration [16], whole-brain energy metabolism is not affected in healthy individuals 
until plasma glucose levels fall below ~2.8 mmol/L [17,18]. in other words, although glucose 
availability is reduced, the human brain is able to endure moderate hypoglycemia. this 
discrepancy has been attributed to oxidation of alternative substrates. However, this alone is 
probably not sufficient to sustain brain metabolism. in healthy subjects, it has been estimated 
that lactate oxidation can only account for 25% of the energy (AtP) loss due to reduced glucose 
availability during (moderate) hypoglycemia [19]. our data provides support that this proportion 
is higher in patients with iAH due to an enhanced transport capacity for lactate across the 
blood-brain barrier, an upregulated capacity to oxidize lactate and an increased cBF, and 
thus substrate delivery, in response to hypoglycemia. However, it remains to be determined 
whether this is sufficient to compensate completely for the glucose deficit. it is likely that 
besides these mechanisms, more cerebral adaptations are involved in the pathogenesis of 
iAH. notably, as iAH represents a continuum ranging from a diminished perception of the 
onset of hypoglycemia to complete hypoglycemia unawareness, the (multifactorial) cerebral 
mechanisms involved in the development of iAH may differ from person to person and may 
develop with severity of iAH.
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fig ure 8.1 simplifi ed illustration of the possible role(s) for lactate in the brain in patients with type 1 diabetes 
and impaired awareness of hypoglycemia (iAH) during euglycemia (left) and hypoglycemia (right). glucose 
is the main energy source during euglycemia, but also small amounts of lactate are metabolized [14,15]. 
under physiological circumstances, it is estimated that the contribution of lactate to cerebral metabolism 
is ~10% [15]. glucose is transported across the blood-brain barrier (BBB) by glucose transporters (glut). 
Lactate is transported across the BBB by monocarboxylate transporters (mcts), and co-transported with 
H+. during hypoglycemia, cerebral glucose levels decline linearly with plasma glucose which normally 
limits energy production (indicated by the dashed arrow). in patients with iAH, lactate transport capacity 
is reported to be upregulated during hypoglycemia (described in chapter 5 and in [1,2]) (depicted by bold 
arrow). Lactate can be converted to pyruvate to (Pyr) and as such contribute to energy production via the 
tcA cycle. A fall in cerebral lactate levels upon hypoglycemia (as described in chapter 4) suggests an 
increased lactate oxidation rate in patients with iAH (depicted by bold arrow). Alternatively, lactate may 
act as an signalling molecule (indicated by the grey arrow and + sign) that helps to preserve glucose 
metabolism during hypoglycemia.
open Questions and future direCtions
1H-mrs enables quantifi cation of cerebral metabolite levels, but provides no information about 
fl uxes or consumption of metabolites. A decrease in brain lactate concentration can be the result 
of (at least) four mechanisms: a decrease in lactate production through glycolysis, an increase 
of lactate export from the brain, a decrease in lactate uptake from plasma and an increase in 
lactate oxidation. in the studies presented in this thesis, we did not measure these processes 
independently. As such, we can only speculate about the mechanisms behind adaptations in 
cerebral lactate handling in iAH. Alternatively, the combination of 13c-mrs with the infusion 
of 13c-labeled substrates, such as glucose or lactate, can provide information about metabolic 
processes in the brain. ultimately, a study in which the contribution of both substrates to 
energy metabolism in the brain during hypoglycemia can be determined, is needed. this could 
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be accomplished by simultaneous infusion of 13c-labeled glucose and 13c-labeled lactate, in 
combination with 13c-mrs and adequate metabolic modelling [20]. Although such studies will 
be technically challenging and very expensive, they may confer further inside into exactly how 
changes in brain lactate handling contribute to the pathogenesis of iAH. currently, studies 
are lacking that compare cerebral (lactate and/or glucose) metabolism during hypoglycemia 
between patients with nAH and iAH, and between physiological and supraphysiological plasma 
lactate levels. discrimination between effects of diabetes, level of awareness and plasma 
lactate levels is therefore currently not possible.
 Another open question is whether the cerebral adaptations found in iAH are the 
result of an altered glucose threshold to induce these protective mechanisms, or the result 
of the pathogenesis of iAH per se. it remains unclear whether patients with nAH or healthy 
controls show similar adaptations as patients with iAH (e.g., a fall in brain lactate levels and an 
increased global cBF) if hypoglycemia would have been deeper. this is difficult to elucidate in 
a study with human participants, as more profound hypoglycemia is generally not accepted as 
safe, but could be studied in an animal model of diabetes. Answering this question may offer 
further insight in how exactly iAH is related to recurrent and/or severe hypoglycemia. 
 An additional metabolic effect observed in our studies was that glutamate levels drop 
upon hypoglycemia in healthy controls and patients with nAH, but not in patients with impaired 
awareness (chapters 4 and 6). interestingly, this drop in brain glutamate also occurred in 
patients with nAH when awareness was compromised by lactate infusion. the latter is in line 
with earlier studies who could not relate the hypoglycemia-induced decrease in glutamate to 
the release of adrenaline [13,21]. in future research, it is worth exploring via which pathways 
(e.g., glutamate oxidation via the tcA cycle, reduced glutamate production, via anaplerotic 
pathways or other) hypoglycemia leads to a reduced glutamate content and how this is related 
to (impairments in) awareness of hypoglycemia.
ConClusion
the research described in this thesis investigated cerebral adaptations in response to 
hypoglycemia in patients with type 1 diabetes and impaired awareness of hypoglycemia (iAH). 
We focussed on two possible mechanisms that may contribute to the development of iAH: 
altered cerebral lactate handling and changes in cerebral blood flow (cBF). We demonstrated 
that cerebral lactate levels fall in patients with iAH in response to hypoglycemia, which is 
compatible with an increased capacity to oxidize lactate. Also, when plasma lactate levels were 
substantially elevated, brain lactate levels increased most in patients with iAH, indicating an 
increased cerebral lactate transport capacity across the blood-brain barrier. Finally, global 
cBF increased in response to hypoglycemia in iAH while it remained unaltered in patients with 
normal awareness of hypoglycemia and non-diabetic controls. Both mechanisms thus seem to 
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occur, but do not exclude the contribution of other, as yet unidentified pathways. these cerebral 
adaptations in patients with type 1 diabetes and iAH are likely aimed at neuroprotection, but 
at the same time, impede hypoglycemic sensing by the brain, and as such, contribute to the 
pathogenesis of iAH.
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samenvatting
type 1 diabetes (suikerziekte) is een auto-immuun ziekte waarbij de insulineproducerende 
cellen in de alvleesklier worden afgebroken. insuline is een hormoon dat erg belangrijk is 
voor het reguleren van de bloedsuikerspiegel. insuline is onmisbaar, en daarom moeten 
patiënten met type 1 diabetes behandeld worden met insuline; zij moeten insuline inspuiten. 
de huidige richtlijnen voor het gebruik van insuline bij patiënten met type 1 diabetes raden 
aan om een zo normaal mogelijke bloedsuikerspiegel na te streven, aangezien hyperglykemie 
(hoge bloedsuiker) een grote risicofactor is voor micro- en macrovasculaire complicaties, zoals 
blindheid, nierfalen en hart- en vaatziektes. maar in de praktijk blijkt het erg lastig om deze 
richtlijn na te streven. Als er te weinig insuline wordt gespoten stijgt de bloedsuikerspiegel, 
terwijl een te hoge dosis insuline juist te lage bloedsuikerspiegels kan veroorzaken. een te 
lage bloedsuikerspiegel wordt een hypoglykemie (hypo) genoemd, en gemiddeld gebeurt dit 
ongeveer twee tot drie keer per week. dit betekent dat een patiënt met type 1 diabetes in zijn 
leven duizenden hypo’s zal hebben. een hypo kan zeer storend en lastig zijn, voor zowel de 
patiënt als zijn omgeving.
 normaalgesproken leidt een hypo tot kenmerkende symptomen, zoals zweten, trillen, 
duizeligheid, een hongergevoel, etc. ook komen er bij een hypo hormonen, zoals adrenaline 
en glucagon, vrij. Hierdoor kunnen de meeste patiënten het goed aanvoelen wanneer de 
bloedsuikerspiegel te ver daalt, en dit kan vervolgens opgelost worden door koolhydraatrijk 
voedsel te eten. echter, bij ongeveer een derde van de patiënten met type 1 diabetes ontstaan 
deze symptomen en hormoonreactie niet meer of enkel bij hele lage bloedsuikers; zij zijn dus 
minder gevoelig voor hypo’s. deze aandoening wordt impaired awareness of hypoglycemia (iAH) 
genoemd. Patiënten met type 1 diabetes en iAH lopen een groot risico op ernstige, en mogelijk 
gevaarlijke hypo’s; de glucosespiegel is dan zo laag dat er zelfs een verminderd bewustzijn of 
een coma kan intreden. 
 Het is niet bekend hoe iAH exact ontstaat, maar zeer waarschijnlijk spelen 
veranderingen in het brein, ten gevolge van herhaaldelijke hypo’s, een rol. de studies 
beschreven in deze thesis focussen op twee mechanismen in het brein die mogelijk kunnen 
bijdragen aan het ontstaan van iAH: aanpassingen in de energiehuishouding (metabolisme) 
van het brein en aanpassingen in de cerebrale perfusie. dit is onderzocht met behulp van 1H 
magnetische resonantie spectroscopie (1H-mrs) en perfusie mri (AsL-mri).
 hoofdstuk 1 en hoofdstuk 2 geven een introductie over iAH en over de mr technieken 
die in deze thesis gebruikt zijn. Hoofdstuk 2 gaat dieper in op het cerebrale glucose metabolisme 
in het algemeen, en de effecten van een hypo op het cerebrale glucose metabolisme in het 
bijzonder. data van verschillende functionele en metabole neuroimaging studies hebben laten 
zien dat ons brein normaal gesproken in staat is om het cerebrale glucose metabolisme op 
pijl te houden tijdens een (milde) hypo. echter, dit kan leiden tot veel aanpassingen in het 
brein van patiënten met iAH. deze aanpassingen kunnen betrekking hebben op de regionale 
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toevoer of transport van glucose naar het brein, de verwerking van glucose of van alternatieve 
brandstoffen (zoals lactaat) door het brein, alsmede op de activatie of deactivatie van regio’s in 
het brein die betrekking hebben op gedrag.
 in verschillende studies in deze thesis hebben we 1H-mrs gebruikt om concentraties 
van metabolieten in het brein te bepalen, met de focus op het meten van de hoeveelheid lactaat 
in het brein. dit metaboliet kan het beste gemeten worden met een zogenaamde J-difference 
editing mrs techniek. dit houdt in dat er telkens twee mr spectra worden opgenomen, waarbij 
in één van deze spectra frequentie selectieve radiofrequente (rF) pulsen worden geplaatst 
op het gekoppelde spinsysteem van lactaat. in de andere opname worden deze rF pulsen 
niet gebruikt. dit resulteert in twee spectra: een ‘aan’ en ‘uit’ spectrum. deze ‘aan’ en ‘uit’ 
spectra worden van elkaar af getrokken. dit levert een mr spectrum op met alleen het signaal 
van lactaat. omdat er kleine fase en/of frequentie verschuivingen zullen zijn tussen het ‘aan’ 
en ‘uit’ spectrum, is het erg belangrijk dat deze precies goed zijn uitgelijnd ten opzichte van 
elkaar voordat ze van elkaar worden afgetrokken. in hoofdstuk 3 presenteren we een nieuwe 
methode hiervoor, die gebruik maakt van het genormaliseerde scalaire product tussen twee 
spectra. deze methode is geschikt om zowel grote als kleine fase en frequentie verschuivingen 
te corrigeren, en is zelfs geschikt om te gebruiken bij een lage signaal-ruis ratio (snr).
 in hoofdstuk 4 hebben we het effect van een hypo op de hoeveelheid lactaat in het 
brein, bepaald met J-difference editing 1H-mrs, vergeleken in drie groepen proefpersonen: 
gezonde proefpersonen zonder diabetes, patiënten met type 1 diabetes en een normale 
gevoeligheid voor hypo’s (normal awareness of hypoglycemia; nAH) en patiënten met type 1 
diabetes en iAH. de lactaat concentratie in het brein werd bepaald tijdens euglykemie (normale 
bloedsuikerwaarde) en tijdens hypoglykemie. de hoeveelheid lactaat in het brein nam met 
ongeveer 20% af tijdens de hypo bij patiënten met iAH, terwijl de hoeveelheid stabiel bleef bij 
patiënten met nAH en bij proefpersonen zonder diabetes. We concludeerden dat de daling in 
brein lactaat waarschijnlijk het gevolg is van een toename van lactaat oxidatie tijdens de hypo. 
Als lactaat inderdaad als alternatieve brandstof wordt gebruikt tijdens de hypo door patiënten 
met iAH kan dit de behoefte voor glucose te niet doen. dit zou het ontbreken van symptomen 
tijdens de hypo bij deze patiënten kunnen verklaren.
 daarna hebben we het effect van verhoogde plasma lactaat concentraties op brein 
lactaat tijdens een hypo onderzocht. Aangezien een andere verwerking van lactaat in het brein 
mogelijk betrokken is bij het ontstaan van iAH, kan de capaciteit om lactaat naar de hersenen 
te transporteren tijdens een hypo relevant zijn voor de pathogenese. eerst hebben we het effect 
van endogeen verhoogde plasma lactaat concentraties onderzocht (hoofdstuk 5). Vergelijkbare 
groepen proefpersonen (proefpersonen zonder diabetes, patiënten met type 1 diabetes en nAH 
en patiënten met type 1 diabetes en iAH) ondergingen een hypo nadat ze een interval training 
met een hoge intensiteit (high-intensity interval training, Hiit) hadden uitgevoerd. een Hiit 
zorgt ervoor dat de plasma lactaat spiegel sterk stijgt. Hoewel de plasma lactaat concentratie 
na het uitvoeren van de Hiit geleidelijk daalde, bleef deze wel verhoogd tijdens de hypo. Voor de 
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Hiit en tijdens de hypo hebben we de hoeveelheid lactaat in het brein bepaald met J-difference 
editing 1H-mrs. na de Hiit, aan het begin van de hypo, nam de hoeveelheid lactaat in het brein 
toe in elke groep, maar het meest in patiënten met iAH. tijdens de hypo daalde de hoeveelheid 
lactaat in brein in patiënten met iAH tot een waarde die lager was dan de beginwaarde, terwijl 
in de andere twee groepen de hoeveelheid daalde tot aan de beginwaarde. dit is vergelijkbaar 
met wat we eerder zagen. deze resultaten ondersteunen dat de transportcapaciteit voor 
lactaat naar het brein verhoogd is bij patiënten met iAH, en dat zij een verhoogde capaciteit 
hebben om lactaat te oxideren tijdens de hypo.
 Het uitvoeren van een Hiit zorgt ervoor dat de endogene plasma lactaat spiegel 
stijgt, maar deze zal na het sporten geleidelijk weer terug naar zijn beginwaarde gaan. in 
de volgende studie hebben we een lactaat infuus gebruikt, om ervoor zorgen dat de plasma 
lactaat spiegel constant verhoogd is (hoofdstuk 6). Het is herhaaldelijk aangetoond dat de 
toediening van lactaat ervoor zorgt dat de hormonale en symptomatische reactie op een hypo 
aanzienlijk afzwakt. dit lijkt op de situatie zoals in patiënten met iAH. de hoeveelheid lactaat 
die we hebben toegediend zorgde er inderdaad voor dat de symptomatische en hormonale 
reactie op een hypo verminderde bij patiënten met nAH. Patiënten met nAH ondergingen 
twee keer een euglykemische-hypoglykemische clamp. de ene keer kregen ze lactaat via een 
infuus toegediend en de andere keer een fysiologische zoutoplossing (placebo). Brein lactaat 
concentraties, opnieuw gemeten met J-difference editing 1H-mrs, waren licht verhoogd 
tijdens de lactaat infusie. We hebben dezelfde metingen uitgevoerd bij patiënten met iAH, en 
de toename in brein lactaat was vergelijkbaar met wat we zagen bij patiënten met nAH. Het 
ontbreken van een duidelijke/sterke toename in brein lactaat, terwijl de plasma lactaat spiegels 
wel constant verhoogd waren, kan betekenen dat de overmaat aan lactaat onmiddellijk wordt 
gebruikt door de hersenen als brandstof. dit kan vervolgens de onderdrukkende effecten van 
lactaat op de gevoeligheid voor het merken van een hypo bij patiënten met nAH verklaren.
 Los van veranderingen in glucose en/of lactaat metabolisme tijdens een hypo, zijn 
er mogelijk ook veranderingen in cerebrale perfusie (cerebral blood flow, cBF) bij patiënten 
met iAH. hoofdstuk 7 beschrijft een onderzoek waarbij we met arterial spin labeling (AsL) 
mri veranderingen in zowel de globale als regionale cBF ten gevolge van een hypo hebben 
onderzocht, bij patiënten met iAH, patiënten met nAH en proefpersonen zonder diabetes. 
Zoals verwacht hadden patiënten met nAH en proefpersonen zonder diabetes last van de 
gebruikelijk symptomen van een hypo, terwijl dit niet het geval was bij patiënten met iAH. 
Bij zowel patiënten met nAH als bij proefpersonen zonder diabetes zorgde de hypo voor een 
redistributie van (regionale) cBF richting de thalamus, wat geassocieerd kan worden met 
activatie van deze regio in het brein, aangezien de thalamus betrokken is bij de autonome 
reactie op een hypo. deze redistributie werd niet gevonden in patiënten met iAH. omgekeerd 
nam de globale cBF toe bij patiënten met iAH tijdens de hypo, maar niet bij de andere twee 
groepen. een toename van globale cBF kan er voor zorgen dat de toevoer van voedingsstoffen 
(bijv. glucose) naar het brein toeneemt, en dat dus het glucose metabolisme op pijl blijft. dit 
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zou kunnen betekenen dat de hersenen de hypo niet, of vertraagd, detecteren, waardoor er 
geen symptomen optreden. Al met al suggereren deze resultaten dat ook veranderingen in 
cBF tijdens een hypo bijdragen aan het ontstaan van iAH. 
ConClusie
deze thesis beschrijft verschillende studies over aanpassingen in het brein van patiënten 
met type 1 diabetes en een verminderde gevoeligheid voor hypo’s (impaired awareness of 
hypoglycemia, iAH). We hebben op twee mogelijke aanpassingen gefocust: een aangepaste 
verwerking van lactaat in het brein en aanpassingen in de cerebrale perfusie. de concentratie 
van lactaat in het brein daalt in patiënten met iAH als gevolg van een hypo, wat verenigbaar is 
met een verhoogde capaciteit om lactaat te oxideren. ook hebben we aangetoond dat, wanneer 
de plasma lactaat spiegel substantieel verhoogd is, de concentratie van lactaat in brein het 
meeste stijgt bij patiënten met iAH, wat wijst op een verhoogde capaciteit om lactaat via de 
bloed-brein barrière te transporteren. ten slotte nam de globale cerebrale perfusie toe als 
reactie op een hypo bij patiënten met iAH. dit was niet het geval bij patiënten met een normale 
gevoeligheid voor hypo’s (normal awareness of hypoglycemia, nAH) en bij proefpersonen 
zonder diabetes. Beide mechanismes lijken dus aanwezig te zijn bij patiënten met iAH, maar 
dit sluit de bijdrage van andere, nog niet geïdentificeerde mechanismes niet uit. Waarschijnlijk 
zijn deze aanpassingen in het brein van patiënten met type 1 diabetes en iAH gericht op 
bescherming van het brein, maar tegelijkertijd belemmeren zij het vermogen van het brein om 
lage bloedsuikers te herkennen, en als zodanig, kan dit bijdragen aan de pathogenese van iAH.
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list of abbreviations
AFP  adiabatic full passage
AnLs  astrocyte-to-neuron lactate shuttle
AnoVA   analysis of variance
AsL  arterial spin labeling
Asp  aspartate
Auc  area under the curve
AtP  adenosine triphosphate
BBB  blood-brain barrier
Bmi   body mass index
cBF  cerebral blood flow
cmrglu  cerebral metabolic rate of glucose
coV  coefficient of variation
ct   computer tomography
Fid  free induction decay
FoV  field of view
gABA  gamma-aminobutyric acid
gir  glucose infusion rate
glc-6-P  glucose-6-phosphate
gln  glutamine
glu  glutamate
gLut1  glucose transporter protein 1
glx  glutamate and glutamine
HAAF  hypoglycemia-associated autonomic failure
HbA1c  glycosylated hemoglobin
Hiit  high-intensity interval training
iAH  impaired awareness of hypoglycemia
Lac  lactate
LdH  lactate dehydrogenase
mcA  monocarboxylic acid
mcts  monocarboxylic acid transporters
mi  myo-inositol
mm  macromolecules
mri  magnetic resonance imaging
mrs  magnetic resonance spectroscopy
nAH  normal awareness of hypoglycemia
nALs  neuron-to-astrocyte lactate shuttle
nLme  nonlinear mixed effects
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nmr  nuclear magnetic resonance
pcAsL  pseudo-continuous arterial spin labeling
Pet  positron emission tomography
ppm  parts per million
Pyr  pyruvate
rF  radio frequency
riA  radioimmunoassay
scyllo  scyllo-inositol 
sd  standard deviation
sem  standard error of the mean
sLAser  semi-localized by adiabatic selective refocusing
snr  signal-to-noise ratio
t  tesla 
t1dm  type 1 diabetes mellitus
tA  acquisition time
tau  taurine
tcA cycle tricarboxylic acid cycle
tcho  total choline
tcre  total creatine
te  echo time
tnAA  total n-acetylaspartate
tr  repetition time
VmH  ventromedial nucleus of the hypothalamus
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